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1 SUMMARY 
The Epithelial Cell Adhesion or Activating Molecule (EpCAM, CD326) was selected as a 
target for a multitude of immunotherapeutic approaches treating human malignancies. How-
ever, EpCAM is also expressed on various non-malignant cells. So far, all well tolerated drug 
candidates suffer from weak efficacy, whereas severe systemic side effects accompany more 
potent immunotherapies. Thus, to prevent clinical failure, a new systemic immunotherapy 
targeting EpCAM requires adequate pre-clinical models to study the efficacy in the face of 
systemic tolerability. 
MT110 is an antibody of the BiTE format and represents a new systemic immunotherapeutic 
approach targeting EpCAM+ tumors. BiTEs are bispecific single chain antibodies recruiting 
the high cytotoxic potential of T cells to eradicate cancer cells. With one of its two specific 
binding sites MT110 attaches to the pan T cell antigen CD3e and with the other one to the 
EpCAM antigen present on tumor cells. This physical link induces an immunological syn-
apse, leading to the death of the adjacent cancer cell.  
MT110 promises good potency in clinical use, as it shows high anti-tumor efficacy in xeno-
graft models established in immune deficient NOD/SCID mice grafted with human T cells. 
However, due to its species-specific reactivity mouse models are not adequate to directly 
evaluate toxicological effects of MT110 in immune competent hosts. This demanded the de-
velopment of the mouse specific surrogate muS110. Analogous to MT110, muS110 redirects 
mouse T cells to lyse mouse EpCAM positive tumor cells. The following study describes the 
in vitro characterization of muS110 as well as the in vivo evaluation of its efficacy and toler-
ability. The primary and secondary pharmacology of muS110 were analyzed with special em-
phasize on its influence on T cell functions.     
In the presence of target cells muS110 led in vitro to a dose dependent proliferation of T cells, 
cytokine secretion, up-regulation of activation markers, and a transformation of resting to 
cytotoxic effector T cells, resulting in the specific elimination of EpCAM positive target cells. 
In quality and quantity muS110 mediated T cell activation was similar to that obtained by a 
full anti-CD3/CD28 stimulation in the presence of IL-2. 
To the extent possible, muS110 was constructed to yield structural and biological characteris-
tics similar to those of drug candidate MT110. MuS110 has comparable affinity to the Ep-
CAM antigen and binds to the orthologous epitope in mouse as MT110 does in human. With 
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respect to EpCAM expression, a significant overlap was found between mouse and human 
tissues. However, a key difference was EpCAM expression on mouse lymphocytes, which 
was not seen on human lymphocytes.  
In vivo muS110 induced a dose dependent onset of side effects including hemoconcentration, 
hypomotility, piloerection, body weight reduction, hypothermia and diarrhea up to 24 hours 
after injection. Most probably, these adverse side effects were caused by a transient release of 
inflammatory cytokines through T cells, systemically activated by an encounter with Ep-
CAM+ lymphocytes and muS110. No lesions were found in healthy EpCAM+ tissue, which 
seemed to be non-accessible for BiTE induced lysis. All observed clinical signs were previ-
ously described for mice in response to agonistic anti-CD3 monoclonal antibodies and termed 
anti-CD3-induced acute syndrome.  
All dose-dependent side effects were self-limiting and animals adapted to repetitive treatment 
with muS110. This phenomenon was already observed after treatment with anti-CD3 antibod-
ies. However, the cause of adaptation was different for BiTE and conventional anti-CD3 anti-
bodies. 
MuS110 induced only very transient lymphocytopenia but most probably no T cell depletion, 
no down-modulation of the TCR/ CD3 complex, no immune deviation to a TH2 immune re-
sponse and no anergy of T cells. However, it led to a transient, not IL-2 reversible block of 
cytokine secretion upon in vitro re-stimulation in T cells. In vivo administration led to a per-
sistent release of IL-10, an expansion of CD4+CD25+FoxP3+ regulatory T cells in the spleen 
and an increase of the CD8+/CD4+ ratio in the blood. This might be indicative for the in-
volvement of regulatory cells in the adaptation to muS110, which, however, had no negative 
impact on muS110 mediated lysis of EpCAM+ target cells. These immune modulating effects 
together with the elimination of EpCAM+ lymphocytes over time might be the reason for ad-
aptation to repeated treatment with muS110. 
The adaptation to muS110 was implemented in a dose escalation scheme to improve the anti-
tumor efficacy. Thus, a higher, but still well tolerated drug load was achieved in mice. 
Thereby, muS110 showed an exceptionally good efficacy against solid 4T1 tumors. It led to a 
99% reduction of these rapid and aggressive tumors in immune competent mice and pre-
vented outgrowth in five of six mice totally. This might resemble the assumable therapeutic 
window of MT110 in humans and would promise high clinical potential. 
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2 INTRODUCTION 
2.1 Epithelial Cell Adhesion Molecule (EpCAM) and its role in cancer 
2.1.1 Structure and tissue distribution 
The Epithelial Cell Adhesion or Activating Molecule (EpCAM, CD326) was not only the first 
human tumor-associated antigen discovered, but also the target of the first monoclonal anti-
body (mAb17-1A, later named edrecolomab and Panorex®) applied in cancer therapy (1-4). 
Identification of closely related sequences in all mammalian and avian genomes indicates an 
important functional role of EpCAM (5). Due to its versatile functions and its status as pan-
carcinoma marker it was independently discovered several times and is known under many 
synonyms as 17-1A, 323/A3, AUA1, CD326, CO-17A, EGP2, EGP34, EGP40, Ep-CAM, 
ESA, GA733-2, HEA125, KSA, KS1/4, MH99, MK-1, MOC31, TACST-1, Trop1, amongst 
others (2, 6, 7). A recently revised structure model is shown in Figure 1 (2). 
 
Figure 1: Structural model of EpCAM (according to Baeuerle and Gires (2)) 
(A) EpCAM is shown with N- (N) and C-terminus (C), signal peptide (SP), transmembrane do-
main (TM), N-linked carbohydrates (CHO), EGF-like domain (EGF) and thyroglobulin repeat 
domain (TY). (B) EpCAM is depicted as a tetramer showing three additional subunits with dot-
ted lines. Cleavage sites for two proteases releasing the intracellular portion of EpCAM are in-
dicated by red arrows, and the domain of EpCAM interacting with the listed proteins is shown 
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EpCAM is a 40 kDa transmembrane glycoprotein (314 aa) located in the basolateral plasma 
membrane of epithelial cells. It consists of a short cytoplasmatic domain (26 aa) containing 
two a-actinin binding sites, a single transmembrane domain (23 aa) and three extracellular 
domains (242 aa; SP=23 aa) with three N-glycosylation sites (8). The external portion consists 
of an epidermal growth factor (EGF) like repeat and a thyroglobulin (TY) repeat domain fol-
lowed by a cysteine-poor domain (2, 5, 9). Most likely EpCAM forms  dimers and tetramers 
at the cell surface (9).  
In healthy individuals, EpCAM is expressed in almost all simple, pseudo stratified and transi-
tional epithelial cells but not in mature squamous epithelia. It is considered to be a marker for 
cells of epithelial lineage (10). Exceptions are some fully differentiated epithelial derived cell 
types, like keratinocytes, hepatocytes, thymic cortical epithelia, gastric parietal cells and 
myoepithelial cells. EpCAM is not expressed by mesodermal or neural cell membranes, neu-
rons, stromal cells, endothelial cells, syncytiotrophoblasts and bone marrow derived cells (ex-
cept on plasma B cells and thymic T cells in mice) (6).  
2.1.2 Biological functions of EpCAM  
Initially, EpCAM was described as a Ca2+-independent homophilic cell adhesion molecule 
(CAM) of the group of type 1 transmembrane proteins (11). It can form homophilic cell-cell 
interactions with molecules on surrounding epithelial cells via its EGF-like domain. The TY-
like domain mediates lateral interactions of EpCAM molecules (12). The short cytoplasmic 
tail links EpCAM to the actin cytoskeleton (8, 13). 
However, EpCAM is structurally not related to any of the four archetypal families of CAMs, 
the cadherines, the selectins, the integrins or the immunoglobulin (Ig) cell adhesion molecule 
superfamily (7). EpCAM is distributed equally on the basolateral plasma membrane of polar-
ized epithelial cells. It is neither enriched in any of the major types of cell adhesion structures, 
like tight junctions, adhesive junctions, desmosomes or hemidesmosomes, nor does it form 
any structures similar to  those mentioned above (8). The cell-cell adhesion mediated by Ep-
CAM is weak in comparison to that of other CAMs, and there is not sufficient evidence that 
EpCAM mediated adhesion is required for epithelial cell support (8, 11).   
Beside their direct mechanical role as interconnectors of cells, CAMs also constitute an im-
portant group of signal-transducing molecules. They are responsible for a variety of dynamic 
processes in cell proliferation, migration and differentiation (14). It has been shown that Ep-
CAM is strongly associated with cellular proliferation and inhibition of terminal epithelial 
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differentiation in developing pancreatic islet cells and a transformed keratinocyte cell line 
(14-18). However, the current knowledge of EpCAM´s function in tissue morphogenesis and 
morphogenetic movements of cells is still incomplete. Identified ligands and possible EpCAM 
related functions are summarized in Figure 2 after Trzpis et al. (7).   
EpCAM seems to play a morphoregulatory role in embryogenesis, as it is already expressed 
in the first developmental stages (19). It is detected in fetal lung, kidney (proximal tubes), 
liver, pancreas, skin, and germ cells (8). In the initial phases of morphogenesis it is expressed 
by epithelial precursor cell as well as by cells not yet assigned to a certain cell fate. In later 
stages of epithelial development, EpCAM acquires a strictly epithelial specific expression, 
whereas in terminally differentiated cells EpCAM expression is lost (7). Small bile duct cana-
liculi in the adult liver express EpCAM, whereas hepatocytes and large bile ducts are negative 
for EpCAM (15). The germinal regions of the colonic mucosal lining in colonic crypts display 
high EpCAM expression, which steadily decreases as cells differentiate and migrate to the top 
of the villi (20). Progenitor cells of skin epithelium express EpCAM, whereas differentiated 
cells do not (21).   
One mode of EpCAM’s function in morphogenesis might be its negative impact on E-
cadherin, one of the major morphoregulatory molecules in epithelia (14). EpCAM is thought 
to affect the connection between the cadherin adhesion complexes and the cytoskeleton, as it 
binds to p85, the regulatory subunit of the Phosphatidylinositol 3 kinase (PI3K) (14, 22). 
PI3K is known to bind to a-actin and down-regulate cadherin-mediated cell adhesion (10). 
Consequently, upon EpCAM induction, cadherin-mediated adhesion is replaced by the 
weaker EpCAM-mediated adhesion. Inhibition of cadherin-mediated adhesion, however, is 
associated with poor differentiation, increased invasiveness and metastasis formation of tu-
mors. In contrast, silencing of EpCAM expression by small interfering RNA rescued func-
tionality of E-cadherin, a and b–catenin in different breast cancer cell lines. The increased 
cadherin-mediated cell-to-cell adhesion correlated well with a decrease in proliferation, cell 
migration and invasion (23).  
Thus, EpCAM can weaken tight cell-cell adhesions and modulate proliferation, differentiation 
and migration. A disturbed regulation of these processes in neoplastic cells could result in an 
increased metastatic capacity. Hence, it might explain the promotional effect of EpCAM 
overexpression upon metastasis, although its nature as CAM would rather argue for a negative 
impact (24). 
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Figure 2: Schematic representation of identified EpCAM ligands and their possible func-
tions (according to Trzpis et al. (7)) 
(1) The extracellular domain of EpCAM interacts with a second EpCAM molecule resulting in 
homotypic cell-cell adhesion. (2) EpCAM forms a complex with tetraspanins, e.g. CD9 or D6.1A, 
with CD44v4-v7 (carcinoma associated variants of CD44) and with claudin-7, a protein required 
for the formation of tight junctions. This complex is recruited to tetraspanin enriched membrane 
domains and promotes apoptosis resistance and enhanced metastasis. (3) (4) Direct interactions of 
a-actinin with the intracellular domain of EpCAM links this molecule to the cytoskeletal organi-
zation. (4) EpCAM indirectly associates with E-cadherin. The adaptor proteins that facilitate this 
complex formation are yet to be identified (5) EpCAM modulates the expression of NF-kB, c-
myc, and E-FABP. The interplay of EpCAM with E-cadherin (4) and the CD9/CD44v4-
v7/claudin-7 complex (2), as well as the influence of EpCAM on NF-kB, c-myc, and E-FABP (5) 
provides a link for its involvement in cell migration, metastasis, and cell signaling. E-FABP, epi-
dermal fatty acid-binding protein. 
EpCAM can act as a signaling molecule on its own as well. Signaling was found to be in-
duced either by soluble EpCAM or through zones of cell-cell contact, suggesting that its own 
oligomerisation might be a trigger. These signals led to a cleavage of EpCAM, releasing an 
intracellular protein termed EpIC. EpIC in turn binds to intracellular adaptor molecules, form-
ing a multi-protein signaling complex translocated to the nucleus. This complex is involved in 
target gene induction and growth-promoting effects (2). Consistent with its role as an onco-
gene, overexpression of EpCAM can induce upregulation of the proto-oncogene c-myc and 
promote cell proliferation via upregulated synthesis of cyclin A and E (25). It was also shown 
that upregulation of EpCAM decreased growth factor requirement and enhanced the colony 
EpCAM 
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forming capacity of cells, which are prerequisites for cancer stem cells (25, 26). Interestingly, 
EpCAM surface expression is enhanced upon cell cycle arrest by various chemotherapeutics 
(27). Immunotherapy targeting EpCAM+ cells might therefore address chemotherapy resis-
tant, slowly dividing cancer stem cells.  
2.1.3 EpCAM as a prognostic carcinoma marker and its role in cancer 
EpCAM is not only present on cancer stem cells, but high levels of EpCAM are found in most 
of the major human malignancies, i.e. epithelial carcinomas of colon, lung, prostate, liver, 
pancreas, breast and ovary as summarized in Table 1 according to Balzar et al. (8, 28, 29).  
However, EpCAM expression in tumors itself can be heterogeneous, and is probably nega-
tively affected by a shift from tumor cell differentiation to either mesenchymal or squamous 
cell phenotypes (8). EpCAM is not expressed on neurogenic tumors, sarcomas, lymphomas or 
melanomas (30).  
 
Table 1: EpCAM expression in human malignancies (according to Balzar et al. (8, 28, 29)) 
Most carcinomas express EpCAM whereas tumors derived from non-epithelial tissues are EpCAM 
negative. The level of EpCAM expression is indicated by (–) for no expression, (+) for low expression 
levels, (++) for intermediate expression levels and (+++) for high expression levels. Data on distribu-
tion and expression levels was obtained from multiple studies using different EpCAM specific mono-
clonal antibodies (mAb).  
 
 Type of Tumor EpCAM Expression 
Carcinoma of small intestine, colorectal adenocarcinoma, lung car-
cinoma, adenocarcinoma of cervix 
+++ 
Oral mucosal basal cell carcinoma, gastric adenocarcinoma, pancre-
atic carcinoma, cholangiocarcinoma (liver), biliary duct carcinoma, 
basal cell carcinoma of skin, renal cell carcinoma, transitional cell 
carcinoma of bladder, thyroid carcinoma, prostate carcinoma, ovar-
ian carcinoma, endometrium carcinoma, squamous cell carcinoma of 
cervix, mammary carcinoma, epithelioid mesotheliomas 
++ 
Oral mucosal squamous cell carcinoma, laryngeal (squamous cell) 
carcinoma, esophageal (squamous cell) carcinoma,  
+ 
Germ cell tumor, Wilm´s tumor (epithelial component) +/- 
Melanom, sarcoma, lymphoma, meningioma, non-epithelioid meso-
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Tumors originating from epithelial cells over-express EpCAM, e.g. gastric carcinoma, or ex-
press it de novo, e.g. hepatocellular carcinoma. De novo expression can be detected already in 
precursors of carcinomas of squamous epithelia and serves as an early marker for (pre-) ma-
lignancies (17, 31). The number of EpCAM expressing cell and the grade of EpCAM 
(over)expression increases with the grade of neoplasia and dysplasia. Its overexpression usu-
ally correlates with poor prognosis for instance in ampullary carcinoma of the pancreas, 
squamous cell cancer of head and neck, squamous cell carcinoma of the esophagus, breast 
cancer, gall bladder cancer and ovarian cancer (32-36). However, some patients over-
expressing EpCAM show prolonged survival in clear cell renal cell carcinoma and in gastric 
carcinoma (37-40). Finally, in prostate and lung cancers intensity of EpCAM expression has 
no impact on prognosis (41, 42). Therefore, the prognostic value of EpCAM is still controver-
sial although it is clearly considered to be a pan-carcinoma marker.  
Experiments addressing the role of EpCAM in metastasis reveal contradictory results. Surface 
expression of EpCAM on disseminated tumor cells was shown to be increased. EpCAM over-
expression promotes metastasis in fibrosarcomas (24) and is required for proliferation, migra-
tion and invasiveness of breast cancer cell lines (23, 43). Additionally, a complex formed by 
EpCAM with the CD44 isoform v6, the tetraspanins CO-029 or CD9, and the tight junction 
protein claudin-7 facilitates metastasis formation in colorectal cancer cells (Figure 2) (12, 44, 
45). The presence of this complex also correlated inversely with disease free survival and di-
rectly with apoptosis resistance. On the other hand, carcinoma cells disseminated from their 
primary tumor and circulating in the blood stream had ten times reduced EpCAM expression 
in comparison to cells within the primary tumor (43, 46). Furthermore, Songun et al. found a 
correlation between a loss of EpCAM expression in stomach cancer and enhanced malig-
nancy. They consider this to be due to enhanced metastasis of carcinoma cells upon loss of 
EpCAM (37). Went et al. argue that similarly to the CAM CD44, both, tumor environment 
and expression level of EpCAM, might determine the outcome of its adhesive or anti-
adhesive and mitogenic effects and either block or facilitate metastasis (47, 48).  
2.1.4 Therapeutic antibodies targeting EpCAM in cancer 
EpCAM is a prime target for immunotherapies in the major human malignancies. The most 
common human cancers show a low frequency of EpCAM negative tumors and mostly an 
insignificant influence of tumor staging on EpCAM expression. In an EpCAM+ tumor, Ep-
CAM expressing cells represent normally a high percentage of resident cells (49). EpCAM 
was selected as a target antigen in a multitude of immunotherapeutic approaches. This in-
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cludes vaccines, mouse and human mAbs and antibody conjugates with bacterial toxins and 
chemotherapeutics (8). Currently, a number of EpCAM specific immunotherapies are in 
phase I and II clinical trials. These are the anti-EpCAM antibodies ING-1, adecatumumab, 
and edrecolomab, as well as the locally applied immunotoxin proxinium and some locally 
applied tri-specific approaches recruiting cytotoxic cells to EpCAM+ tumor cells (50-56).  
Edrecolomab is a well-tolerated low affinity mouse antibody against EpCAM, which was 
temporarily marketed in Germany. A significant increase in overall survival of colorectal can-
cer patients was found in the adjuvant setting in two of four trials. But the short half-life, the 
rapid neutralization of the drug by a humoral immune response against the mouse antibody, 
and a borderline clinical activity asked for further development (57-60). Administration of 
this antibody induced the production of neutralizing anti-idiotypic antibodies. Their efficacy 
was analyzed in clinical trials using small amounts of edrecolomab as a subcutaneously ad-
ministered vaccine called IGN101. Only in a subgroup of stage IV rectal cancer patients a 
significant survival benefit was observed. No significant impact was observed in the majority 
of patients in a double-blind placebo controlled phase II trial in several carcinoma indications 
(2). ING-1 is a high-affinity monoclonal antibody. A phase I trial in patients with advanced 
adenocarcinoma caused acute pancreatitis with severe abdominal pain, nausea, and vomiting. 
The risk of pancreatitis and the marginal anti-tumor effect precluded further monotherapy 
studies (50, 61). Adecatumumab (MT201) is a fully human anti-EpCAM antibody, currently 
analyzed in two phase II studies with metastatic breast cancer and early-stage prostate cancer, 
as well as in a phase I study testing the safety of a combination with the chemotherapeutic 
agent docetaxel (Taxotere®). So far the human antibody was well tolerated and no signs of 
pancreatitis were found (51).  
Catumaxomab is a hybrid mouse/rat antibody, generated by the hybrid-hybridoma technique. 
It is tri-specific for EpCAM, CD3 and via its Fc portion for antigen-presenting cells as well as 
NK cells. Phase I clinical trials analyzing intraperitoneal administration to ovarian cancer pa-
tients suffering from ascites and peritoneal carcinomatosis, showed profound clinical activity. 
Catumaxomab appears to be a promising agent for the local treatment of peritoneal carcino-
matosis, but systemic treatment was hampered by systemic intolerability (2, 55). This was 
also observed for the hybrid antibodies HEA125xCD3, recruiting CD3 positive T cells, and 
HEA125x197, recruiting activated neutrophils and monocytes, using a similar tri-specific 
approach to kill EpCAM positive cancer cells. HEA125xCD3 showed an inhibition of ascites 
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production in 8 of 10 patients in ovarian cancer patients. A dramatic, 1000 fold increase of 
local TNF-a concentration indicated a very strong local inflammatory response (2, 56).   
Proxinium is a stability-engineered, single-chain humanized anti-EpCAM antibody fused to a 
subunit of the bacterial Pseudomonas exotoxin. It is currently in a phase II/III trial for local 
treatment of head and neck cancer. In former phase I/II phase trials in head and neck cancer 
proxinium had positive impact on overall survival and showed 88% response rate. Currently 
an improved immunotoxin is under development with a replacement of the furin cleavage site 
by a metalloproteinases-2 and -9 cleavage site. These metalloproteinases are selectively ex-
pressed by tumor cells and might improve the therapeutic window of the immunotoxin (2, 
53).  
EpCAM is expressed on various sides on normal epithelial tissue as well as on cancer cells. 
Low affinity EpCAM binders showed only a borderline clinical activity (57-60). High affinity 
EpCAM binders induced pancreatitis, gastrointestinal toxicity and collateral damage of nor-
mal EpCAM-expressing tissues (61, 62). Systemic intolerability of tri-specific formats and 
immunotoxins led to mostly local usage in cancer therapy (2). Therefore, finding a therapeutic 
window of EpCAM specific drugs with profound clinical activity and good systemic tolerabil-
ity is still a major concern for researchers. Thus, appropriate pre-clinical models are manda-
tory, to evaluate the efficacy and toxicity of newly developed systemic immunotherapies tar-
geted against EpCAM.        
2.2 The concept of bispecific T cell engagers (BiTEs) 
2.2.1 Structure of BiTEs 
BiTE antibodies are designed to direct cytotoxic T cells against tumor cells and represent a 
different therapeutic approach in cancer immunotherapy. The BiTE protein consists of a sin-
gle polypeptide chain of approximately 55 kDa length, which is folded into two tandemly 
arranged single-chain antibody fragments (scFv). These are of different specificity and con-
nected by a flexible peptide linker. The scFv is build up by a variable domain of a heavy 
chain (VH) linked by a stretch of synthetic peptides to a variable domain of a light chain (VL) 
and resemble a truncated Fab fragment of a conventional antibody.  One scFv recognizes 
CD3e, which is a common T cell signaling molecule and part of the T cell receptor (TCR). 
The other scFv shows specificity for the tumor cell antigen of interest. The basic design of a 
BiTE antibody and its structural relationship to its two parental mAb molecules is depicted in 
Figure 3 (63). 
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Figure 3: Structural relationship of BiTE antibody to its parental monoclonal antibodies 
Generation of a BiTE antibody is principally shown. Note that only variable VH and VL domains 
of antibodies are used and all other non-binding parental antibody parts are spared. Linkers con-
nect VH and VL domains to create single chain antibody fragments (scFv). A second linker joins 
two scFv of different specificity to form a BiTE antibody. The flexible linkers enable free rota-
tion and kinking of the two scFv arms to bind to two epitopes on different cells at once. Recom-
binant DNA technology is used to combine the four different gene products into one gene cod-
ing for a single, bispecific protein.   
The scFv consist only of the variable regions of the heavy and the light chain domains of their 
respective parental antibodies. Any other part that is not necessary for antigen binding is 
avoided to minimize immunogenicity (64). The scFv are joined by a short linker that allows 
for a much closer approximation of opposing cells than it is possible with larger bispecific 
formats such as quadroma antibodies (65). The flexible linkage is expected to enable free ro-
tation and kinking of the two scFv arms. Thus, simultaneous recognition of two epitopes pre-
sent on two opposing cell membranes is possible (66). The low molecular mass of bispecific 
antibodies might facilitate penetration into tumors, as it has been shown for Fab or Fv anti-
body fragments (67, 68). 
2.2.2 Mode of action of BiTEs 
Cytotoxic T lymphocytes (CTL) are the most abundant and powerful specific effector cells in 
the adaptive immune response and eliminate virus-infected or cancerous target cells (69, 70). 
Thereby, an individual T cell clone finds its specific target cell via its unique TCR, recogniz-
ing only a distinctive combination of peptide antigen and major histocompatibility complex 
(MHC) I. In concert with other stimulating signals, this binding leads to the formation of a 
cytolytic synapse. There, delivery of the cytotoxic proteins perforin and granzymes B is trig-
gered, mediating target cell apoptosis (71-73). Tumor cells can interfere at each level with this 
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late the occurrence of T cell stimulating or suppressing molecules, like members of the B7 
family, tumor growth factor-β (TGF-β) and interleukin (IL)-10 (74-78). This immune-editing 
enables tumor cells to finally grow out into a large tumor mass, as they escape from an adap-
tive immune response, surviving in the presence of T cells.  
BiTEs leverage the high cytotoxic potential of T cells without the many restrictions imposed 
by specific T cell recognition and counter-acting tumor evasion mechanisms (79). They pro-
vide a temporary physical link between any T cell and a tumor cell independently of MHC-
peptide restrictions of T cells or altered MHC I expression of tumor cells. With one of its two 
specific binding sites the BiTE antibody attaches to the pan T cell antigen CD3 (e-subunit), 
whereas the other one binds to a selected surface antigen on tumor cells. This transient T 
cell/target cell binding induces a fully functional cytolytic synapse between T cells and tumor 
cells, eliciting a polyclonal T cell response against tumor cells. Interestingly, activation can 
occur independent of normally required co-stimulating molecules, like CD28 or IL-2, even in 
previously un-stimulated naive T cells (Figure 4) (80, 81).  
 
Figure 4: BiTEs bypass elements of regular T cell activation  
(A) Via its unique T cell receptor (TCR) a T cell recognizes its target cell through specifically 
binding to the major histocompatibility complex (MHC) I loaded with a foreign peptide. In con-
cert with other stimulating signals, like CD28, this binding leads to the formation of a cytolytic 
synapse that mediates apoptosis of the tumor cell by the release of toxins. (B) BiTEs bypass the 
MHC-peptide restriction of T cells and provide a link between any T cell and a tumor cell via 
binding to the CD3e antigen and a selected tumor surface antigen. This induces the formation of 
a functional cytolytic synapse indistinguishable from a physiologically induced one and leads to 
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Offner et al. showed that the BiTE-induced cytolytic immunological synapse was indistin-
guishable in composition, sub-domain arrangement and size from regular MHC I-peptide 
(erbB2) induced synapses and was formed even with MHC I negative cells. Granules with the 
typical signaling molecules Phosphokinase Cθ (PKCθ), Leukocyte specific protein tyrosine 
kinase (Lck), CD3 and secretory molecules granzyme A, B and perforin were distributed to 
the immunological synapse. Markers of the immunological synapses like CD3, intracellular 
adhesion molecule–1 (ICAM-1), leukocyte functional antigen 1 (LFA1), VAV1 and talin 
showed similar surface distribution. In both cases, CD45 was excluded from the synapse (82). 
Of note, no activation of T cells by BiTEs was seen in the absence of target cells, implying 
that for TCR mediated activation binding to a second binding partner was crucial. Elimination 
of target cells was shown to be restricted only to cells expressing the selected antigen (79). 
Hoffmann et al. demonstrated that BiTEs recruit T cells to multiple rounds of target cell 
elimination, which might explain the high biological activity of BiTE antibodies already at 
very low concentrations [10-100 pg/ml] and at very low ratios of T cells to target cells (1:10) 
(66).  
The binding affinities of BiTEs to CD3e have dissociation constants (KD) of approximately 
10-7 M whereas the affinity to the tumor antigen is >10-100 times higher with KD in the 
nanomolar range. This means that BiTEs cover the surface of antigen positive target cells and 
turn them to a T cell activating matrix rather than “arming” polyclonal T cells with single 
chain antibodies specific for the tumor antigen (66). The clustering of BiTEs on the target cell 
surface results in gain of avidity for subsequent CD3 binding.  
With their properties, BiTE antibodies are a new class of bispecific antibodies that could ef-
fectively perform in the conditions typically found in the in vivo tumor environment such as 
low T cell numbers, immune-suppression and low drug concentrations (83). First clinical data 
of phase I/II clinical trials in Non-Hodgkin’s lymphoma patients with MT103, a BiTE recog-
nizing CD19 positive lymphoma cells, confirm the potency of the BiTE format. Partial or 
complete tumor regression was found in all seven patients treated at a dose level of 0.06 
mg/m2/day (84).  
2.2.3 MT110 and muS110 
MT110 is a bispecific single chain antibody of the BiTE format, recognizing the tumor anti-
gen EpCAM. The KD for human EpCAM is 13 +/- 0.25 nM and 100 +/-15 nM for human 
CD3e (85). It is constructed to redirect T cells to lyse EpCAM positive tumor cells. In vitro, 
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MT110 shows specific lysis of a large panel of EpCAM positive human target cell lines, e.g. 
KatoIII or SW480, over a low nanomolar range. The half maximal lysis [EC50] of target cells 
by human peripheral blood mononuclear cells (PBMC) is at a concentration of 0.65 +/- 0.5 
ng/ml (85). MT110 mediates target cell death independent from co-stimulatory signals, as it 
was able to redirect unstimulated human PBMC to lyse rodent cells transfected with human 
EpCAM. The same cells transfected with the mouse orthologe were not killed, which demon-
strates the high specificity of the MT110-induced anti-tumor activity (79). In the presence of 
appropriate target cells MT110 induces polyclonal T cell activation, resulting in a dose de-
pendent up-regulation of the activation marker CD69 and CD25, T cell proliferation, induc-
tion of cytokine release and granzyme synthesis (79). Although all CD4+ and CD8+ T cells 
were redirected to lyse target cells, closer analysis revealed a major contribution of CD8+ ef-
fector memory cells.  
The in vivo anti-tumor capacity of MT110 was tested in immune deficient NOD/SCID mice. 
Its mode of action relies completely on the presence of human T cells, and tumor cells as well 
as human T cells can be grafted to these mice. However, unlike tumor cells, T cells have only 
a limited life span in these animals, which handicaps the evaluation of MT110´s efficacy 
against established tumors. In a model inoculating subcutaneously a mixture of SW480 cells 
and naive human PBMCs (effector to target = 1:1), as few as five daily intravenous injections 
of 1 µg MT110 per animal were sufficient, to completely prevent tumor outgrowth. Five daily 
doses of 10 µg per animal were able to eradicate already established tumors of ~ 0.1 mm3. In 
a more physiological model pieces of metastatic tumor tissue from ovarian cancer patients 
were transplanted to NOD/SCID mice. Schlereth et al. showed that using solely the tumor-
resident T cells as effector cells five daily doses of 5 µg per animal MT110 prevented or at 
least slowed down the growing of the tumor grafts (86). 
MT110 is specific for human targets and has no cross-reactivity to other species except chim-
panzee. Therefore, toxicological studies would be only possible in chimpanzees, which are 
limited due to strict animal protection rights, ethical considerations and huge costs. Develop-
ment of the mouse specific surrogate muS110 for extended animal toxicology and efficacy 
studies in immune competent animals was therefore mandatory. MuS110 binds to the mouse 
orthologes of EpCAM and CD3 and mediates death of mouse tumor cells. A prerequisite to 
this attempt was the good comparability of mouse and human. A histo-pathological analysis 
of multiple mouse and human tissues revealed largely overlapping expression patterns of Ep-
CAM, which was primarily seen on epithelial cells (Table 2).  
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Table 2 Comparison of EpCAM staining patterns of human and mouse tissues (Amann et al. 
(85))  
Sections of fresh frozen mouse and human tissues were stained. All slides were evaluated by a certi-
fied pathologist to ensure that the quality of staining was sufficient for interpretation. The relative 
density of positive cells and the intensity of staining was graded on the following scale: 0 = no labeled 
cells; 1+ = light staining and/or occasional cells/types of cells “Minimal”; 2+ = light-medium staining 
and/or small numbers of cells/types of cells “Mild”; 3+ = moderate staining and/or medium numbers 
of cells/types of cells “Moderate” and 4+ = dark staining and/or large numbers of cells/types of cells 
“Marked”. Mouse and human tissues both expressing EpCAM are highlighted by mint color; unique 
EpCAM staining is highlighted in pink.  
Antibodies Anti-murine EpCAM Isotype Control Anti-human EpCAM Isotype Control
Concentration 1 µg/mL 1 µg/mL 1 µg/mL 1 µg/mL
Pos. ctrl [CHO/Ep-CAM] 4 0 4 0
Neg. ctrl [CHO] 0 0 0 0
Adrenal 0 0 1 0-1
Bladder 2 0 3 0
Bone Marrow 2 2 2 2
Breast/Skin 2 1 2-3 0
Cerebellum 0 0 0-1 0
Cerebral cortex 0 0 0-1 0
Colon 4 0-1 3 0-2
Endothelium 0 0 0 0
Eye 2 0 2 0
Fallopian Tube 3 0-1 2-3 0-1
GI Tract 4 2 3 0-1
Heart 0 0 0-1 0
Kidney 3 2 4 1
Liver 3 2 3 0-1
Lung 2 1 4 0-1
Lymph Node 2 1 1-2 0-1
Ovary 0 0 0-1 0-1
Pancreas 3 0 4 0-1
Pituitary 2-3 0 4 0
Prostate 3 0 3 0
Spinal Cord 0 0 0-1 0
Spleen 1 1 1-2 1-2
Striated muscle 0 0 0 0
Testes 0 0 3 0
Thymus 2 1 2-3 0-1
Thyroid 3-4 0 4 0-1
Tonsil - - 2-3 1
Ureter/uterine Horn 3 1 1-2 0-1
Vagina/cervix 3 1-2 1-2 0-1
Mouse Tissues Human Tissues 
 
 




In both species, EpCAM was largely confined to the cell surface, showed no difference with 
respect to polarized expression on epithelial cells, and stained a similar proportion of cells in 
tissues. Human epithelia of breast, bladder, colon, intestine, kidney, bile ducts, lung, pancreas, 
pituitary, prostate, thyroid and uterus expressed EpCAM, and so did all respective mouse tis-
sues. Likewise, certain tissues were not stained with either human or mouse EpCAM-specific 
mAbs, including bone marrow, cerebrellum, cerebral cortex, endothelium, heart, ovary, spinal 
cord, spleen and striated muscle. The only differences in EpCAM expression between man 
and mouse were noted for adrenal gland and testis tissues, which were stained in human but 
apparently not in mouse tissue samples (85). The amino acid sequence homology between 
human and mouse EpCAM is 82 % (87). 
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3 AIM OF THIS STUDY  
As MT110 is only specific for human targets, the mouse specific surrogate muS110 was de-
veloped for extended toxicology and efficacy studies in immune-competent animals. MuS110 
binds to the mouse orthologes of EpCAM and CD3 and mediates death of mouse EpCAM 
positive tumor cells. 
The following study describes first the in vitro characterization of muS110 and thereafter the 
in vivo evaluation of its efficacy and tolerability. Thereby, the impact of muS110 on healthy 
EpCAM+ tissues, EpCAM+ tumor cells and T cells was addressed in immune–competent 
mice. Special emphasize was laid on the analysis of immediate effects on T cells, but also on 
its impact on T cell effector functions after repeated and prolonged administration. Addition-
ally, glucocorticoids were tested as a way to increase the therapeutic window of muS110. 
Thereby, potential changes in systemic tolerability as well as T cell effector functions were 
analyzed after glucocorticoid co-treatment. Lastly, these findings were implemented in differ-
ent in vivo tumor models, to evaluate the anti-tumor efficacy of muS110 and improve its 
therapeutic window.    
The outread of all described experiments was used for the pre-clinical development of 
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4 MATERIAL AND METHODS 
4.1 Material 
4.1.1 Cell lines 
All non-transfected cell lines were either obtained by the American type culture collection 
(ATCC, Manassas, USA) or from “Deutsche Sammlungen von Mikroorganismen und 
Zellkulturen GmbH (DMSZ, Braunschweig, Germany). All transfected cell lines were pro-
vided by the department for BiTE research. Cells were either transfected with full length 
mouse EpCAM (NCBI entrez Nucleotide, http://www.ncbi.nlm.nih.gov/sites/entrez, 
NM_008532) or full length human EpCAM (NCBI entrez Nucleotide, 
http://www.ncbi.nlm.nih.gov/sites/entrez, NM_002354).  
CHO dHFR- (ATCC) 
CHO dHFR- cells are Chinese hamster ovary cells isolated from healthy cricetulus griseus. 
They are of epithelial origin and grow semi-adherent. These cells are deficient in dihydro-
folate reductase (dHFR) and die in the absence of adenosine and thymidine. Cells were culti-
vated in HyQ PF CHO liquid soy medium (Thermo Scientific) supplemented with 10 µg/ml 
adenosine (Sigma-Aldrich), 10 µg/ml 2´desoxyadenosine (Sigma-Aldrich) and 10 µg/ml 
thymidine (Sigma-Aldrich) at 37°C, 95% humidity and 5% CO2. 
CHOmuEpCAM+, CHOhuEpCAM+ 
CHOmuEpCAM+ cells are CHO dHFR- cells (ATCC) transfected with the eukaryotic expres-
sion vector pEF-dHFR containing full length mouse EpCAM. CHOhuEpCAM+ are CHO 
dHFR- cells (ATCC) transfected with the eukaryotic expression vector pEF-dHFR containing 
full length human EpCAM. The pEF-dHFR vector encodes the dihydrofolate reductase and 
enables successfully transfected CHO dHFR- cells to grow without exogenous nucleoside 
supply (68). These semi-adherent cells were cultivated in pure HyQ PF CHO liquid soy me-
dium (Thermo Scientific) for selection. For gene amplification 20 mM of the dHFR inhibitor 
methotrexate (MTX, Sigma-Aldrich) was added. Cells were grown at 37°C, 95% humidity 
and 5% CO2. 
4T1 (ATCC) 
4T1 cells were established of the 410.4 mammary gland tumor from mus musculus (BALB/c). 
These cells of epithelial origin are tumorigenic in NOD/SCID and BALB/c mice and produce 
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highly metastatic tumors that can metastasize to lung, liver, lymph nodes and brain while the 
primary tumor is growing in situ.  The resulting disease closely mimics human breast cancer 
and is an animal model for stage IV human breast cancer. The cells show a natural expression 
of mouse EpCAM. The adherent cells were cultivated in RPMI 1640 medium w 2.0 g/l Na-
HCO3 (Biochrome AG) supplemented with 10% FCS (Gibco) and 1% penicillin/streptomycin 
(Biochrome AG) at 37°C, 95% humidity and 5% CO2.  
B16F10muEpCAM+  
B16F10muEpCAM+ cells are B16F10 cells (ATCC) transfected with the eukaryotic expres-
sion vector pEFNEO containing full length mouse EpCAM. The B16F10 cell line was estab-
lished of skin melanoma from mus musculus (C57BL/6). The fibroblast-like cell line shows 
adherent growth and is tumorigenic in NOD/SCID and C57BL/6 mice. The cells were culti-
vated in RPMI 1640 medium w 2.0 g/l NaHCO3 (Biochrome AG) supplemented with 10% 
FCS (Gibco) and 1 mg/ml G418 (PAA) for selection at 37°C, 95% humidity and 5% CO2. 
CT26muEpCAM+  
CT26muEpCAM+ cells are CT26.WT cells (ATCC) transfected with the eukaryotic expres-
sion vector pEFNEO containing full length mouse EpCAM. The CT26.WT cell line was es-
tablished of an N-nitroso-N-methylurethane induced, undifferentiated colon carcinoma from 
mus musculus (BALB/c). The adherent growing cells are tumorigenic in NOD/SCID and 
BALB/c mice. The cells were cultivated in RPMI 1640 medium w 2.0 g/l NaHCO3 (Bio-
chrome AG) supplemented with 10% FCS (Gibco) and 1 mg/ml G418 (PAA) for selection at 
37°C, 95% humidity and 5% CO2. 
CTLL-2 (ATCC) 
The CTLL-2 cell line was established of a clone of CTLs derived from mus musculus 
(C57BL/6). The suspension cells  were cultivated in ISCOVE medium (Biochrome AG) sup-
plemented with 10% FCS (Gibco), 0.1 mg/l penicillin/ streptomycin (Sigma-Aldrich), 50 nM 
2-mercaptoethanol (Invitrogen) and 5.5 ng/l recombinant human IL-2 (Chiron Corp. Lim.) at 
37°C, 95% humidity and 5% CO2. 
Kato III (DSMZ) 
The Kato III cell line was established of gastric carcinoma cells from pleural effusion, supra-
clavicular and axillary lymph nodes and Douglas cul-de-sac from a 55 year old Asian male. 
The cells show adherent growth and natural expression of human EpCAM. They were culti-
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vated in RPMI 1640 medium w 2.0 g/l NaHCO3 (Biochrome AG) supplemented with 10% 
FCS (Gibco) and 1% penicillin/streptomycin (Biochrome AG) at 37°C, 95% humidity and 5% 
CO2. 
4.1.2 Mouse strains 
All animals were between 6 to 12 weeks of age and were obtained either from Charles River 
Laboratories (Sulzfeld, Germany) or the Institut for Immunology (Munich, Germany). 
BALB/c (Charles River Laboratories and Institute for Immunology) 
BALB/c mice are immune-competent, inbred laboratory mice that develop preferentially T 
helper cell type 2 (TH2) responses with release of typical TH2 cytokines like IL-4 and IL-10, 
are more susceptible to intracellular parasite infection, have a higher tumor incidence and are 
more resistant to the induction of autoimmune diseases compared to C57BL/6 mice.    
C57BL/6N (Charles River Laboratories and Institute for Immunology) 
C57BL/6N mice are immune-competent, inbred laboratory mice which show preferentially 
TH1 dominated cellular immune response and release of typical TH1 cytokines like IFN-g and 
IL-2 upon challenge with pathogens.    
C3H/HeJ (Charles River Laboratories) 
The inbred strain shows resistance to endotoxin due to a mutation of the toll-like receptor 4 
gene. This impairs the activation of cells of the innate immunity by lipopolysaccharide. 
C3H/HeJ mice are highly susceptible to infection by gram-negative bacteria and show de-
layed chemokine production, impaired nitric oxide generation and attenuated cellular immune 
responses. 
CD-1 (Charles River Laboratories) 
The CD-1 strain is an outbreed mouse line derived from Swiss mice and has a high degree of 
genetic variation. They are most often used in toxicology and carcinogenicity bioassays. 
4.1.3 Reagents, media and enzymes 
2 Desoxyadenosine  Sigma-Aldrich 
2 Mercaptoethanol (50 mM) Gibco 
Adenosine Sigma-Aldrich 
Ammonium Chloride (NH4) Sigma-Aldrich 
Biocoll Separating Solution (r = 1.079 g/ml) Biochrome AG 
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Bovine Serum Albumine (BSA) V Paessel & Lorei 
Brefeldin A (Penecillium Brefeldianum)  Sigma-Aldrich 
Cell Dissociation Solution Sigma-Aldrich 
DELFIA® BATDA Solution  Wallac Oy 
DELFIA® Europium Solution  Wallac Oy 
DELFIA® Lysis Buffer  Wallac Oy 
Dexamethasone Sigma-Aldrich 
Disodium Hydrogenphosphate (Na2HPO4 * (H2O)2 ) Merck 
Eosin G Roth 
Etylene-di-nitro-tetra-acetic-acid (EDTA) Sigma-Aldrich 
G418 Sulphate PAA 
Heat inactivated Fetal Calf Serum (FCS) Gibco 
Hepes Buffer (1 M) Sigma-Aldrich 
Human soluble EpCAM Micromet AG 
Hydrochlorid Acid 1 M (HCl) Merck 
HyQ PF CHO Liquid Soy Thermo Scientific 
Ionomycin, Calcium salt Sigma-Aldrich 
Iscove medium Biochrome AG 
Isoflurane CP Pharma 
Isotonic NaCl solution Freeflex 
Para-nitro-phenyl-phosphate substrate Sigma-Aldrich 
Phosphate Buffered Saline (PBS), Dulbeco´s Gibco/ Invitrogen 
Phorbol Myristate Acetate (PMA) Sigma-Aldrich 
Potasium-di-hydrogen-phosphate (KH2PO4) Merck 
Methotrexate  Sigma-Aldrich 
Methylprednisolone (mPDS) Sigma-Aldrich 
MSD Blocker A  MSD 
MSD Reading buffer MSD 
Mouse soluble EpCAM Micromet AG 
Neutral buffered Formalin (10%) Sigma-Aldrich 
Non Essential Amino Acids (NEA) Biochrome AG 
Penicillin/ Streptamycine (10.000 U/l) Biochrome AG 
Phenol Red (0.5% (w/v)) Biochrome AG 
Potassium Chloride (KCl)   Merck 
Propidium Iodide (PI) Sigma-Aldrich 
Sodium Azide (NaN3) Merck 
Sodium Chloride (NaCl) Merck 
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Sodium Heparin  (25000 I.E./5ml)  Braun 
Sodium Hydroxide (1 M; NaOH) Merck 
Sodium Pyruvat (100 mM) Sigma-Aldrich 
Sulfuric Acid (2M, H2SO4) Merck 
Recombinant human IL-2 (rhuIL-2) Chiron Corp. Lim. 
RPMI 1640 medium  Gibco 
RPMI 1640 medium + L-GLN + 25 mM Hepes  Gibco 
RPMI 1640 medium w 2.0 g/l NaHCO3 low endotoxin  Biochrome AG 
Thymidine  Sigma-Aldrich 
Tissue Tek O.C.T. Compound Sakura 
Trypsin/EDTA Gibco 
Tween 20 Sigma-Aldrich 
Xylazine Hydrochloride (2%) CP Pharma 
  
4.1.4 Kits 
BD Cytofix/Cytoperm Kit BD Bioscience 
Caspase-Glo 3/7 Assay Promega 
Dynabeads Mouse CD3/CD28 T Cell Expander Invitrogen (Dynal) 
Dynal Mouse T Cell Negative Isolation Kit Invitrogen (Dynal) 
Dynal T Cell Negative Isolation Kit Ver. II Invitrogen (Dynal) 
Human T Cell Enrichment Column R&D Systems 
Human TH1/TH2 CBA Kit BD Bioscience 
Human/mouse TGF-ß1 ELISA Ready Set Go!  Natutec (eBioscience) 
Mouse GM-CSF CBA Flex- Set (Bead A4) BD Bioscience 
Mouse IFN-g CBA Flex- Set (Bead A4) BD Bioscience 
Mouse IL-2 CBA Flex- Set (Bead A5) BD Bioscience 
Mouse IL-3 CBA Flex- Set (Bead A4) BD Bioscience 
Mouse IL-4 CBA Flex- Set (Bead A7) BD Bioscience 
Mouse IL-6 CBA Flex- Set (Bead B4) BD Bioscience 
Mouse IL-10 CBA Flex- Set (Bead C4) BD Bioscience 
Mouse Inflammation CBA Kit BD Bioscience 
Mouse Regulatory T Cell Staining Kit#2 Natutec (eBioscience) 
Mouse/Rat Soluble Protein Master Buffer Kit BD Bioscience 
Mouse T Cell Enrichment Columns R&D Systems 
Mouse TH1/TH2 CBA Kit BD Bioscience 
Mouse TNF CBA Flex- Set (Bead C8) BD Bioscience 
PKH-26 Red Fluorescent Cell Linker Kit Sigma 
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ToxiLight Bioassay Kit Cambrex 
TruCount Tubes BD Bioscience 
Vybrant CellTracerTM CFSE Cell Proliferation Kit Molecular Probes 
4.1.5 Buffer 
Erythrolysis buffer  PBS (pH = 7.4) 
 155 mM  NH4  150 mM NaCl 
   10 mM KHCO3        3 mM KCl 
 100 µM EDTA      8 mM Na2HPO4 
       2 mM KH2PO4 
In ddH2O   In ddH2O  
     
FACS Buffer   Cytotoxicity Media 
1% (v/v) (v/v)      FCS          1 mM NEA 
0.05 % (w/v) NaN3  10 mM Hepes Buffer 
   50 µM 2-b-Mercaptoethanol 
   1% (v/v) Sodium Pyruvat 
   100 U/ml Penicillin/ Streptomycin 
In PBS   In RPMI 1640 w 2.0g/l NaHCO3 
    
4.1.6 Antibodies 
For FACS analysis  
Rat anti-mouse CD3 e (KT3; #CBL1317) Cymbus Biotech. 
Hamster anti-mouse CD3 e (145/2C11; #553063, #553058)  BD Bioscience  
Rat anti-mouse CD4 (RM4-5; #553051, #553046) BD Bioscience 
Rat anti-mouse CD4 (RM4-5; #35-0042-82) Natutec 
Rat anti-mouse CD4 (H129.19; #553653) BD Bioscience 
Rat anti-mouse CD4 (GK1-5; #11-0041-86) Natutec 
Rat anti-mouse CD8a (53-6.7; #553030, #553032, #553034, #553035) BD Bioscience  
Rat anti-mouse CD11b (M1/70; #550993) BD Bioscience  
Rat anti-mouse CD11b (M1/70; #25-0112-82) Natutec 
Hamster anti-mouse CD11c (HL3; #553802) BD Bioscience 
Hamster anti-mouse CD11c (N418; #27011482) Natutec 
Rat anti-mouse CD19 (1D3; #557398, #557399) BD Bioscience 
Rat anti-mouse CD19 (MB19-1; #17-0191) Natutec 
Rat anti-mouse CD25 (3C7; #553075) BD Bioscience  
Rat anti-mouse CD25 (PC61, #557192) BD Bioscience  
Rat anti-mouse CD25 (PC61.5; #25-0251) Natutec 
Rat anti-mouse CD44 (IM7;#553134) BD Bioscience  
Rat anti-mouse CD45 (30-F11; #559864, #553082) BD Bioscience  
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Rat anti-mouse CD45R/B220 (RA3-6B2,#553091, #553092) BD Bioscience 
Rat anti-mouse CD45R/B220 (RA3-6B2, #25-0452) Natutec 
Rat anti-mouse CD49b/Pan-NK Cells (DX5; #553857, #553858) BD Bioscience 
Hamster anti-mouse CD62L (MEL-14; #553150) BD Bioscience  
Hamster anti-mouse CD69 (MEL-14; #55237, #553236, #552879) BD Bioscience  
Hamster anti-mouse CD127 (SB/199, #552543) BD Bioscience  
Rat anti-mouse CD152 (UC10-4F10-11; #12-1522-81) Natutec 
Rat anti-mouse EpCAM (G8.8; #552370, #624048) BD Bioscience  
Rat anti-mouse FoxP3 (FJK-16s, #11-5773-82, #2528545) Natutec 
Rat anti-mouse Granzyme B (16G6; #2528545) Natutec 
Rat anti-mouse IFN-g ( XMG1.2; #554412 ) BD Bioscience 
Rat anti-mouse IL-10 (JES5-16E3; #1899932) Natutec 
Rat anti-mouse Ly-6C (AL-21; #553104) BD Bioscience  
Rat anti-mouse Ly-6G (RB6-8C5, #553126) BD Bioscience  
Isotype controls  
Hamster IgG1k  (A19-3; #553971, #553972 ) BD Bioscience 
Hamster IgG1l  (G2352356; #554711) BD Bioscience 
Rat IgG1 (R3-34; #554686)  BD Bioscience 
Rat IgG1 (A110-1; #554684)  BD Bioscience 
Rat IgG2a k (R35-95; #554688, #555844, #554690) BD Bioscience 
Rat IgG2b k (A95-1; #553988, #553989, #553991) BD Bioscience 
Rat IgM (pooled mouse Ig; #553943)  BD Bioscience 
Blocking antibodies  
Rat anti-Mouse CD16/CD32/Fcg III/II Receptor Block BD Bioscience 
For ELISA  
Mouse anti-Pentahistidine conjugated with Biotin (#3440) Qiagen 
Streptavidin conjugated with Horse Radish Peroxidase (#P0397) Dako 
Streptavidin conjugated with Phycoerythrin (#554061) BD 
Streptavidin conjugated with MSD SULFO-TAG (#R32AD-1) MSD 
  
4.1.7 BiTEs 
All BITEs were provided by the department of BiTE research (Micromet). 
MT110 was engineered by recombinant DNA technology using the gene sequence of an anti-
body specific for human EpCAM (clone 5-10) and human CD3 (clone diL2K) (88).  To gen-
erate muS110, the gene sequence of an antibody specific for mouse CD3 (clone CD3-1) and 
an antibody specific for mouse EpCAM (clone G8.8) was used. To generate the hyS110 con-
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trol antibody, gene sequences of antibodies specific for mouse CD3 (clone CD3-1) and human 
EpCAM (clone 5-10) were used. For engineering of the muMEC14 control BiTE, the gene 
sequence of an antibody specific for mouse CD3 (clone CD3-1) was used as effector cell rec-
ognizing scFv. The target cell binding moiety was directed against the herbicide Mecoprop 
comprising of a structure completely absent in the human or mouse system. However, the 
control BiTE was proven to be fully functional in the respective setting. The specificity and 
parental offspring of all used BiTEs is summarized in Table 3.   
The hybridoma producing rat anti-mouse EpCAM mAb was obtained from the Developmen-
tal Studies Hybridoma Bank, developed under the auspices of the NICHD and maintained by 
the Department of Biological Sciences (University of Iowa). The mouse variable domains 
recognizing human EpCAM were obtained by phage display. The gene sequence for the scFv 
binding moiety to Mecoprop (clone Mec14) was retrieved from Li et al.(89). Human T helper 
cell epitopes and MHC class II anchor amino acids were removed from the anti-human CD3 
antibody (L2K) resulting in a deimmunized antibody (diL2K) (90).  
The arrangement of the variable domains for all used BiTEs is VL – VH for the N-terminal 
scFv and VH – VL for the C-terminal scFv. All used BiTEs are equipped with a HIS-6 Tag on 
the C-terminal end of the protein for purification and detection. Sequences encoding the vari-
able domains of the respective antibodies were amplified and modified as described by Mack 
et al. (68). Expression plasmids were transfected into dHFR-deficient CHO cells and protein 
expression was performed as described by Kaufman et al. (91). All BiTEs were purified from 
cell culture supernatants as described by Kufer et al. (80). 
Table 3: Specificity and parenteral offspring of used BiTEs 
Target Target Reactivity CD3 Reactivity Name 
     Parent Specificity     Parent Specificity 
MT110 huEpCAM 5-10 Human diL2K Human 
muS110 muEpCAM G8.8 Murine CD3-1 Murine 
HyS110 huEpCAM 5-10 Human CD3-1 Murine 
muMec14 Mecoprop Mec14 Herbicide CD3-1 Murine 
huMec14 Mecoprop Mec14 Herbicide diL2K Human 
      
4.1.8 Equipment 
Axiovert 25 microscope  Carl Zeiss 
DAS-6007 scanner PLEXX 
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DM-FZ 30eGLumix digital camera Panasonic 
Dynal MPC-1 magnetic separator Invitrogen (Dynal) 
ELISA reader PowerWave select X  Bio Tek Instruments Inc. 
ELISA washer Molecular Devices 
FACS Calibur 4CA  Becton Dickinson 
FACS Canto II  Becton Dickinson 
Heating box VetTech solution 
Hemacytometer Marienfeld 
Hematokrit sealing kit  Heiland 
Heraeus Heracell incubator Kendro Laboratory Products GmbH 
Heraeus Herasafe HS 12 flow Kendro Laboratory Products GmbH 
Heraeus Multifuge 3 S Kendro Laboratory Products GmbH 
IPTT-300 transponder PLEXX 
Isotec3 isoflurane evaporator Völker GmBH 
Spectra Fluor Plus Fluorometer Tecan 
MiniCAPS capillaries (NaHep 5 µl) Hirschmann Laborgeräte 
Microtainer  SST tubes BD Bioscience 
Micro hematocrit centrifuge Hawksley 
Mikro hematokrit capillaries (NaHep, 50 µl)         Heiland 
Mikro 20 Typ: 2004 centrifuge Hettich 
MoFlo high performance cell sorter  DAKO 
MS1 minishaker  IKA® Werke GmbH 
MSD high bind plate MSD 
MXX - 212 balance  Denver instruments 
Leucosept tubes Greiner 
Omnican 0.3x12mm 0.01-1 ml syringe Braun 
Sektor imager 2400 MSD 
Sterican100 0.05x16mm 25Gx5/8“ syringe needle Braun 
Victor Multilabel counter  Wallac Oy 
WB4 45 waterbath Memmert GmbH+Co.KG 
4.1.9 Software  
DAS Host software PLEXX 
Prism 4 GraphPad Software 
Cell Quest Pro Becton Dickinson 
FACS Diva software Becton Dickinson 
FCAP Array software  SoftFlow 
WinNonlin Professional 4.1  Pharsight Corporation 
 - MATERIAL AND METHODS - 27 
 
4.2 Methods 
4.2.1 Cell culture 
All cells were maintained at 37°C in an atmosphere containing 5% CO2 in the indicated me-
dia. The cell count was determined using a hemacytometer (Marienfeld). The vitality of cells 
was determined using 0.5 % (v/v) isotonic EosinG solution (Roth). All cells were split three 
times a week 1:4 to 1:10. The suspension cells CHO dHFR-, CHOmuEpCAM+, CHOhuEp-
CAM+ and CTLL-2 were split by replacing the excess amount of cell suspension with fresh 
media. To detach the adherent cell lines 4T1, B16F10muEpCAM+, CT26muEpCAM+ and 
KatoIII, the supernatant was removed, the cell culture flask was rinsed with PBS (Gibco) and 
cells were incubated for 5 to 10 minutes in PBS (Gibco) containing 1% (v/v) Trypsin/EDTA 
solution (Gibco) at 37°C. Cells were detached by gently tapping the flask. Excess Trypsin was 
inactivated by addition of FCS (Gibco). Cells were washed with media and spun down by 
centrifugation in a Heraeus Multifuge 3 (Kendro Laboratory Products GmbH) at 300xg for 5 
minutes at room temperature (RT). The cell pellet was resolved in media and the respective 
amount was transferred back into the cell culture flask containing fresh media.  
4.2.2 Preparation of leukocytes 
In general, centrifugation was performed at 500xg for 5 min at RT using a Heraeus Multifuge 
3 (Kendro Laboratory Products GmbH). If not otherwise indicated samples were filled up 
with indicated media for washing and supernatant was discarded after centrifugation. The cell 
count was determined using a hemacytometer (Marienfeld). The vitality of cells was deter-
mined using 0.5 % (v/v) isotonic EosinG solution (Roth). 
4.2.2.1 Isolation of PBMC from human and mouse blood 
PBMCs were isolated by Ficoll density gradient centrifugation with leucosept tubes (Greiner 
Bio one). Leucosept tubes, containing a porous high-density polyethylene barrier or "frit", 
were used to facilitate the layering process. The Biocoll separation solution (Biochrome AG) 
containing Ficoll in a density of 1.079 g/ml was spun down under the frit. Heparinized blood 
was diluted 1:1.5 with PBS (Invitrogen) to optimize separation efficacy. The Biocoll was 
over-laid by diluted blood. Centrifugation for 30 minutes at 400xg and RT in a Heraeus Mul-
tifuge 3 (Kendro Laboratory Products GmbH) led to the formation of following layers (from 
top to bottom): plasma and other constituents, a “buffy coat” containing PBMC, the Ficoll-
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plaque, and an erythrocyte/granulocyte pellet. The buffy coat fraction was transferred to a 
new tube and washed three times with cytotoxicity media (see 4.1.5).  
4.2.2.2 Isolation of mouse leukocytes from spleen and lymph nodes 
Isolation was performed in cytotoxicity media (see 4.1.5). The spleen or respective lymph 
nodes were removed and stored in cytotoxicity media on ice until usage. The organs were 
homogenized grinding them through a cell strainer (70 µm, BD) with a plunger of a syringe. 
The cell suspension was washed once with media and the pellet was resolved in erythrolysis 
buffer (see 4.1.5). Erythrolysis was performed for 10 min at 37°C in a water bath. Afterwards 
cells were washed twice and filtered through a cell strainer (70 µm, BD) to remove conglom-
erated, dead cell debris.  
4.2.2.3 Enrichment of CD3 cells 
For enrichment of untouched T cells mouse T cell enrichment columns (R&D Systems) were 
used with splenocytes. The T cell enrichment column contains glass beads covered with anti-
IgG antibodies, to retain B cells, and with an IgG cocktail to retain monocytes binding to their 
Fc receptors. The resulting column eluate contains highly enriched CD3+ T cells with a purity 
of 81-88%. Of note, NK cells were not removed by this method.  
0.5 to 2*108 cells were resolved in provided washing buffer and were loaded onto columns 
pre-equilibrated with washing buffer. To allow adherence of B cells and monocytes, cells 
were incubated for 10 min at RT followed by elution with washing buffer. The resulting en-
riched T cell fraction was washed twice with cytotoxicity media (see 4.1.5).   
4.2.2.4 Negative isolation of CD3 cells 
To obtain more pure untouched T cells, Dynal negative T cell isolation kit ver II for the hu-
man setting and Dynal mouse T cell negative isolation kit (both Invitrogen) for the mouse 
setting were used. In a first step all cells with exception of T cells were labeled with a cocktail 
of monoclonal antibodies. In a second step all labeled cells were bound with antibodies to 
magnetic beads. And in a third step all magnetic beads and therefore also bound non-T cell 
were removed using the MPC-1 magnetic separator (Dynal). The resulting bead free super-
natant contains T cells in a purity of > 99 %.  
The isolation was performed in PBS (Gibco) containing 1% FCS (Invitrogen) and 2 mM 
EDTA (Sigma Aldrich), which is further termed Dynal buffer. Prior to usage Dynal magnetic 
depletion beads were washed with Dynal buffer. For that the recommended amount of beads 
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was transferred to a 15 ml tube (Greiner), which was filled up with Dynal buffer. The tube 
was incubated for 2 minutes on the MPC-1 magnetic separator (Dynal), the supernatant was 
removed and the beads were solved with Dynal buffer in the initial bead volume.  Each 1*107 
cells were resolved in 100 µl Dynal buffer and stained with 20 µl provided antibody cocktail 
in the presence of 20 µl FCS (Invitrogen) for 20 minutes at 4°C. Cells were washed twice 
with Dynal buffer to remove excess antibodies. Afterwards cells were resuspended in 200 µl 
(human setting) and 100 µl (mouse setting) provided magnetic depletion beads, respectively, 
and samples were filled up to 1 ml total volume with Dynal buffer. Antibodies were allowed 
to bind to Dynal beads for 15 minutes at RT. Samples were filled up to 10 ml with Dynal 
buffer and were incubated for 2 minutes on the MPC-1 magnetic separator (Dynal). The su-
pernatant containing untouched T cells was transferred to another tube and the magnetic sepa-
ration was repeated once again to improve purity. Afterwards cells were washed once with 
cytotoxicity media (see 4.1.5).   
4.2.2.5 Stimulation of T cells  
T cells were in vitro stimulated using the Dynabeads mouse CD3/CD28 T cell expander (Invi-
trogen). Anti-CD3 and anti-CD28 antibodies are coupled to the same Dynabeads, mimicking 
in vivo stimulation by antigen presenting cells. The simultaneous presentation of optimal 
stimulatory signals to the T cells in culture allows their full activation and expansion. 
The stimulation was conducted in cytotoxicity media containing 10 - 100 U/ml rhIL-2. T cells 
were seeded with a density of 1x106 T cells/ml. 10 µl washed bead solution per each 1*106 T 
cells was added to the T cell culture. Cells were incubated at 37°C, 5%CO2 for 3 to 4 days 
whereby 10-100 U/ml rhIL-2 was added daily. Stimulation of T cells with IL-2 and anti-CD3 
antibodies led to internalization of surface CD3. To guaranty proper CD3 surface expression, 
T cells were therefore washed with cytotoxic media and were allowed to recover overnight in 
a density of 0.5*106 cells/ml prior to cytotoxicity assays.  
4.2.3 Cell staining and FACS analysis 
In general, centrifugation of cells was performed at 500xg for 5 min at RT using a Heraeus 
Multifuge 3 (Kendro Laboratory Products GmbH). If not otherwise indicated samples were 
filled up with indicated media for washing and supernatant was discarded after centrifugation. 
For compensation single stains of each antibody present in the staining cocktail were per-
formed. After staining cells were washed once with FACS buffer and were either resolved in 
60 µl FACS buffer for analysis on a FACSCantoIITM flow cytometer running FACSDivaTM 
 - MATERIAL AND METHODS - 30 
 
Software (all BD Bioscience) or they were resolved in 200 µl FACS buffer and were trans-
ferred to U tubes (Micronics) for analysis on a FACSCaliburTM flow cytometer running Cell 
Quest Pro Software (all BD Bioscience). To determine cell vitality 1 µg/ml PI (Sigma) was 
added to samples directly before measurement.  
4.2.3.1 FACS analysis of cell surface proteins 
0.5 – 1*105 cells/well were spun down in a 96 well V bottom plate (Hartenstein). Cells were 
resolved in 25 µl FACS buffer (see 4.1.5) containing the antibody cocktail of choice and were 
then incubated for 20 minutes at 4°C in the dark. 
4.2.3.2 FACS analysis of intracellular proteins 
The Cytofix/ Cytoperm Kit (BD Bioscience) was used for intracellular staining. The provided 
BD Cytofix/Cytoperm fixation/ permeabilization solution contains 0.1 % of the detergent 
saponin and 4% formaldehyde. Saponin perforates the cell membrane; formaldehyde fixates 
proteins via cross-linking of amides and side chains of arginine and aromatic amino acids.  
The provided permeabilization/ washing solution contains additionally to saponin 1% FCS, 
which reduces unspecific staining.  
To enhance signal to noise ratio, cells were activated by PMA / ionomycin treatment in the 
presence of Brefeldin A prior to intracellular staining of cytokines. The phorbol ester PMA 
activates protein kinase C whereas the calcium ionophore ionomycin leads to an intracellular 
rise of Ca2+. This mimics a full blown T cell activation via the TCR and up-regulates cytokine 
secretion. Brefeldin A prevents the transport of proteins to the cell surface, enriching secreted 
proteins in the cell. Briefly, PBMC or splenocytes were incubated at a density of 2-4 * 106 
cells/ml at 37°C in an incubator for 4 to 6 hours in pre-warmed cytotoxicity media (see 4.1.5) 
containing 20 ng/ml PMA (Sigma-Aldrich), 1 µg/ml ionomycin (Sigma-Aldrich) and 
10 µg/ml Brefeldin A (Sigma Aldrich).  
0.5-1*106 cells/well were seeded in a 96-well V-bottom plate (Hartenstein).To identify cell 
types surface stain was performed as described in 4.2.3.1. Afterwards, cells were fixed and 
permeabilized by addition of 100 µl fixation/ permeabilization solution and a subsequent in-
cubation for 20 min at 4°C. Cells were washed twice with permeabilization/ washing solution. 
Unspecific staining was blocked additionally by incubation with a 1:100 dilution of anti-
mouse CD16/CD32 FCg Block (BD Bioscience) for 15 min at 4°C. Afterwards, the recom-
mended amount of intracellular antibody was given directly into the blocking solution and the 
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incubation was prolonged for another 30 minutes to allow intracellular staining. Cells were 
washed once with permeabilization/ washing buffer. 
4.2.3.3 FACS analysis of whole blood  
20 µl of blood was transferred to a 96 well V bottom plate (Hartenstein). Erythrolysis was 
performed for 7 minutes at 37°C in an incubator after addition of 200 µl erythrolysis buffer 
(see 4.1.5). Cells were spun down and erythrolysis was repeated a second time. Cells were 
washed once and normal surface stain was performed as described in 4.2.3.1. The FACSCan-
toIITM flow cytometer allows the concrete event count of any stained cell type in a precise 
sample volume. Therefore, it was possible to calculate the blood cell count of any identified 
cell type. To ensure precise numbers the method of reverse pipetting was used.  
4.2.4  Labeling of target cells 
In general, centrifugation of target cells was performed at 300xg for 5 min at RT using a Her-
aeus Multifuge 3 (Kendro Laboratory Products GmbH). If not otherwise indicated samples 
were filled up with indicated media for washing and supernatant was discarded after centrifu-
gation. The cell count was determined using a hemacytometer (Marienfeld). The vitality of 
cells was determined using 0.5 % (v/v) isotonic EosinG solution (Roth). 
4.2.4.1 PKH staining  
Target cells were stained using the PKH-26 Red Fluorescent Cell Linker Kit (Sigma). PKH is 
an aliphatic reporter molecules stably incorporated into the cell membrane. The excitation and 
emission maxima lay at 490 nm and 504 nm, respectively. 
Briefly, 1*107 cells were washed twice with PBS (Invitrogen). Cells were re-suspended in 
500 µl provided Solution C (Sigma), and 500 µl Solution C containing 16 µl PKH dye 
(Sigma) was added. Cells were incubated for 5 min at 37°C and afterwards 1 ml FCS (Gibco) 
was added to stop the reaction. Cells were washed twice with cytotoxicity media (see 4.1.5). 
Correct labeling was approved by flow cytometry.  
4.2.4.2 CFSE labeling  
To track proliferation, lymphocytes were labeled with 50 nM Carboxy-Fluorescein diacetate, 
Succinimidyl Ester (CFSE) using the Vybrant CFDA SE Cell Tracer Kit (Invitrogen). CFDA-
SE diffuses passively into cells where it becomes membrane impermeable and fluorescent 
when it is cleaved by intracellular esterases to CFSE. It is equally distributed to daughter cells 
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during cell division. The intensity of the fluorescent signal is reduced by half with each sub-
sequent generation, giving a possibility to track cell proliferation. The CFSE excitation and 
emission maxima lay at 490 nm and 518 nm, respectively. 
The staining was performed in PBS (Gibco). 1x105 T cells were incubated with 50nM CFDA-
SE (Molecular Probes) for 15 min at 37°C. The reaction was stopped by addition of excess 
amount of cytotoxicity media and cells were washed twice. The cells were allowed to recover 
for 30 min at 37°C to ensure complete conversion of the dye by esterases. Correct labeling 
was approved by flow cytometry.  
4.2.5 Cytotoxicity assay 
The aim of a cytotoxicity assays is to determine the amount of redirected lysis or apoptosis of 
target cells mediated by the BiTE of interest. Apoptosis or redirected lysis of target cells was 
induced by incubating them with effector cells in the presence of different concentrations of 
BiTE. If not otherwise indicated, a 10fold dilution row ranging from [1 pg/ml] to [1 µg/ml] 
and a blank sample as reference was prepared for that purpose. Each set was performed in 
duplicates or triplicates. Used effector cells were PBMCs, splenocytes, leukocytes isolated 
from lymph nodes and naive or activated T cells. The cytotoxic bioactivity of BiTEs was ana-
lyzed determining the ability to induce apoptosis (caspase assay) or cell lysis (ToxiLight as-
say and FACS based assay). The index of apoptose or the specific lysis was plotted against 
the logarithm of antibody concentration using Prism software (Graph Pad Software Inc., ver-
sion 4.02). The resulting dose-response curves were analyzed with the integrated four-
parameter nonlinear fit model accepting only series with R2 values >0.9. Calculated concen-
trations of the half-maximal kill (EC50) were used as indicator for specific bioactivity.   
4.2.5.1 ToxiLight assay 
The redirected lysis of target cells was determined using the ToxiLight Bioassay Kit com-
bined with the ToxiLight 100% Lysis Control Set (both Cambrex). The kit is based on the 
bioluminescent measurement of the adenylate kinase (AK) which is present in all cells. A loss 
of cell integrity through damages to the plasma membrane results in leakage of AK from cells 
into the surrounding medium. External added adenosindiphosphate (ADP) can be converted to 
adenosintriphosphate (ATP) by the present AK. The emerging ATP is utilized by added 
luciferase to catalyze the reaction of luciferin and O2 to form oxyluciferin and CO2. During 
this reaction light is emitted in a stoichiometrical manner. The intensity of the emitted light is 
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proportional to the AK concentration in the supernatant and therefore to the redirected lysis of 
cells present in the sample and can be determined with a luminometer.   
 The assay was conducted in pure RPMI1640 (Gibco) containing 10% FCS (Invitrogen). 
1*104 target cells/well and 1*105 effector cells/well were plated to a white flat-bottom 96-
well plate (Nunc) in 50 µl media and different concentrations of BiTE antibody in 50 µl me-
dia or pure media as blank sample were added. Each set was performed in triplicates. Samples 
were incubated for 48 hours at 37°C, 5% CO2. Spontaneous lysis was determined in samples 
containing only target cells and effector cells (blank sample).  Maximal lysis was determined 
adding 25 µl Toxilight 100% Lysis reagent (Cambrex) to blank samples followed by incuba-
tion for 10 min at RT. The same volume of medium was added to all other samples to ensure 
equal volumes.  100 µl of ToxiLight reagent (Cambrex) was added to all samples and the 
plate was incubated at RT for 5 minutes in the dark. Thereafter luminescence was read out in 
a Spectra Fluor Plus Fluorometer (Tecan) using the luminescence mode (Gain 150, Integra-
tion time 1000 ms). Background luminescence was measured of pure cell culture medium 
(RLUM) and was subtracted from luminescence of samples (RLUS) and blank value before 
and after maximal lysis (RLUB and RLUMax). The specific lysis was calculated according to 
following mathematical equation: 











RLURLURLURLU*100%% Lysis Specific  
4.2.5.2 Caspase assay 
The Caspase-Glo 3/7 Assay (PROMEGA) is a luminescent assay that measures the activity of 
caspase 3 and 7, which are known to play a key role in apoptosis in mammalian cells. The 
assay provides a proluminescent caspase-3/7 substrate, which contains the tetrapeptide se-
quence DEVD. Addition of the Caspase-Glo 3/7 reagent results in cell lysis and therefore in 
release of intracellular caspase 3 and 7. These enzymes cleave in turn the substrate, generating 
a luciferase mediated luminescent signal. This is proportional to the amount of caspase-3 and 
-7 present and thus also to the number of apoptotic cells. 
The assay was performed in pure RPMI1640 (Gibco) containing 10% FCS (Invitrogen). 
1*104 target cells/well and 0.5 – 1*105 effector cells/well were plated to a white flat-bottom 
96-well plate (Nunc) in 50 µl media and different concentrations of BiTE in 50 µl media or 
pure media as reference were added. Each set was performed in duplicates. Samples were 
incubated for 48 hrs at 37°C, 5% CO2. Caspase-Glo 3/7 reagent (Promega) was added in a 
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volume ratio of 1:1 and samples were incubated at RT for 45 minutes. Thereafter lumines-
cence was read out in a Spectra Fluor Plus Fluorometer (Tecan) using the luminescence mode 
(Gain 150, Integration time 1000 ms). Background luminescence was measured of pure me-
dium (RLUM) and was subtracted from luminescence of samples (RLUS) and the blank value 
(RLUB). The index of apoptosis was evaluated calculating the ratio of caspase activity of 
















4.2.5.3 FACS based assay 
The vitality of target cells was determined via PI (Sigma-Aldrich) exclusion in a FACS based 
assay. PI is a fluorescent, DNA intercalating molecule that is membrane impermeable. As it 
can only pass the disintegrated membrane of necrotic cells, its exclusion can be used to differ-
entiate between viable and non-viable cells. Once the dye has bound to nucleic acids, its fluo-
rescence is enhanced 20 to 30fold which can be measured by flow cytometry.   
The assay was performed in cytotoxicity media (see 4.1.5). In some cases target cells were 
labeled in advance with the PKH-26 Red Fluorescent Cell Linker (Sigma-Aldrich) as de-
scribed in 4.2.4.1. Then, 1*105 target and 1*106 effector cells/well were plated to an U-
bottom 96-well plate (Greiner) in 100 µl media and different concentrations of BiTE in 50 µl 
media or pure media as blank control were added. Samples were incubated for 24, 48 or 72 
hrs at 37°C, 5% CO2. After incubation cells were stained with antibodies against EpCAM, 
CD3 or CD4/CD8, to identify unlabeled target and effector cells. The number of living target 
cells (n) was evaluated by flow cytometry on a FACSCantoIITM and FACSCaliburTM flow 
cytometer, respectively, running FACSDivaTM or Cell Quest Pro Software (all BD Biosci-
ence), respectively. The vitality of cells was determined via PI (Sigma-Aldrich) exclusion. 
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4.2.6 Determination of cytokine concentration 
The cytometric bead array (CBA) technology uses the method of a bead - based immunoas-
say. Each bead is identifiable by discrete fluorescence intensity and provides a capture surface 
for a specific cytokine via coupled cytokine specific antibodies. Bead bound cytokine is then 
detected with a secondary phycoerythrin (PE) - labeled cytokine specific antibody. The 
amount of bound secondary PE – labeled antibody, and therefore the emitted red fluores-
cence, is directly proportional to the amount of a specific cytokine and can be determined 
with flow cytometry. For the detection of cytokines two different CBA assays where used. 
The used CBA kits, e.g. human and mouse Th1/Th2 CBA kit and the mouse inflammatory 
CBA kit (all BD Bioscience), allow analysis of an already preformed set of cytokines. The 
CBA flex sets offers the analysis of up to 89 freely combinable cytokines at once. Beads used 
in the preformed CBA kits are identified with one distinct fluorescent signal whereas two are 
used for this purpose in the CBA flex set system giving a greater combinatorial possibility. 
CBA Flex sets used were mouse IL-2 CBA Flex set, mouse IL-6 CBA Flex set, mouse IL-10 
CBA Flex set, mouse TNF CBA Flex set, mouse IFN-g CBA Flex set, mouse IL-3 CBA Flex 
set, mouse GM-CSF CBA Flex set and mouse IL-4 CBA Flex set (all BD Bioscience). 
The assay was conducted in a 96-well V bottom plate (Hartenstein). All washing steps were 
accomplished by centrifugation at 200xg for 5 min at RT. The cocktails containing the differ-
ent Flex set beads and Flex set secondary detection antibodies, respectively, were prepared in 
accordance to the manufacturer’s instructions. A twofold serial dilution row ranging from 20 
to 5000 pg/ml of provided cytokines was prepared as standard. Serum samples or cell culture 
supernatants were diluted with provided assay diluent if recommended. Serum or cell culture 
supernatants were incubated with the bead cocktail and thereafter with secondary antibody 
cocktail, each for one hour at RT in the dark. Samples were washed once and the bead pellet 
was solved in provided wash buffer for analysis on a FACSCantoIITM and FACSCaliburTM 
flow cytometer, respectively, running FACSDivaTM and Cell Quest Pro Software (all BD Bio-
science), respectively. The cytometer was calibrated for analysis using the cytometer setup 
beads as described in the manufacturer’s instructions. The data was analyzed by the FCAP 
ArrayTM Software (V 1.0, SoftFlow Inc. Hungary). The lower limit of quantification for each 
analyte was below 20 pg/ml. Concentrations calculated below this value were reported as 
zero.  
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4.2.7 TGF-b enzyme linked immuno sorbent assay (ELISA) 
Mouse serum concentrations of TGF-b were determined using the human/mouse TGF-b 
ELISA ready set Go! (Natutec). The provided anti-TGF-b capture and detection antibodies 
(#eB-461/25D8) recognize only the active form of TGF-b.This molecule is secreted from 
cells predominantly in its latent form. It is converted to its active form by proteolytic cleavage 
and subsequent release of the resulting latency associated protein at the source and the target 
site. For measurement of complete TGF-b content, serum samples were treated with hyper-
chloric acid to convert all latent TGF-b to the immune-reactive form.  
Between each antibody staining or blocking steps the plates were washed 5 times with 250 
µl/well PBS (Invitrogen) containing 0.05% (v/v) Tween 20 (Sigma) using the ELISA washer 
(molecular devices). All serum samples were diluted 1:5 with PBS (Invitrogen). For acid acti-
vation 100 µl diluted sample was acidified with 20 µl of 1 M HCl (Merck) for 10 minutes at 
RT. Samples were then neutralized with 20 µl of 1 M NaOH (Merck). As standard a twofold 
serial dilution row of the provided recombinant active TGF-b [8000 pg/ml - 125 pg/ml, blank] 
was produced with the provided assay diluent. Maxisorp 96 well ELISA pates (NUNC) were 
coated with 100 µl of the provided capture antibody mix at 4°C overnight. Plates were 
blocked with 200 µl/well provided assay diluent for one hour at RT. For binding of TGF-b 
wells were incubated with 100 µl standard, acid activated or normal diluted sample for two 
hours at RT. To allow the formation of the sandwich ELISA complex, samples were subse-
quently incubated with 100 µl provided biotin conjugated detection antibody and 100 µl pro-
vided streptavidin conjugated with horse radish peroxidase (Dako), each for one hour at RT. 
Finally, plates were incubated with 100 µl provided tetramethylbenzidine substrate for 15 
minutes at RT for detection. The reaction was stopped by the addition of 50 µl 2N H2SO4 
(Merck). Absorbance was read at 405 nm on a Power WaveX select (Bio-Tek instruments). 
Standard curves were fitted by four-parameter analysis. The corresponding OD values of the 
samples were used to calculate the concentration of active and total TGF-b, respectively. 
4.2.8 Determination of whole blood cell count 
If not otherwise indicated whole blood cell count was determined as described in 4.2.3.3. In 
some cases, however, the blood cell count was analyzed using BD TruCount tubes (BD) in 
accordance to the manufacturer instruction. To maximize accuracy of cell count, centrifuga-
tion was avoided and erythrolysis and antibody staining of whole blood cells took place in 
one provided tube, containing a concrete amount of lyophilized beads. These were distin-
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guishable in the forward scatter and side scatter from blood cells. By comparing cellular 
events to bead events, the absolute number (cells/µl) of positive cells in the sample was calcu-
lated.  
Prior to erythrolysis, 50 µl of whole blood was directly stained with 20 µl of the antibody 
cocktail of choice for 20 minutes at RT in the dark. Afterwards, erythrocytes were simultane-
ously lysed and stained cells were fixed by adding 350 µl BD FACS lysing solution (BD Bio-
science). After 20 minutes cells were analyzed with flow cytometry. CD45 positive cells were 
considered as leukocytes and subpopulations were defined by co-expression of surface mark-
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Additionally the hematokrit was determined to rule out injection induced volume effects on 
the blood cell count.  
4.2.9 Depletion of EpCAM+ cells from mouse splenocytes and PBMC  
In vitro depletion of EpCAM+ cells was achieved using a combination of depleting Dynabeads 
followed by fluorescence activated cell sorting. Briefly, mouse PBMC were labeled with rat 
anti-mouse EpCAM mAb (G8.8, BD Bioscience). Anti-rat IgG coated magnetic Dynabeads 
(Invitrogen) were added to bind selectively to cells coated with anti-mouse EpCAM mAbs. 
The Dynabeads with bound EpCAM+ cells were then removed using the MPC-1 magnetic 
separator (Dynal).   
The isolation was performed in Dynal buffer (see 4.2.2.4). Prior to usage anti-rat IgG coated 
magnetic Dynabeads (Invitrogen) were washed with Dynal buffer as described in 4.2.2.4. 
1*106 cells were resolved in 100 µl Dynal buffer containing 10 µg/ml rat anti-mouse EpCAM 
mAb (G8.8, BD Bioscience) for 20 minutes at 4°C. Cells were washed twice with Dynal 
buffer to remove excess antibodies. Afterwards cells were resolved in 100 µl Dynal buffer 
and 6.25 µl pre-washed anti-rat IgG coated magnetic Dynabeads (Invitrogen) were added. 
Antibodies were allowed to bind to Dynal beads for 30 minutes on ice. Separation was per-
formed as described in 4.2.2.4. The magnetic separation was repeated twice to improve purity. 
The supernatant containing EpCAM depleted mouse PBMCs was subjected to further fluores-
cence activated cell sorting. Cells were stained with PE-conjugated anti-mouse EpCAM mAb 
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(BD Bioscience) as described in 4.2.3.1 and were then negatively sorted by a MoFlo High 
Performance Cell Sorter (DAKO).  
4.2.10 Analysis of BiTE serum concentrations  
All assays analyzing BiTE serum concentrations were performed and established by the bio-
analytical department of Micromet AG (Munich, Germany). 
4.2.10.1 Bioassay based BiTE quantification 
The method is based on loading cells with a membrane permeable acetoxymethyl ester of a 
fluorescence enhancing ligand (BATDA). Within the cells its ester bonds are hydrolyzed to 
form a hydrophilic ligand (TDA), which is trapped in the cells. TDA released by dead cells 
can form a fluorescent chelate (EuTDA) in the presence of europium solution. The measured 
signal correlates directly with the amount of lysed cells.  
MuS110 serum concentrations were quantified by a bioassay measuring the TDA release of 
BATDA-labeled CHOmuEpCAM+ cells lysed by muS110 redirected T cells. In general, cen-
trifugation of cells was performed at 300xg for 5 min at RT using a Heraeus Multifuge 3 
(Kendro Laboratory Products GmbH). If not otherwise indicated, samples were filled up with 
indicated media for washing and supernatant was discarded after centrifugation.  
CHOmuEpCAM+ cells were labeled with the DELFIA® BATDA reagent (Wallac Oy) accord-
ing to manufacturer instruction. 1*106 cells were incubated with 4 µl BATDA reagent in cyto-
toxicity media (see 4.1.5) for 30 minutes at 37°C. Samples were washed four times afterwards 
with cytotoxicity media. Serum samples or control serum, BATDA-labeled target cells 
(2.5*103/well) and CTLL-2 effector cells (1.5 * 105/well) were incubated together for 3 hours 
at 37°C, 5% CO2, to allow redirected lysis. 20 µl supernatant containing TDA released by 
dead cells was incubated for 60 minutes at RT with 100 µl DELFIA® Europium solution 
(Wallac Oy) to allow stable formation of EuTDA. The amount of EuTDA was quantified by 
analysis of the relative fluorescence intensity (RFUS) at 520 nm with a Victor Multilabel 
Counter (Wallac Oy). Fluorescence intensity of background lysis (RFUB) was determined in 
control serum samples. Fluorescence intensity of maximal lysis (RFUM) was determined us-
ing DELFIA® lysis buffer (Wallac Oy) according to manufactures instructions. Standard sam-
ples were generated by a fourfold serial dilution of muS110 [2 µg/ml – 7.6 pg/ml] and spe-
cific cell lysis was plotted against muS110 concentrations using Prism 4 (Graph Pad 
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Software). The limit of quantification was determined as 1 ng/ml. The percentage of specific 
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4.2.10.2 BiTE quantification with Meso Scale Discovery (MSD) 
The muS110 PK ELISA is based on the electrochemiluminescence detection technology de-
veloped and established from the company Meso Scale Discovery (MSD). This technology 
uses SULFO-TAGTM labels that emit light upon electrochemical stimulation initiated at the 
electrode surfaces of MULTI-ARRAYâ micro plates. This signal is measured as a mean sig-
nal in the detector (emission at ~620 nm). Thus, the stimulation mechanism (electricity) is 
decoupled from the signal (light), leading to minimal background signals and high signal to 
background ratios. The procedure of the assay is based on the ELISA “sandwich” method.  
According to manufactures’ instructions, a 96-well MSD High Bind Plate (MSD) was coated 
with 5 µl soluble mouse EpCAM ([64 µg/ml], Micromet AG) for 2 hours at RT and blocked 
with MSD Blocker A (MSD) for 1 hour at RT. 25 µl mouse serum was added and plates were 
incubated for 75 minutes at RT to capture muS110 present in the serum. This step was fol-
lowed by a first incubation with 25 µl biotin-conjugated anti-pentahistidine antibody ([1 
µg/ml], Qiagen) and a second incubation with 25 µl MSD SULFO-TAG labeled streptavidin 
([2 µg/ml], MSD) to form a detectable sandwich complex. Both incubations were at 25°C for 
30 minutes. Between each antibody staining or blocking steps the plates were washed 5 times 
with 250 µl/well PBS (Invitrogen) containing 0.05% (v/v) Tween 20 (Sigma) using the 
ELISA washer (molecular devices). After addition of 150 µl MSD Reading buffer the electro-
chemical signal of the bound ELISA sandwich was quantified with a SECTOR™ Imager 
2400 (MSD). For calibrations, a 4-fold serial dilution of muS110 [2 – 7.6 pg/ml] was per-
formed. Unknown muS110 concentrations in mouse serum were back calculated with the help 
of the muS110 calibration curve using Prism 4 (Graph Pad Software). The limit of quantifica-
tion was determined to be 0.2 ng/ml.  
4.2.11 Saturation binding analysis and calculation of receptor occupancy 
In general, centrifugation of cells was performed at 300xg for 5 min at RT using a Heraeus 
Multifuge 3 (Kendro Laboratory Products GmbH). If not otherwise indicated, samples were 
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filled up with indicated media for washing and supernatant was discarded after centrifugation. 
The cell count was determined using a hemacytometer (Marienfeld).  
1*105 cells/well were incubated for 1 hour at RT with various concentrations of the respective 
BiTE antibody using a 4 fold serial dilution ranging from 1 µg/ml to 0.24 ng/ml in FACS 
buffer. Cells were washed twice with FACS buffer to remove unbound BiTE. To detect bound 
BiTE antibody, cells were incubated first with a hexahistidine tag–specific secondary anti-
body labeled with biotin (Dianova) and then with PE-labeled streptavidin (BD Bioscience). 
Both incubation periods were at RT for 30 minutes and cells were washed twice with FACS 
buffer in between. Binding was analyzed by flow cytometry on a FACSCantoIITM device run-
ning FACS Diva software (both BD Biosciences). The mean fluorescence values of PE were 
plotted against the different BiTE concentrations. KD values were determined using the one 
site hyperbola fit function in Prism4 (Graph Pad Software). 
At equilibrium condition the fraction of all receptor molecules that are bound to the antibody 
can be calculated if the concentration [mAb] and the dissociation constant KD of the respec-
tive antibody are known. The amount of a mAb bound to its receptor can be estimated from 
the following binding relationship:  
Equation 1:         ( ) ( ) ( )CcomplexmAbreceptorBmAbAReceptor -¾®¬+  
The binding dissociation constant (KD) of the respective antibody is represented by:  
Equation 2:         






Finally the fractional occupancy, fraction (F) of all receptor molecules that are bound to the 
antibody can be calculated by: 
Equation 3:        [ ][ ] [ ]mAb-receptorreceptor
mAb-receptorF
+
=        
Formation of equation 2 and substitution in equation 3 results in: 





Histological and pathological studies were contracted to Huntingdon Life Sciences Ltd (UK). 
Eyes were fixed in Davidson’s fluid, testes and epididymides were fixed in Bouin´s solution 
prior to transfer to 70% industrial methylated spirit. All other samples were fixed in 10% neu-
tral buffered formalin (adrenals, brain, caecum, colon, duodenum, femurs, gall bladder, 
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harderian glands, heart, ileum, jejunum, kidney, lachrymal glands, larynx, liver, lungs, lymph 
nodes mandibular and mesenteric, mammary area (caudal), esophagus, optic nerves, ovaries, 
pancreas, pituitary, prostate, rectum, salivary glands, seminal vesicles, skeletal muscle, spinal 
cord, spleen, stomach, thymus, thyroid with parathyroid’s, tongue, ureters, urinary bladder, 
uterus and cervix, vagina). Tissue samples were dehydrated, embedded in paraffin wax, sec-
tioned at approximately 4-5 micron thickness and stained with haematoxylin and eosin. A 
reviewing pathologist undertook a peer review of the microscopic findings.   
4.2.13 Mouse models and in vivo work 
4.2.13.1 Housing 
All experiments were performed according to the German Animal Protection Law with per-
mission from the “Ethical Committee on Animal Care and Use” of the government of Bava-
ria, Germany. All efforts were made to keep their number and suffering limited to the mini-
mum. Animals were kept in a temperature (25 ± 2 ºC) and humidity (50 ± 5%) controlled 
room with an artificial 12 hour light-dark rhythm and rodent food pellets (Sniff, Soest) and 
autoclaved tab water available ad libitum. Animals were housed in standard Microloan type II 
- long cages (Beech) in individually ventilated cages to achieve specified pathogen - free con-
ditions. Health status of animals was checked twice a year monitoring sentinels according to 
FELASA criteria. Commercially obtained animals were allowed to adapt to their surroundings 
at least 7 days before they were included to experiments.  
4.2.13.2 Monitoring of health, body weight and temperature  
Body weight was obtained with a MXX - 212 balance (Denver instruments). To measure 
body temperature, animals were chipped with temperature sensitive IPTT-300 transponders 
(PLEXX). The transponder was implanted subcutaneously between the two scapulae. Prior to 
implantation, mice were anaesthetized with 3-4% isoflurane (CP Pharma) for up to 1 minute 
using an Isotec3 isoflurane evaporator (Voelker GmbH). Chipped animals were allowed to 
recover for 4 days before they were included to experiments. The temperature was scanned 
with a DAS-6007 scanner running DAS Host software (both PLEXX). Animals were moni-
tored prior and during experiments for the appearance of diarrhea, healthy fur appearance, 
relaxed posture, frequency of movements and breathing. Piloerection (ruffled fur), hypomotil-
ity, diarrhea, gasping and hunched posture was assessed as absent (-), mild (-/+) or strong (+). 
In some cases pictures and videos were made with a DM-FZ 30eGLumix digital camera 
(Panasonic) for documentation.     
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4.2.13.3 Application techniques 
Used application techniques were intravenous (i.v.) injection via the tail vein, subcutaneous 
(s.c.) application under the skin of the left abdominal flank and intraperitoneal (i.p.) injection 
into the body cavity. For all injections Omnican syringes (0.3x12mm, 0.01-1 ml, Braun) were 
used. 
The treatment dose was given in mg/kg. The agent was either injected according to individual 
mouse weight (10 µl agent per 1g mouse), whereby the concentration of the injection solution 
(cInjection) was always calculated as (dose * 0.02 kg/ 0.2 ml), or cInjection was calulated with the 
mean group body weight (mBW) and a fixed injection volume (VInjection) according to follow-














For s.c. application mice were first immobilized by grasping the excess skin over the animal's 
back between the thumb and forefinger and fixing the tail with the smallest finger. Whilst the 
mouse was lying on its back within the palm of the hand, the substance was applied in a vol-
ume of 50 µl under the skin in the lower left quadrant.  
For i.p. application mice were restrained as described above and held with their ventrum ex-
posed and head pointed downwards. This causes the freely moveable abdominal organs to 
move towards the animal's diaphragm, making accidental puncture of organs less likely. The 
needle was inserted into the abdominal cavity in the lower right quadrant to avoid the caecum 
and urinary bladder and the substance was applied in a volume of 200 µl.  
For i.v. application animals were pre-warmed for 5 minutes using a heating box (VetTech 
Solutions) to increase visibility of the tail vain. Animals were fixed in a plexiglass restraining 
cylinder. The needle was inserted in the lateral tail vein by directing the needle with its bevel 
pointing upward at an angle of approximately 20 degrees. Once the vein's wall had been pene-
trated the needle was directed cranially and the substance was applied according to individual 
mouse weight (10 µl agent per 1g mouse) or in a fixed volume of 200 µl within 15 seconds. 
4.2.13.4 Blood sampling 
Blood was obtained either via heart punctuation or retro-orbital bleeding. For retro-orbital 
bleeding animals were anaesthetized with 3-4% isoflurane for up to 1 minute using an Isotec3 
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Isoflurane Evaporator (Voelker GmbH). Blood was taken from the ruptured peri-orbital sinus 
with heparinized MiniCAPS capillaries (5 µl, Hirschmann Laborgeräte). Prior to heart punc-
tuation animals were euthanized on dry ice. The thorax was opened to expose the heart and 
venous blood was obtained from the right ventricle of the heart using a Sterican100 needle 
(0.05x16mm, 25Gx5/8“, Braun).  
For serum preparation blood was collected in microtainer SST Tubes (BD Bioscience) and 
allowed to coagulate for 1 hour at RT. Samples were then spun down with 7000xg for 5 min-
utes at RT in a Mikro 20 centrifuge (Type 2004, Hettich) to separate serum from blood cells. 
Serum was stored at -80°C for subsequent cytokine analysis and at -20°C for determination of 
BiTE serum concentrations. In all other cases blood was collected in pre-heparinized contain-
ers and 5 µl heparin was added to prevent coagulation. Samples were stored on ice until fur-
ther usage.  
In some experiments hematokrit of 50 µl freshly sampled blood was determined with 
heparinized Mikro hematokrit capillaries (Heiland) using the hematokrit sealing kit (Heiland). 
Capillaries filled with blood were spun with 13.000xg for 2 minutes at RT in a hematokrit 
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4.2.13.5 Tumor models 
Prior to tumor inoculation, respective exponential growing tumor cells were cultivated and 
harvested as described in 4.1.1. Mouse T cells were prepared as described in 4.2.2. Cells were 
washed with PBS and spun down by centrifugation in a Heraeus Multifuge 3 (Kendro Labora-
tory Products GmbH) at 300xg for 5 minutes at RT. The cell pellet was resolved in PBS and 
the cell count was determined using a hemacytometer (Marienfeld). The vitality of cells was 
determined using 0.5 % (v/v) isotonic EosinG solution (Roth). Cells were only used, if vitality 
was higher than 92%. Until inoculation cells were stored on ice. In solid tumor models lym-
phocytes were mixed to tumor cells prior to tumor inoculation, to resemble the physical situa-
tion of lymphocyte infiltrated human tumors. Cells were applied with a Sterican100 cannula 
(0.05x16mm 25Gx5/8, Braun) and syringes were loaded without a cannula to avoid cell dis-
ruption. 
 
lcell =  length of red blood cell pellet 
ltotal = length of all 
Hematokrit  
capillary 
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For the orthotopic 4T1 mouse breast carcinoma model, a mixture of 104 4T1 tumor cells and 
indicated amount of mouse T cells was injected in a final volume of 50 µl PBS into the 
mammary fat pad of BALB/c mice. The solid 4T1 Tumors were measured on the indicated 
days with a caliper in two perpendicular dimensions and tumor volumes calculated according 
to the following equation. In compliance with the Animal Protection Law, mice had to be 






For the CT-26 lung cancer model, 1 x 105 CT-26muEpCAM+ tumor cells were intravenously 
injected in the lateral tail vein of BALB/c mice in a final volume of 200 µl PBS. For the 
B16F10 lung cancer model, 1 x 105 B16F10muEpCAM+ tumor cells were intravenously in-
jected into the lateral tail vein of C57BL/6N mice in a total volume of 200 µl PBS. CT-
26muEpCAM+ or B16F10muEpCAM+ tumor cells were trapped in the small pulmonary 
venules around the alveoles of the lung, where they form small tumor colonies on the lung 
surface. The body weight was determined daily to check animal health status. The observation 
period was limited to 17 days for ethical reasons because of the severe effects of high lung 
tumor burden on respiration. Animals were sacrificed and the number of CT-26muEpCAM+ 
or B16F10muEpCAM+ tumor cell colonies on the lung surface was determined macroscopi-
cally. 
Statistical analysis of the mean tumor volume or the lung metastasis burden of the corre-
sponding treatment groups versus the vehicle control group was performed using the Stu-
dent’s t test.  
4.2.13.6 Dissection, isolation of organs and fixation 
Animals were sacrificed on frozen CO2 or with cervical dislocation during isoflurane anesthe-
sia. Gross pathology of animals was performed and abnormalities were noted. In some cases 
pictures were made with a DM-FZ 30eGLumix digital camera (Panasonic) for documentation. 
In some cases tumor tissue, lung, thyme, spleen, mesenterial lymph nodes, superficial cervical 
lymph nodes, inguinal lymph nodes or payers patches were isolated and stored in cytotoxicity 
medium (see 4.1.5) on ice until further ex vivo analysis. In some cases the brain, the gastroin-
testinal tract (caecum, colon, duodenum, ileum, jejunum, esophagus, and rectum), the heart, 
the kidney, the liver, the lungs, the cervical and mesenteric lymph nodes, the spleen and the 
thymus were removed and fixed in 10% neutral buffered formalin (Sigma-Aldrich) for further 
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histo-pathological analysis. Tumor tissue and organs infiltrated by tumor metastasis were em-
bedded in tissue tec O.C.T compound (Sakura), frozen in liquid nitrogen and stored at -80°C 
until further histological analysis.  
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5 RESULTS 
5.1 In vitro characterization of muS110 
5.1.1 Binding affinities of muS110 to CD3 and EpCAM 
Saturation binding assays were performed with CD3-enriched mouse T cells and CHOmuEp-
CAM+ cells. The cells were incubated with a 4-fold serial dilution row of muS110. Bound 
BiTE antibody was quantified by flow cytometry after staining with a hexahistidine tag–
specific antibody labeled with biotin followed by streptavidin-PE. The equilibrium binding 
constants (KD) were obtained by computational analysis with Prism 4 (one side hyperbola fit) 
plotting the normalized binding signal against the various muS110 concentrations (Figure 5).   
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Figure 5: Saturation binding of muS110 to cells expressing EpCAM or CD3 
Saturation binding assays were performed with CHO cells, (A) CHO cells transfected with 
mouse EpCAM antigen or (B) CD3 enriched mouse splenocytes. The cells were incubated with 
a 4-fold serial dilution row of muS110. Bound BiTE antibody was quantified with flow cytome-
try after staining with a hexahistidine tag–specific antibody labeled with biotin followed by 
streptavidin-PE. For saturation binding curves the mean fluorescence was normalized to the re-
spective strongest signals and plotted against various muS110 concentrations. The KD values 
were obtained by computational analysis with Prism 4 (one side hyperbola fit) and are indicated 
in the corresponding graphs. Error bars indicate standard error of the mean (SEM) of triplicates.                                                                                                                                   
MuS110 binds only to cells expressing either mouse CD3e or mouse EpCAM. No signal was 
detected with CHO cells lacking these antigens. The KD values for mouse EpCAM were 21 
+/- 2.6 nM and 2.9 +/- 0.4 nM for CD3e. The binding affinities for EpCAM were comparable 
for muS110 and MT110 (21 +/- 2.6 nM to 13 +/- 0.25 nM).  The binding affinity to the CD3e 
antigen was about 35 times stronger for muS110 than for MT110 (2.9 +/- 0.4 nM to 100 +/-15 
nM) (85).  
A B 
 - RESULTS - 47 
 
5.1.2 Redirected lysis of respective target cells mediated by muS110  
The potency of muS110 to mediate redirected lysis of mouse EpCAM positive target cells 
was tested for the mouse breast cancer cell line 4T1, naturally expressing EpCAM, and for 
CHO hamster cells, CT26 mouse colon carcinoma cells and B16F10 mouse skin melanoma 
cells, all transfected with mouse EpCAM. The respective target cells were incubated for 48 
hours with CD3+-enriched mouse splenocytes at an effector to target (E:T) ratio of 10:1 in the 
presence of increasing concentrations of muS110. Similar assays were performed with the 
control BiTE hyS110 to assess the specificity of BiTE kill. HyS110 shares the CD3 binding 
part with muS110 but the target cell binding moiety is directed against human EpCAM in-
stead of mouse EpCAM. The cytotoxic activity of muS110 was analyzed as the ability to in-
duce apoptosis (caspase assay) or cell lysis (ToxiLight assay; FACS based assay) (Figure 6). 
The caspase index or the specific lysis was plotted against the antibody concentrations to ob-
tain the half-maximal kill (EC50) as indicator for specific bioactivity.  
MuS110 was able to mediate lysis of all EpCAM expressing target cells by naive CD3-
enriched splenocytes in a dose dependent fashion. The EC50 for all analyzed cell lines was 
over a range of 0.3 – 3 ng/ml muS110, namely 0.3 +/- 0.1 ng/ml for 4T1 cells, 1.6 +/- 0.7 
ng/ml for CHOmuEpCAM+ cells, 1.1 +/- 0.9 ng/ml for CT26muEpCAM+ cells and 2.1 +/- 1.1 
ng/ml for B16F10muEpCAM+ cells. However, the magnitude of the induced cytotoxic effect 
differed for each cell line and was additionally dependent on the test system. These differ-
ences most probably reflected individual sensitivity of each test system for the death of re-
spective cell lines. Cell lines differ in the ability to produce adenylate kinase, maintain enough 
cell integrity upon lysis for detectable PI incorporation, and the fraction played by apoptosis 
and lysis in their destruction. The control BiTE hyS110 did neither induce redirected lysis nor 
apoptosis in any of the tested cell lines with exception of B16F10muEpCAM+ cells analyzed 
by a FACS-based assay. However, this cell line seemed to be particularly sensitive to PI in-
corporation. The determined EC50 value for muS110 mediated re-directed lysis was also in-
creased for more than an order of magnitude in comparison to all other assessed cell lines, 
which was not seen for the caspase or the ToxiLight assay. The unspecific lysis of 
B16F10muEpCAM+ target cells by hyS110 was clearly less pronounced and only detectable 
at high doses.  
It was shown that the half-maximal lysis of CHO cells transfected with the respective target 
antigen was comparable for MT110 (0.65 +/- 0.5 ng/ml, n=5) and muS110 (2.51 +/- 1.2 
ng/ml, n=10) (85). 
































































































































Figure 6: MuS110 redirected lysis of EpCAM+ target cells 
The respective target cell line was incubated for 48 hours with CD3-enriched mouse splenocytes 
at an effector to target (E:T) ratio of 10:1 in the presence of increasing concentrations of 
muS110 (right side) or the control BiTE hyS110 (left side). (A, B) Potency to induce apoptosis 
was quantified with the caspase assay. (C - F) Potency to kill target cells was assessed with (C, 
D) the ToxiLight assay, or (E, F) the FACS based analysis of propidium iodide incorporation. 
Specific lysis was calculated as percentage of living cells in the sample corrected by that of the 
blank value. Dose response curves were obtained plotting the caspase index or the specific lysis 
against the antibody concentrations. Error bars indicate SEM of triplicates. Each cell line with 
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5.1.3 T cell activation mediated by muS110  
5.1.3.1 Cell proliferation in cytotoxicity assays 
To assess muS110 induced T cell proliferation, PKH-26-labeled CHOmuEpCAM+ cells were 
incubated with mouse splenocytes at an E:T ratio of 10:1 in the presence of increasing con-
centrations of muS110 or the control BiTE hyS110. After 48 and 72 hours cells were stained 
for CD4 and CD8 to identify effector cells. The absolute number of alive T cells and target 
cells was determined by PI exclusion using flow cytometry (Figure 7).  
MuS110 induced T cell proliferation in a dose dependent way and led to a 3-fold increase 
after 48 hours and a 5-fold increase in T cell numbers after 72 hours. However, the highest 
dose of muS110 led in some cases to a strong reduction of T cell vitality. The EC50 values of 
proliferation were an order of magnitude lower than that observed for target cell lysis. The 
control BiTE hyS110 was not mitogenic (Figure 7A). Target cell numbers increased over time 
as well and almost doubled every 24 hours in the blank values and for the control BiTE. 
However, the total number of alive and dead target cells decreased in a reverse, concentration 
dependent way and decreased at high muS110 concentrations far below the initial applied 
numbers (Figure 7B). Dead target cells lost their cell integrity already after 48 hours and 
could not be detected by PI inclusion anymore. Therefore, the percentage of PI positive dead 
cells in a sample underestimated the percentage of cells killed by muS110-mediated redi-
rected lysis. As a result specific lysis calculated as percentage of dead cells in the sample cor-
rected by that of the blank value underrated the biologic potency of muS110 (Figure 7F). This 
affected mostly the amplitude but also to a smaller extend the EC50 values of specific lysis. 
The magnitude of this systemic error depended on the proliferative ability of the respective 
target cell, duration of the test and on the integrity of dead target cells. This could be circum-
vented by calculating specific lysis from the actual numbers of living PI negative target cells 
in the sample (nSample) and the blank value (nBlank) as 100* [1 – (nSample/ nBlank)] (Figure 7E). 
First, it takes the assay dynamic in account and second, it resembles more closely the situation 
in vivo, in which the tumor growth of an untreated animal is compared to that of a treated 
animal. Assays relying on the release of apoptotic factors (caspase assay) or cellular enzymes 
(ToxiLight assay) suffer from a similar systemic error. The amount of all target cells present 
in the blank value was much higher than that in samples with high muS110 concentrations. 
The amount of effector cells rises with increasing muS110 concentrations. The resulting E:T 
ratio after 48 or 72 hours depends on the BiTE concentration (Figure 7E).  
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Figure 7: MuS110 mediated T cell proliferation and FACS analysis of redirected lysis 
CHOmuEpCAM+ cells, labeled with PKH-26, were incubated for 48 or 72 hours with mouse 
splenocytes at an E:T ratio of 10:1 and increasing concentrations of muS110 or the control BiTE 
hyS110. T cells were stained for CD4 and CD8 and the vitality of cells was determined by PI 
exclusion. Cell number of (A) total T cells (of note, in some assays, the highest concentrations 
of muS110 reduced T cell vitality, therefore the number of all T cells is shown). (B) target cells 
and (C) all cells were determined with flow cytometry. (D) The E:T ratio was plotted against the 
increasing BiTE concentrations. Specific lysis was calculated (F) as percentage of living target 
cells in the sample corrected by that of the blank value or (E) with the number of living target 
cells in the sample and the blank value after following equation 100* [1 – (nSample/ nBlank)]. Error 
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Therefore, the source and the amount of measurable factors released by spontaneous or 
maximal lysis are different for each respective muS110 concentration. Normalization of 
muS110 induced lysis to spontaneous and maximal lysis of the blank value implies a systemic 
error. Unlike in the FACS based assay, the magnitude of this systemic error cannot be evalu-
ated. There is no way to determine the fraction of soluble factors released by effector cell ly-
sis, as it relies on BiTE-induced mitogenicity, which is depending on target cell presence. 
Hence, the cytotoxic bioactivity of muS110 was determined only by FACS based assays in 
the following sections.   
5.1.3.2 Up-regulation of T cell activation marker induced by muS110  
CD25 is the  a- chain of the IL-2 receptor, which induces T cell proliferation and activation 
upon IL-2 ligation. Activation by the IL-2 receptor leads in a negative regulatory loop to its 
own down modulation and to the expression of inhibitory receptors like CD152 (92). CD69 is 
a glycoprotein acquired during lymphoid activation and functions as a signal-transmitting 
receptor. As both surface antigens are up-regulated upon normal T cell activation, their ap-
pearance was monitored during muS110-mediated redirected lysis of target cells. CHO-
muEpCAM+ cells were incubated for 24, 48 or 72 hours with negatively isolated naive T cells 
at an E:T ratio of 10:1 in the presence of increasing concentrations of muS110 or the control 
BiTE muMec14. Like hyS110, muMEC14 shares the CD3 binding arm with muS110 but 
cannot bind to any other mouse protein, and was therefore alternatively used as second con-
trol BiTE. Cells were stained for CD4 and CD8 to identify T cells and for CD25 and CD69 to 
analyze T cell activation by flow cytometry (Figure 8). 
MuS110 led to a dose dependent up-regulation of CD69 and CD25 on almost all CD4+ and 
CD8+ T cells. The EC50 values for CD69 and CD25 up-regulation were 1.1 +/- 0.2 ng/ml after 
24 hours, 0.5 +/- 0.2 ng/ml after 48 hours and 0.3 +/- 0.1 ng/ml after 72 hrs. Hence, a trend 
towards a time dependent reduction of EC50 values was visible. The amplitude of CD69 up-
regulation was most pronounced after 24 hours and decreased thereafter, whereas CD25 up-
regulation was strongest after 72 hours. This is in concert with CD25 being an intermediate 
activation marker up-regulated 24 to 72 hours after T cell activation, whereas CD69 is known 
as one of the earliest inducible cell surface activation markers. Most probably it was already 
starting to be down regulated 24 hours after the initial T cell stimulus. Slight up-regulation of 
CD25 (20-40%) and CD69 (10-30%) was also observed at the highest concentration of con-
trol BiTE (1 µg/ml) although no up-regulation of activation marker were seen at lower doses.  































































































Figure 8: Up-regulation of the activation marker CD25 and CD69 induced by muS110  
CHOmuEpCAM+ target cells were incubated for 24, 48 or 72 hours with negatively isolated 
mouse T cells (spleen) at an E:T ratio of 10:1 and increasing concentrations of muS110 or the 
control BiTE muMec14. Cells were stained with antibodies against CD4, CD8 and EpCAM to 
differentiate between target and T cells and with antibodies against CD25 and CD69 to monitor 
T cell activation. Cell were analyzed by flow cytometry to determine percentage of (A) CD69 
and (C) CD25 CD4+ T cells and (B) CD69 and (D) CD25 CD8+ T cells. Error bars indicate 
SEM of triplicates. The experiment was repeated two times.   
The stimulating potential of muS110 was also compared to a standard technique of in vitro T 
cell stimulation. Freshly isolated mouse splenocytes were activated with surface bound anti-
CD3 and anti-CD28 antibodies (Dynabeads Mouse CD3/CD28 T cell expander) in the pres-
ence of IL-2 [100 U/ml] for 48 hours. Activated and naive mouse splenocytes were incubated 
with CHOmuEpCAM+ target cells (E:T = 10:1) for 48 hours in the presence of 100 ng/ml 
muS110. Naive splenocytes and activated splenocytes were analyzed for the activation mark-
ers CD134, CD62L and CD127, before and after the cytotoxic assay (after CT) by flow cy-
tometry (Figure 9). An intracellular staining was performed to detect CD152, granzyme B and 
IFN-g,  which were also shown to be induced by MT110 (88).  
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Figure 9: MuS110 induced T cell activation and transformation of naïve to effector T cells
  
To assess muS110 induced activation of T cells freshly isolated mouse splenocytes (naive T 
cells) or activated T cells were incubated with CHOmuEpCAM+ target cells (E:T = 10:1) for 48 
hours in the presence of 100 ng/ml muS110. For T cell activation cells were stimulated for 48 
hours with the Dynabeads Mouse CD3/CD28 T cell expander in the presence of 100 U/ml 
rhuIL-2. After muS110 stimulation (after CT) cells were stained with antibodies against CD4 
and CD8 to identify T cells. A part of the cells were stained with antibodies against the surface 
marker CD127, CD62L and CD134. The rest was stimulated with PMA/ ionomycin in the pres-
ence of Brefeldin A for 4 hours and afterwards intracellular staining with antibodies against 
granzyme B, IFN-g and CD152 was performed using the Cytofix/ Cytoperm Kit. (A, B) Per-
centage of granzyme B, IFN-g, CD152 and CD134 positive CD4 (A) and CD8 (B) cells. (C, D) 
Percentage of naive/ central memory T cells (TNaive/ CM, CD62L+ CD127+), intermediate T cells 
(TInt, CD62L+ CD127-),  effector T cells (TEff, CD62L- CD127- ), and  effector memory T cells 
(TEM, CD62L- CD127+) in the CD4+ (C) and CD8+ (D) T cell compartment. The results are rep-
resentative for four similar experiments.  
Granzyme B is a serine protease released by cytoplasmic granules of cytotoxic effector T cells 
to induce apoptosis and cell destruction of target cells. IFN-g is primarily secreted by acti-
vated T cells and natural killer cells and mediates a plethora of effects. It can promote macro-
phage activation, mediates antiviral and antibacterial immunity, enhances antigen presenta-
tion, orchestrates activation of the innate immune system, coordinates lymphocyte-
A B 
C D 
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endothelium interaction, regulates the TH1/TH2 balance, and controls cellular proliferation 
and apoptosis (93). CD152, better known as CTLA-4, is up-regulated during TCR- and 
CD28-mediated T cell activation. It is an inhibitory receptor for B7 molecules and antago-
nizes the positive CD28 co-stimulus (94). CD134, also known as Ox40, is a member of the 
tumor necrosis factor (TNF) receptor superfamily and is expressed 24-72 hours following T 
cell activation. OX40 has a critical role in the maintenance of an immune response beyond the 
first few days onwards to a memory response due to its ability to enhance survival (95). Addi-
tionally the relative amount of naive or central memory T cells (TNaive/ CM, CD62L+ CD127+), 
intermediate T cells (TInt, CD62L+ CD127), effector T cells with high lytic potential (TEff 
CD62L-CD127-) and effector memory T cells (TEM, CD62L- CD127+), known to produce 
huge amounts of IL-2 and proliferate strongly upon antigen stimuli, were determined (96).  
The strength of muS110 induced T cell activation was comparable to that imposed by a full 
CD3/CD28 stimulation in the presence of IL-2. There was a similar up-regulation of gran-
zyme B and CD134 and an even stronger up-regulation of CD152. Noticeable, approximately 
50% of CD4+ and almost 80 % of CD8+ T cells were granzyme B positive and therefore 
armed to destroy EpCAM+ target cells. In contrast to CD3/CD28/IL-2 stimulated splenocytes 
no rise of intracellular INF-g was detected after muS110-induced activation of splenocytes 
(Figure 9A and B). However, subsequent muS110 activation of pre-activated T cells led to a 
strong increase of IFN-g secreting T cells and almost 75% of CD4+ and more than 90% of 
CD8+ T cells were stained positively. CD3/CD28/IL-2 stimulation resulted in a comparable 
transition of TNaive/CM and TEM to TEff and TInt cells as muS110 stimulation of naive spleno-
cytes. The fraction of TEff cells was additionally increased by subsequent stimulation of pre-
activated T cells with muS110 (Figure 9C and D). In this case more than 50% of CD4+ and 
~80% of CD8+ T cells were armed effector cells, which correlated well with the percentage of 
granzyme B positive T cells.  
Taken together in the presence of target cells muS110 induced potent cytotoxic effector T 
cells similar to that obtained by a full CD3/CD28 stimulation in the presence of IL-2. This 
was observed for naive T cells as well as already pre-activated T cells. The dose-dependent 
up-regulation of CD25 and CD69 might indicate the dose-dependency of this process. The 
high percentage of activated T cells (>80 % CD25+ and CD69+ cells) after only 24 hours of 
stimulation and the almost complete absence of TNaive/CM cells already after 48 hours might 
implicate that muS110 can fully activate all T cells and not only a small fraction of CD28 
independent TEM. Hence, muS110 would be depending only on a second binding partner but 
 - RESULTS - 55 
 
not on any co-stimulatory signals provided by antigen presenting cells. For concentrations 
lower than 1 µg/ml, this activation was strictly dependent on the presence of appropriate tar-
get cells. No up-regulation of the most sensitive marker CD69 was observed for the control 
BiTE muMEC14. But in contrast to the human setting, higher doses were able to induce a less 
pronounced activation independently of a second binding partner. 
5.1.3.3 Cytokine release induced by muS110 
The in vitro potency of muS110 to induce cytokine secretion was additionally analyzed. 
Splenocytes or negatively isolated mouse T cells were incubated with or without CHOmuEp-
CAM+ target cells (E:T= 10:1) in the presence of increasing concentrations of muS110 for 48 
hours. The supernatant was analyzed for IL-2, IFN-g, TNF- a, IL-6, IL-3, GM-CSF, IL-10 
and IL-4 using the CBA flex set system (Figure 10).  
MuS110 led to a dose dependent release of all cytokines tested, when target cells were pre-
sent. In the absence of target cells only a slight increase in IFN-g and TNF-a was observed for 
high doses of muS110. For IFN-g the peak concentration was 5.4 ng/ml, for GM-CSF it was 
3.4 ng/ml, for IL-2 it was 3 ng/ml, for IL-4 it was 2 ng/ml, for IL-10  it was 1.4 ng/ml, for 
TNF-a it was 0.2 ng/ml, for IL-3 it was 0.2 ng/ml, and for IL-6 it was 0.1 ng/ml. The EC50 
values of cytokine secretion were mostly between 0.5 and 5 ng/ml, namely 0.5 ng/ml for IL-6, 
1.4 ng/ml for IFN-g and TNF-a, 1.7 ng/ml for IL-2 and GM-CSF, 3.1 ng/ml for IL-4, 4.8 
ng/ml for IL-10 and 14.5 ng/ml for IL-3.  
Of note, some cytokines showed a comparable magnitude of secretion independently of the 
used effector cell preparation (IFN-g, IL-2, TNF-a, IL-4 and GM-CSF) whereas others were 
weaker induced with naive negatively isolated T cells than with crude splenocytes as effector 
cells (IL-10 and IL-3). No secretion of IL-6 was measured with pure T cells as effector cells.  
Taken together, in the presence of target cells muS110 led to proliferation of T cells, cytokine 
secretion, up-regulation of activation marker and a shift towards cytotoxic effector T cells 
resulting in the elimination of antigen positive target cells. The EC50 values of its bioactivity 
ranged mostly between 0.5 and 5 ng/ml, and its effects were almost completely saturated at 
concentrations of 10-100 ng/ml. In terms of quality and quantity of their bioactivities muS110 
can be considered as valid surrogate of MT110. However, in contrast to the human setting, 
muS110 lost its strict dependency on the presence of antigen positive target cells inducing a 
minor T cell activation at high doses by itself. 
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Figure 10: Cytokine secretion induced by muS110  
To assess muS110 induced release of cytokines, splenocytes or negatively isolated mouse T 
cells (spleen) were incubated with or without CHOmuEpCAM+ target cells (E:T= 10:1) for 48 
hours in the presence of increasing concentrations of muS110. The supernatant was analyzed for 
(A) IL-2, (B) IFN-g, (C) TNF-a, (D) IL-6, (E) IL-3, (F) GM-CSF, (G) IL-10 and (H) IL-4 using 
the CBA flex set system. Error bars indicate SEM of duplicates. The experiment was repeated 
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5.2 Pharmaco-toxicological effects of muS110 in vivo 
5.2.1 Characterization of single dose administration  
5.2.1.1 Adverse effects induced by a single dose of muS110 
The safety profile of muS110 was analyzed following i.v. injection of 5, 15 and 50 µg/kg 
muS110, and the control BiTE hyS110 (500 µg/kg) to 20 female BALB/c mice per treatment 
group. At the indicated time points serum concentrations of mus110 were determined to 
evaluate muS110 serum exposure. Overall, dose-dependent muS110 exposure could be dem-
onstrated. Serum concentrations fell below the limit of quantification within 1 to 2 hours in 
animals, which had received 5 and 15 µg/kg muS110. Therefore, the terminal serum half-life 
of 4 hours could only be determined in the highest dose group receiving 50 µg/kg muS110 
(Figure 11A).  
A time- and dose-dependent onset of side effects was observed up to 24 hours after admini-
stration of muS110 (Figure 11; Table 4). The most prominent side effects were hypomotility, 
piloerection, body weight reduction, hypothermia and diarrhea. Administration of 5 µg/kg 
muS110 resulted in almost no side effects, whereas 15 µg/kg muS110 induced transient hy-
pomotility, piloerection, diarrhea and a decrease in body temperature by approximately 3°C 
within the first 4 hours. Animals showed moderate to strong hunched posture, indicating dis-
comfort but recovered quickly thereafter. Administration of 50 µg/kg muS110 induced more 
pronounced clinical signs, e.g., a pronounced drop in body temperature of 5.7°C persisting for 
at least 10 hours after treatment (Figure 11C). Bolus intravenous doses of ≥500 µg/kg were 
lethal in all animals within 24 hours. Animals treated with 500 µg/kg control BiTE hyS110 
had only mild or no symptoms.  
Table 4: Macroscopic side effects after single dose administration of muS110  
 
MuS110
[µg/kg] 0-2 hrs 2-10 hrs 10-24 hrs 0-2 hrs 2-10 hrs 10-24 hrs 0-2 hrs 2-10 hrs 10-24 hrs
5  +/-  -  -  +/-  +/-  -  -  -  -
15  +  -  -  +  +/-  -  +  -  -
50  +  +/-  -  +  +   +/-  +  +/-  -
50 + Dex.  +/-  +/-  -  +/-  +/-  +/ -  -  -  -
- No effects
+/- Weak effects
+ Moderate to strong effects
Hunched postureHypomotility Diarrhea
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Figure 11: Serum exposure and body temperature after a single dose of muS110   
Female BALB/c mice (n= 20) received i.v. injection of 5, 15 or 50 µg/kg muS110 or 500 µg/kg 
control BiTE antibody in a total volume of 200 µl. (A) Serum concentration of muS110 (n=4); 
(B) body temperature (n= 20) as determined before and 0.5, 1, 2, 4, 6, 8, 10, and 24 hours after 
BiTE antibody injection. The red lines are results with the control BiTE antibody hyS110. Error 
bars indicate SEM. The experiment was conducted 3 times. 
5.2.1.2 Systemic T cell activation induced by a single dose of muS110  
Flow cytometric analysis for activated CD25+ or CD69+ T cells isolated from blood, spleen, 
and from mesenterial, inguinalis superficialis (data not shown) and cervical lymph nodes 
(data not shown) revealed a dose-dependent systemic T cell activation at the indicated time 
points after muS110 administration (Figure 12). The onset of T cell activation was slightly 
faster for CD8+ than for CD4+ cells. Time- and dose-dependent upregulation of CD69 and 
CD25 expression on T cells peaked 4 and 10 hours after intravenous injection of muS110, 
respectively, and sustained thereafter. Administration of 500 µg/kg control BiTE antibody 
induced a less pronounced upregulation of the early activation marker CD69, while expres-
sion of CD25 was hardly affected. Binding of a BiTE antibody solely to CD3 was thus insuf-
ficient to induce strong and sustained T cell activation in vivo even at high doses.   
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Figure 12: Up-regulation of CD69 and CD25 on T cells from mesenteric lymph nodes after 
a single dose of muS110   
Female BALB/c mice (n= 20) received injection of 5, 15 or 50 µg/kg muS110 or 500 µg/kg 
control BiTE antibody in a total volume of 200 µl. Mesenteric lymph nodes were isolated before 
and 1, 2, 4, 10, and 24 hours after muS110 administration. (A and B) CD69 or (C and D) CD25 
up-regulation was determined for CD4+ (right side) and CD8+ (left side) T cells using flow cy-
tometry (n=4 animals). Of note, up-regulation of CD25 was not determined for CD8+ T cells at 
the highest muS110 dose due to experimental problems. Error bars indicate SEM. The experi-
ment was conducted 2 times. 
5.2.1.3 Transient systemic cytokine release induced by a single dose of muS110 
MuS110 induced activation of T cell in vitro was accompanied by secretion of pro–
inflammatory cytokines. High levels of systemic cytokines in vivo have been described to 
induce similar side effects as were observed after administration of muS110 (97-100). The 
serum of muS110-treated mice was analyzed for cytokine concentrations of IL-2, IFN-g, 
TNF-a, IL-4, IL-6, IL-10 as well as IL-12/p70, IL-5, IL-3, MCP-1 and GM-CSF at various 
time points after BiTE antibody administration. MuS110 injection induced a dose-dependent 
and transient release of IL-2, IFN-g, TNF-a, IL-4, IL-6, IL-10 (Figure 13) and IL-12/p70, 
MCP-1 and IL-5 (data not shown). Treatment with 5 µg/kg muS110 resulted in very low se-
rum cytokine concentrations, whereas the 50 µg/kg induced a strong cytokine release.  
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Figure 13: Serum cytokine profiles after intravenous administration of muS110. 
Female BALB/c mice (n= 20) received intravenous bolus injection of 5, 15 or 50 µg/kg 
muS110 or 3750 µg/kg control BiTE antibody muMec14, respectively, in a total volume of 
200 µl. Animals (n= 4) were bled before and 1, 2, 4, 6, 8, 10, 24 hours after BiTE antibody 
administration. Serum samples were pooled and analyzed for (A) IL-2, (B) IFN-g, (C) IL-10, 
(D) IL-4, (E) IL-6 and (F) TNF-a using the mouse Th1/Th2 or inflammatory CBA Kit (BD 
Bioscience). The experiment was conducted three times.   
For most cytokines, the onset of release was fast, and peak values were reached 2 hours after 
intravenous bolus injection of muS110. IL-5, IL-10 and IL-6 reached peak levels not before 6 
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seemed to coincidence with the intensity and the course of clinical symptoms observed at dif-
ferent dose levels. Administration of the only CD3 binding control BiTE muMEC14 at a dose 
of 3750 µg/kg did not result in elevated cytokine levels. 
 
 
5.2.1.4 Peripheral lymphocytopenia induced by a single dose of muS110 
Anti-CD3 mAbs are known to induce peripheral lymphocytopenia in mice (101). Early stages 
of lymphocytopenia are characterized by upregulation of adhesion molecules like CD44 on 
leukocytes and concomitant blood cell redistribution (102). In order to study effects of 
muS110 on blood cell redistribution, mice were treated by a single i.v. injection of 15 µg/kg 
muS110 or the control BiTE antibody hyS110. Total numbers of leukocytes, myeloid derived 
cells (MDC, summarizes all bone marrow derived cells that are not lymphocytes),  natural 
killer (NK) cells, T and B cell were determined at various time points after BiTE administra-
tion (Figure 14). The hematokrit was determined to investigate injection-related effects on 
blood volume.  
Instead of an decrease caused by the injection of 100 µl liquid, a significant increase of the 
hematokrit was observed between 2 and 4 hours after muS110 injection, while only a minor 
increase was determined after injection of control BiTE antibody (Figure 14A). This is most 
likely a consequence of hemoconcentration, which can be caused by cytokine-induced vascu-
lar leakage (103), and may lead to an overestimation of blood cell numbers in animals receiv-
ing muS110. Treatment with 15 µg/kg muS110 led to a rapid decrease in absolute leukocyte 
numbers, which was observed 2 hours after injection, lasted for more than 24 hours, and re-
turned to baseline after 48 hours (Figure 14B). In response to muS110, the number of T cells 
decreased approximately 8-fold and that of B cells 5-fold (Figure 14C and D). The muS110 
induced effect upon absolute numbers of NK cells or monocytes was variable and gave no 
clear result (Figure 14E and F), which might be due to the use of different animals for each 
time point. Administration of the control BiTE antibody had only a minor effect on absolute 
leukocyte or B cell numbers whereas absolute numbers of T cells decreased 2-fold and were 
back to normal levels after 48 hours.  
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Figure 14: Peripheral lymphocytopenia induced by a single dose of muS110  
Female C57BL/6 mice (n= 30) received i.v. injection of 15 µg/kg muS110 or hyS110 control 
BiTE in a volume of 100µl. (A) Hematokrit (B) total numbers of leukocytes (CD45), (C) T cells 
(CD45+CD3+), (D) B cells (CD45+CD19+), (E) NK cells (CD45+CD3-CD49b+)and (F) myeloid 
derived cells (CD45+CD49b-CD11c+) were determined at indicated time points after BiTE anti-
body administration (n=5, each time point different animals) with antibodies directed against 
mouse CD45, CD3, CD49b, CD11c and CD19 with TruCount Tubes. Error bars indicate SEM. 
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5.2.1.5 Comparison of pharmaco-toxicological effects of muS110, KT3 and 145-2C11 
Administration of the conventional anti-CD3 mAbs 145-2C11 and KT3 to mice leads to the 
cytokine release syndrome. Rising systemic levels of pro-inflammatory cytokines, like TNF-
a, IFN-g, IL-2, IL-6 and IL-3 lead to acute but transient systemic symptoms like hypothermia, 
hypoglycemia, hypomotility, piloerection, diarrhea and hypotension resembling a septic 
shock. Doses exceeding 2.5-5 mg/kg are associated with high mortality (101).  
The pharmaco-toxicological effects of the anti-CD3 mAb 145-2C11 and KT3 were directly 
compared to that of the BiTE antibody muS110. 10 female BALB/c mice per group received 
i.v. injection of 5 mg/kg 145-2C11, KT3 or 50 µg/kg muS110. Onset of adverse side effects 
(Table 5, Figure 15A), systemic T cell activation (Figure 15B-D) and systemic cytokine levels 
(Figure 16) were evaluated at indicated time points for all three compounds. 
A similar time- and dose-dependent onset of side effects was observed up to 24 hours after 
administration of all three anti-CD3 antibodies (Figure 15A, Table 5). The magnitude and 
course of macroscopic side effects like hypomotility, piloerection, body weight loss, hypo-
thermia and diarrhea where comparable for all three compounds. However, the onset was 
faster and the duration of side effects shorter after muS110 injection than after administration 
of the complete anti-CD3 antibodies. The faster reversibility of muS110 induced side effects 
might be a direct consequence of the shorter serum half life of a BiTE compared to a mAb. 
The faster onset of clinical symptoms coincidenced with the faster kinetic of systemic T cell 
activation and the faster rise of cytokine serum concentrations observed after muS110 admini-
stration in contrast to the application of KT3 and 145-2C11 (Figure 15C and D, Figure 16). 
 The course of cytokine secretion was comparable but seemed to be delayed by 2 hours. This 
might reflect the dependence of anti-CD3 mAbs on the interaction of the Fc part with Fc re-
ceptors on accessory cells to evolve full activating potential (104-108). The expression of 
these receptors is up-regulated by T cell secreted cytokines (mainly IFN-g), and is therefore 
self energizing but needs time to evolve. MuS110 in contrast needs only the presence of anti-
gen positive target cells to develop its full activating potential.  
Administration of anti-CD3 mAbs results in immunosuppression, which is, at least in part, a 
result of activation induced down-regulation of the CD3 – TCR surface complex impairing 
alloantigen induced T cell activation by antigen presenting cells (109, 110). Unlike bivalent 
anti-CD3 mAbs (111), muS110 treatment did not significantly down-modulate the TCR on T 
cells (Figure 15B). 
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Table 5: Comparison of macroscopic side effects after single dose administration of muS110, 
KT3 and 145-2C11 
Drug [mg/kg] Hypomotility Piloerection Diarrhea 
  0-2 2-10 10-24 0-2 2-10 10-24 0-2 2-10 10-24 
muS110 0.05 + +/- - + + - + +/- - 
145-2C11 5 +/- + +/- +/- + +/- +/- + +/- 
KT3 5 +/- + - +/- + - +/- + - 
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Figure 15: Hypothermia, systemic T cell activation and CD3 down-modulation induced by 
administration of muS110, KT3 and 145-2C11  
Female BALB/c mice (n= 10) received i.v. injection of the complete anti-CD3 mAb 145-2C11 
or KT3 [both 5 mg/kg] or muS110 [50 µg/kg] in a volume of 200µl. (A) Body temperature (n= 
4) as determined before and 1, 2, 4, 6, 8, 10, and 24 hours after antibody injection. (B) Leuko-
cytes of lymph nodes mesenteriales, cervicales and inguinalis superficialis (LNmes, LNcer, LNing) 
and the spleen (n= 2) were isolated 2 hours after antibody injection and were stained with anti-
bodies against CD3, CD4 and CD8. Percentage of CD3- CD4+ cells was determined to evaluate 
antigen binding-induced CD3 down-modulation. (C, D) Mesenteric lymph nodes (n=2) were 
isolated before and 1, 2, 4, 10, and 24 hours after muS110 administration and up-regulation of 
CD69 was determined for (C) CD4+ and (D) CD8+ T cells by flow cytometry. Error bars indi-
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Figure 16: Serum cytokine concentrations after administration of muS110, KT3 and 145-
2C11  
Female BALB/c mice (n= 10) received i.v. injection of 5 mg/kg anti-CD3 mAb 145-2C11, KT3 
or 50 µg/kg muS110 in a volume of 200µl. Animals were bled at 1, 2, 4, 6, 8, 10, and 24 hours 
after injection of the respective antibodies. Serum samples of 2 mice per time point were pooled 
and analyzed for (A) IL-4, (B) TNF-a, (C) IL-2, (D) IFN-g  using the mouse Th1/Th2 CBA Kit 
(BD Bioscience). The experiment was performed twice. 
The adverse effects observed after muS110 administration were comparable to those observed 
after administration of anti-CD3 mAbs. Their progression overlapped with the kinetic of sys-
temic T cell activation and cytokine release. Thus, most likely the T cell activating potential 
of muS110 was responsible for its toxicity. The administration of control BiTEs sharing the 
CD3 moiety but being unable to bind to second binding partners did hardly induce adverse 
symptoms or cytokine release. This confirmed again the similar in vitro findings and the de-
pendency on the presence of a second binding partner to induce profound T cell activation. 
Therefore, we performed histo-pathological analysis to identify an easily and fast accessible 
EpCAM+ target tissue, which could have provided the second binding partner for the immedi-
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5.2.2 Histopathological analysis of mice repeatedly treated with muS110 
Apart from cytokine release by activated T cells, another conceivable adverse reaction for an 
EpCAMxCD3-bispecific BiTE antibody is damage to EpCAM-expressing normal epithelial 
tissues by redirected cytotoxic T cells. Many tissues of mice show expression of EpCAM at 
various intensities, as determined by immunohistochemical staining of tissue with muS110 
(Table 2). In a vehicle-controlled study, sixteen male and female BALB/c mice per group 
received daily intravenous injections of 10 µg/kg/day muS110 for seven days followed by 100 
µg/kg/day muS110 for 28 days. Histopathological analysis of various tissues was performed 
by a certified pathologist. Despite expression of EpCAM on organs such as kidney (score = 
1), lung (= 1), pancreas (= 3), pituitary (= 2-3), parathyroid (= 3-4), colon (= 4), or prostate (= 
3), daily dosing of mice with muS110 for 35 days revealed no evidence for histo-pathological 
detectable lesions in normal tissues expressing the EpCAM target antigen (Table 6). This was 
also true for evaluation of other cohorts after 7 and 14 day treatment (data not shown). No 
lesions were found aiming at the accessible EpCAM+ target cells, necessary as second binding 
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Table 6: Histo-pathological examination of EpCAM+ tissues from mice treated with muS110. 
The EpCAM expression score is described in Amann et al. (85) as follows: 1 = light staining  2 = 
moderate staining 3 = medium-strong staining 4 = intense staining; ‘GI tract other’ includes duode-
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5.2.3 EpCAM+ mouse lymphocytes 
5.2.3.1 Presence of EpCAM+ cells in mouse but not in human lymphocytes 
MT110 induced T cell activation was only found in the presence of huEpCAM+ target cells. 
However, in the mouse system T cell activation by muS110 was observed in the absence of 
added EpCAM+ target cells. This was more prominent with crude splenocyte preparations but 
almost absent with naive, negatively isolated T cells as effector cells. Therefore, mouse lym-
phocytes were analyzed for the presence of EpCAM+ target cells. Mouse PBMC and lympho-
cytes isolated from spleen, mesenteric and cervical lymph nodes were analyzed for EpCAM 
expression by FACS. About 3.1% of CD19+ B cells were found to express EpCAM in the 
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mouse leukocyte population (Figure 17A, right panel). No EpCAM+ cells were found above 
the background of the isotype control antibody in human PBMC, freshly isolated from human 
blood (Figure 17A, left panel (30)). EpCAM expression by murine lymphocytes (CD45, CD3, 
and CD19), NK cells (CD49b) and MDCs (Ly6G) was analyzed in more detail using cell-type 
specific antibodies for FACS analysis. The majority of EpCAM+ cells in mouse blood co-
expressed CD19 or CD45/RB220, showing their B cell origin (Figure 17C). 
EpCAM+ B cells made up for 2-3% of leukocytes found in various lymphoid organs and 
blood. To rule out mouse strain specificity, PBMC from strains CD-1, C57BL/6N, C3H/HEN 
and BALB/c were analyzed for EpCAM+/CD19+ double-positive B cells. As shown in Figure 
17B, the percentage of EpCAM+ B cells did not significantly differ between mouse strains 



































































Figure 17: Existence of EpCAM+ lymphocytes in mice.  
Human PBMC (left panel) and mouse splenocytes (right panel) were double-stained for CD19 
and EpCAM, or with the corresponding isotype control antibodies. (B) PBMC of six female and 
male BALB/c, C57BL/6N, C3H/HEN and CD-1 mice were stained for CD19 and EpCAM and 
analyzed by flow cytometry. (C) Cells isolated from spleen, LNcer, LNmes and from PBMC (n=2) 
were stained for CD3 (T cells), CD19 (B cells), CD49b (NK cells) and Ly6G (MDC) in combi-
nation with an anti-mouse EpCAM mAb, or the corresponding isotype control. Percentage of 
cells positive for EpCAM and the respective markers are shown. Error bars indicate SEM. All 
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5.2.3.2 Dependence of muS110-induced T cell activation on EpCAM+ lymphocytes  
The capacity of small numbers of EpCAM+ cells to induce BiTE -mediated T cell activation 
and cytokine release was evaluated in vitro. A complete depletion of EpCAM+ cells from 
mouse PBMC could not be achieved, even when magnetic bead- and FACS-based approaches 
were combined. However, reduction of EpCAM+ cells in mouse splenocytes from 2.2 to 0.4% 
was found to substantially reduce up-regulation of the activation marker CD25 by muS110 for 
both, CD8+ and CD4+ T cells (Figure 18A and C). Release of cytokines IFN-g, IL-2, TNF-a, 
and IL-4 was almost completely abrogated by reduction of EpCAM+ cells from 2.2 to 0.4%, 
with cytokine levels coming close to those seen with the control BiTE antibody (Figure 18E).  
Complementing, the effect of addition of human EpCAM+ cells to human PBMC was also 
analyzed for MT110 (Figure 18B and D). Human PBMC, which are essentially devoid of Ep-
CAM+ cells, were co-cultivated for 48 hours with different amounts of EpCAM+ human car-
cinoma Kato III cells. No activation of CD8+ or CD4+ T cell could be detected in the absence 
of EpCAM+ target cells (79). However, addition of 2% EpCAM+ cells to human PBMC led to 
activation of approximately 50% of CD8+ and 25% of CD4+ T cells in a MT110 dose-
dependent manner. The upregulation of CD25 was accompanied by release of IFN-g, TNF-a 
and IL-10 from human PBMC (Figure 18 F). Addition of only 0.2% EpCAM+ cells to human 
PBMC no longer strongly induced CD25 expression on CD4+ and CD8+ human T cells by 
MT110. However, the presence of 0.2% EpCAM+ cells still caused a release of TNF-a and a 
small response of IFN-g in response to MT110. 
These data suggest that EpCAM+ B cells in the mouse leukocyte compartment could be 
responsible for the profound and fast T cell activation, robust cytokine release and, ultimately, 
for the acute dose limiting side effects of muS110 injection in mice. In Figure 19 the sum of 
all induced cytokines after 48 hours in an in vitro cytotoxicity assay is plotted against the 
respective muS110 concentrations for naive, negatively CD3 enriched T cells (0.3% EpCAM+ 
lymphocytes) and crude splenocytes (2.3% EpCAM+ lymphocytes) with or without the 
addition of 10% EpCAM+ target cells. This figure shows the magnitude of cytokine secretion 
solely induced by only 2.3 % EpCAM+ lymphocytes.  
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Figure 18: Dependence of muS110 and MT110 induced T cell activation on EpCAM+ tar-
get cells 
 (A, C, E) Mouse splenocytes (2.2% EpCAM+ cells) or splenocytes partially depleted of Ep-
CAM+ cells (0.4% EpCAM+ cells) were incubated for 48 hours with the indicated concentra-
tions of muS110, or with control BiTE antibody in the absence or presence of 10% CHOmuEp-
CAM+ cells. (B, D, F) Human PBMC were incubated for 40 hours in the absence or presence of 
0.2%, 2% or 10% KatoIII cells with the indicated concentrations of MT110. Thereafter CD8+ 
and CD4+ lymphocytes were analyzed for CD25 expression by flow cytometry. (A and B) Per-
centage of CD8+CD25+ and (C and D) percentage of CD4+CD25+ cell are shown. Representa-
tive results of three independent experiments are shown. Error bars indicating SEM are present! 
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(0.4% EpCAM+ cells) were incubated for 48 hours with 100 ng/ml muS110 or control BiTE 
hyS110 with or without 10% CHOmuEpCAM+ cells. (F) Human PBMC were incubated for 40 
hours in the absence or presence of 0.2%, 2% or 10% KatoIII cells with 100 ng/ml MT110. Su-
pernatants were analyzed for cytokine levels using the (E) mouse CBA Th1/Th2 detection kit 
(BD Bioscience) or the (F) human CBA Flex set (BD Bioscience). Error bars indicate SEM. The 
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Figure 19: Dose dependent cytokine release after muS110 induced target cell lysis  
To access muS110 induced release of cytokines negatively isolated mouse T cells (0.3% Ep-
CAM+ cells) or freshly isolated splenocytes containing 2.3 % EpCAM+ lymphocytes were in-
cubated with or without 10% CHOmuEpCAM+ target cells (E:T= 10:1) 48 hours in the presence 
of various concentrations of muS110. The supernatant was analyzed for the presence of IL-2, 
IFN-g, TNF-a, IL-6, IL-3, GM-CSF, IL-10 and IL-4 using the CBA flex set system. The total 
amount of cytokines present after 48 hours of incubation is plotted against the muS110 concen-
trations for (A) T cells with 0.3% EpCAM+ cells, (B) splenocytes containing 2.3% EpCAM+ 
cells, (C) T cells with 0.3% EpCAM+ cells + 10% CHOmuEpCAM+ target cells, or (D) spleno-
cytes containing 2.3% EpCAM+ cells + 10% CHOmuEpCAM+ target cells. Error bars indicate 
SEM of duplicates.  The experiment was repeated twice. 
A B 
D C 
 - RESULTS - 72 
 
5.2.4 Characterization of multiple dose administrations  
5.2.4.1 Adverse effects induced by repetetive doses of muS110 
The safety profile of muS110 was analyzed following i.v. bolus injections for seven consecu-
tive days of 2, 10, and 50 µg/kg/day mus110 or vehicle, to 10 male BALB/c mice per treat-
ment group. At the indicated time points, serum concentrations of muS110 were determined 
in order to evaluate muS110 exposure (Figure 20A). The kinetic profiles averaged over 7 days 
showed that dose-linear muS110 exposure was obtained. 
 Daily i.v. administrations of vehicle or the two lower doses of muS110 (2 and 10 µg/kg/day) 
were generally well tolerated and none of the animals showed severe clinical signs or died 
during the course of the study. Repeated daily treatment with the 50 µg/kg/day dose of 
muS110, however, induced pronounced but mostly reversible clinical signs. Side effects oc-
curred within 8 hours after each muS110 administration. Thirty percent of animals died or 
were euthanized for well-fare reasons after the third or fourth injection (Figure 20B). 
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Figure 20: MuS110 exposure and survival after repeated administration of muS110  
BALB/c mice (n= 10) received daily intravenous bolus injections of vehicle, 2, 10, or 
50 µg/kg/day muS110 for 7 days in a volume of 200 µl. (A) Serum concentration of 
muS110 (n=2) were daily determined 15 min 1, 2, 4, 8, and 24 hours after each injec-
tion. Data shown was averaged for 5 consecutive injections. (B) Survival was followed 
for seven days. Error bars indicate SEM. The experiment was repeated twice. 
Dose dependent side effects, such as hypothermia (Figure 21B), weight loss (Figure 21A), 
piloerection and diarrhea were similar to those observed after single-dose i.v. injection of 
muS110 (5.2.1.1) (112). The highest dose group lost up to 15% body weight after the first 
three injections. Thereafter all mice gained body weight despite ongoing daily muS110 treat-
ment. Animals treated with vehicle, 2 µg/kg/day and 10 µg/kg/day muS110 did not show sig-
A B 
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nificant body weight changes. Relative to the control animals the highest dose group showed a 
drop in body temperature of almost 10% after the first three injections. The hypothermia 
worsened after the second and third injection as the onset was faster and the duration pro-
longed. Temperature was not completely recovered 24 hours after each injection. Animals 
receiving 10 µg/kg/day muS110 showed a less severe drop of only 2.5-5 % and the animals 
recovered completely after 8 hours. Animals receiving 2 µg/kg/day muS110 showed no sig-
nificant alterations of body temperature compared to control animals. After the fourth injec-
tion all side effects declined despite continued muS110 treatment. No treatment related side 
effects were seen after the fifth to seventh injection for all animals. This indicated that dose-
dependent side effects seemed to be self-limiting and animals could adapt to repetitive treat-
ment with muS110.  
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Figure 21: Weight loss and hypothermia caused by repeated administration of muS110 
Repeated dosing of muS110 led to hypothermia and body weight loss. However, animals 
adapted to repeated treatment and recovered after the forth injection despite ongoing muS110 
medication. BALB/c mice (n= 10) received daily i.v. injections of vehicle, 2, 10, or 50 
µg/kg/day muS110 for 7 days in a volume of 200µl. (A) Body weight of all animals was deter-
mined daily prior to injection. Percentage of body weight change in comparison to beginning of 
the experiment is shown. (B) Body temperature was determined before and 2, 4 and 8 hours af-
ter each injection on day 0-3 and 6 of experiment. Percentage of body temperature changes 
normalized to vehicle treated animals is shown. Error bars indicate SEM. The experiment was 
repeated twice. 
5.2.4.2 Cytokine release induced by repetitive muS110 treatment 
 
Daily dosing of muS110 induced a systemic and transient release of inflammatory cytokines, 
including IL-2, IFN-g, TNF-a, IL-6, IL-10, and IL-4 (Figure 23). No active TGF-b was found 
at any time point after muS110 injection. In general, serum concentrations of all cytokines 
returned to baseline levels by approximately 8 hours after each injection. 
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Figure 24: Cytokine release induced by repetitive muS110 treatment 
Male BALB/c mice (n= 10) received daily i.v. injections of 50 µg/kg/day muS110 for 7 days in 
a volume of 200 µl. Animals (n= 2) were bled prior, 15 min, 1, 2, 4, 8, and 24 hours after each 
muS110 administration on day 0, 1, 2, 3 and 6 of the experiment. Serum samples were analyzed 
for (A) IL-6, (B) TNF-a ,(C) IL-4, (D) IFN-g, (E) IL-2, (F) IL-10 using the CBA Flex set (BD 
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Figure 22  Cytokine release induced by repetitive muS110 treatment 
Male BALB/c mice (n= 10) received daily i.v. injections of 50 µg/kg/day muS110 for 7 days in 
a volume of 200 µl. Animals (n= 2) were bled prior, 15 min, 1, 2, 4, 8, and 24 hours after each 
muS110 administration on day 0, 1, 2, 3 and 6 of the experiment. Serum samples were analyzed 
for (A) IL-6, (B) TNF-a ,(C) IL-4, (D) IFN-g, (E) IL-2, (F) IL-10 using the CBA Flex set (BD 
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These kinetics were similar to those observed after single-dose administration of muS110 
(Figure 13)(112). The cytokine release was for each cytokine self-limiting and, with the ex-
ception of IL-10, much reduced after the second and third injection of muS110. No further 
cytokine release was detectable after the fourth to seventh injection. Especially the absence of 
IFN-g, TNF-a and IL-6 after the fourth muS110 injection may explain the observed slowing 
down of side effects. These cytokines are known to be central figures of the cytokine release 
syndrome observed after administration of conventional anti-CD3 antibodies.  
IL-10 had an exceptional time-course of secretion and showed only a slight increase of serum 
concentration 8 hours after the first muS110 injection but was highest after the second and 
third muS110 administration (Figure 22F). 
5.2.4.3 Cytotoxic T cells induced by repetitive doses of muS110  
The appearance of cytotoxic T cells in vivo after repeated muS110 injection was analyzed. 
Four female BALB/c mice per group received daily intravenous bolus injections of vehicle or 
25 µg/kg/day muS110 for 3 days. Splenocytes, PBMC and lymphocytes from mesenteric 
lymph nodes were isolated and stained with antibodies against CD127 and CD62L to deter-
mine distribution of naive or central memory T cells (TNaive/ CM, CD62L+ CD127+), intermedi-
ate T cells (TInt, CD62L+ CD127), effector T cells with high lytic potential (TEff CD62L-
CD127-) and effector memory T cells (TEM, CD62L- CD127+) (96). Additionally intracellular 
staining with antibodies against granzyme B, IFN-g and CD152 was performed.   
Daily treatment with muS110 led to the systemic induction of effector T cells in all analyzed 
compartments. This was most prominent for CD8+ T cells where 50 to 75% of T cells were 
effector T cells in comparison to only 10% in the control animals. Additionally, 25% of CD8+ 
splenocytes and up to 75% of blood CD8+ T cells were also positive for granzyme B, which 
identified them as cytotoxic T cells. Peripheral CD4+ T cells showed magnified granzyme B 
secretion in comparison to control animals (50% versus 10%) and a noticeable gain of effec-
tor T cells (35% versus 25%) whereas CD4+ T cells from spleen and lymph nodes were 
mainly in an intermediate state. Only a minor difference of IFN-g secretion to control animals 
was found for CD4+ and CD8+ splenocytes but was well established in peripheral T lympho-
cytes. The suppressive receptor CD152 was up-regulated, again more prominent for CD8+ 
than for CD4+ T cells. Taken together repetitive treatment with muS110 induces predomi-
nantly cytotoxic CD8+ T cells, which were distributed systemically. Additionally an increase 
of peripheral CD4+ effector T cells positive for granzyme B was noted.  
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Figure 23: Cytotoxic T cells induced by repeated muS110 injections 
BALB/c mice (n= 4) received daily i.v. injections of vehicle or 25 µg/kg/day muS110 for 3 days 
in 200 µl. Splenocytes and PBMC were isolated and stained with antibodies against (A, C) CD4 
and (B, D) CD8 to identify T cells. (A, B) A part of the cells were stained with antibodies 
against the surface marker CD127 and CD62L. Percentage of naive/ central memory T cells 
(TNaive/ CM, CD62L+ CD127+), intermediate T cells (TInt, CD62L+ CD127-), effector T cells (TEff, 
CD62L- CD127-) and effector memory T cells (TEM, CD62L- CD127. (C, D) Intracellular stain-
ing with antibodies against Ly6-C, granzyme B, IFN-g, and CD152 was performed after PMA/ 
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5.2.5 Increased muS110 tolerability and immune modulation 
5.2.5.1 Tolerability increase of muS110 after in vivo depletion of EpCAM+ lympho-
cytes  
Due to its mode of action EpCAM+ lymphocytes should be eliminated by muS110 induced 
target cell lysis over time. A high percentage of CD8+ T cells were granzyme B positive and 
therefore ready to lyse target cells. A reduced number of EpCAM+ target cells should lead to 
reduced systemic cytokine secretion, as the magnitude of cytokine release correlated with the 
amount of target cells present (Figure 18, Figure 19). A decrease of cytokine levels should in 
turn reduce the appearance of side effects, which might be one explanation for the increased 
tolerability of muS110 after repeated administration. For in vivo tumor treatment it was desir-
able to find a way to increase the maximal tolerated dose. Thus, it was tested if an eradication 
of the easily accessible EpCAM+ lymphocytes by low doses of muS110 might increase toler-
ability to high doses.       
A low-dose pre-treatment for 7 days with a daily i.v. dose of 10 µg/kg muS110 was suitable 
for substantial redirected lysis of EpCAM+ B and T cells in mice (Figure 24A). This low-dose 
regimen caused only mild and reversible side effects (5.2.4.1). EpCAM+ B cells were reduced 
from 3.1 to 0.3%, EpCAM+ T cells from 0.8 to 0.2%, still leaving a total of 0.5% EpCAM+ 
lymphocytes in the periphery. Control animals treated with either daily i.v. doses of 10 µg/kg 
control BiTE antibody or PBS vehicle showed no alterations in the number of EpCAM+ 
lymphocytes (data not shown).  
Mice with substantially reduced EpCAM+ lymphocytes and control animals were challenged 
with daily i.v. doses of 100, 300 and 500 µg/kg/day muS110 for a total of 10 days. Animals 
receiving 10 µg/kg/day of the control BiTE antibody (data not shown) showed severe side 
effects and hypothermia, upon high-dose muS110 challenge such that all had to be euthanized 
within 48 hours due to ethical considerations. In contrast, all animals pre-treated with a low-
dose of muS110 survived doses of 100, 300 and 500 µg/kg of muS110 given daily i.v. for 10 
days. Only mild and reversible side effects were noted in these animals such as a modest and 
transient reduction of body temperature (Figure 24B) and body weight (data not shown). 
These side effects could be due to a limited T cell activation triggered by the remaining 0.5% 
EpCAM+ lymphocytes, consistent with the in vitro data obtained with EpCAM depleted T 
cells (Figure 18).  
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Figure 24: Increase of tolerability to muS110 by low-dose pre-treatment  
 (A and B) Female BALB/c mice (n= 5) received daily i.v. injections of vehicle or 10 
µg/kg/day muS110 for 7 days (adaptation). Thereafter, animals were challenged with 
i.v. injections of 100, 300 and 500 µg/kg/day muS110 (challenge). (A) Splenocytes iso-
lated from PBS control and low-dose muS110 pre-treated mice were stained for CD3 
and EpCAM by specific mAbs. The percentage of EpCAM+ cells in the respective gates 
is given relative to the total number of lymphocytes analyzed by FACS. (B) Body tem-
perature (n= 5) profiles were determined for low-dose muS110 adapted and control 
mice following 1, 2, 4, 8, and 24 hours after high-dose BiTE antibody challenge. (C and 
D) Female BALB/c mice (n= 5) received daily intravenous bolus injections of 0.4, 2, or 
10 µg/kg/day muS110 for 7 days (adaptation). Thereafter, animals were challenged 
with daily i.v. injections of 100 µg/kg/day muS110 (challenge). (C) Body weight of all 
animals was determined before each injection on day 1, 2, 3, and 4 of challenge. Per-
centage of body weight changes in comparison to the beginning of the challenge is 
shown. (D) Survival was monitored daily. Error bars indicate SEM. Experiments are 
performed twice. The injection volume was always 200 µl. 
To proof the correlation between lower numbers of EpCAM+ lymphocytes, reduced systemic 
T cell activation and resulting enhanced tolerability the pattern of cytokine release to a 
muS110 challenge was analyzed after low-dose pre-treatment. Female BALB/c mice were 
treated by i.v. injection with low doses of muS110 (0.4, 2, or 10 µg/kg/day), or BiTE control 
antibody (at 10 µg/kg/day), for seven days (‘adaptation’ phase). This was followed by daily 
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riod). During this long-term study, survival (Figure 24D), body weight (Figure 24C), clinical 
condition, and body temperature (data not shown) were monitored. 
Again all animals adapted with 10 µg/kg/day muS110 were protected from mortality by sub-
sequent challenges with 100 µg/kg/day muS110. Animals adapted with 2 µg/kg/day muS110 
followed by 100 µg/kg/day doses survived at least the first seven days of high-dose treatment. 
Pre-treatment of animals with 0.4 µg/kg/day had no protective effect and 40% of animals died 
within the first two days of high-dose treatment, the remaining animals on the fourth day of 
challenge. Pre-treatment of animals with low doses of muS110 also ameliorated in a dose-
dependent fashion the occurrence of side effects, such as reduction of body weight and of 
body temperature (data not shown).  
The increase in tolerability to muS110 by a low-dose adaptation with muS110 coincidenced 
with a reduction of cytokine release (Figure 25).  
 
Figure 25: Protection from cytokine surge after muS110 low dose pre-treatment followed 
by high dose challenge  
Animals adapted with a 7 day low dose treatment with muS110 were protected against a cyto-
kine surge upon a subsequent high dose challenge. This protection correlated with the serum 
levels of IL-10 present at the first day of challenge. Female BALB/c mice (n= 5) received daily 
i.v. injections of 0.4, 2, or 10 µg/kg/day muS110 for 7 days (adaptation) in avolume of 200 µl. 
Thereafter, animals were challenged with daily i.v. injections of 100 µg/kg/day muS110 (chal-
lenge). Animals (n=2) were bled 2 hours after muS110 administration on (A) day 1 and (B) day 
2 of challenge. Serum samples were analyzed for IFN-g, IL-2, TNF-a, IL-6, IL-10, and IL-4. 
Dotted lines and arrows relate to different scales. Error bars indicate SEM. Experiments was 
performed twice. 
Blood was taken 2 hours after muS110 administration during the first five days of the 100 
µg/kg/day challenge, and serum levels of IL-2, IFN-g, TNF-a, IL-6, IL-3, GM-CSF, IL-4, and 
IL-10 were determined. Low-dose pre-treatment with 0.4 µg/kg/day muS110 per day resulted 
in high serum concentrations of IL-2, IFN-g, TNF-a, IL-6, and IL-4 after the first and second 
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day of high-dose challenge. Pre-treatment with 2 µg/kg/day resulted in intermediate cytokine 
levels, and pre-treatment with 10 µg/kg/day muS110 resulted in the lowest serum concentra-
tions of cytokines after the first and second day of challenge. Blunting of cytokine responses 
was thus dependent on the adaptation dose of muS110 and most effective after a one-week 
adaptation of mice at 10 µg/kg/day muS110. 
However, the kinetic of IL-10 release was different from that of all other cytokines in re-
sponse to a first and second high-dose challenge with muS110. IL-10 serum concentrations 
were not decreased but strongly elevated 2 hours after the first high-dose challenge of animals 
pre-treated with 10 µg/kg/day muS110. Induction of IL-10 was not as pronounced in animals 
pretreated with 2 and 0.4 µg/kg/day muS110. 
After the second high-dose challenge, IL-10 expression was reduced in animals pretreated 
with 10 µg/kg/day muS110 while it was strongly elevated in animals, which had received 
lower muS110 doses for pre-treatment. The contra wise time-course of IL-10 ruled against a 
mere depletion of EpCAM+ target cells as solemn cause for increased tolerability after re-
peated muS110 administration. In this case, all cytokines should have been reduced in a simi-
lar way. 
IL-10, also described as a “cytokine synthesis inhibitory factor” (113), is an anti-
inflammatory cytokine and has pleiotropic effects in immune regulation and inflammation. It 
down-regulates the expression of TH1 cytokines IL-2, IFN-g, that of IL-3, TNF-a and GM-
CSF. It reduces the surface expression of MHC class II antigens and costimulatory molecules 
on macrophages. It is mainly expressed in monocytes and TH2 cells, CD4+CD25+FoxP3+ 
regulatory T cells but also in a certain subset of activated T cells and B cells. It was shown 
that short term treatment with anti-CD3 specific antibodies, like kOKt3yl (Ala-Ala), can elicit 
operational tolerance in transplantation and autoimmunity (114). Patients treated with the hu-
manized, FcR non-binding kOKt3yl (Ala-Ala) induced a sub-population of CD4+ T cells, 
which secreted IL-10 and expressed high levels of surface TGF-b. These cells resembled Tr1 
regulatory T cells and might have an important role as immune modulators in using this anti-
body. The prominent appearance of IL-10 might indicate a similar immune regulatory mecha-
nism in the adaptation of animals to repeated muS110 administration although no evidence 
for TGF-b involvement was found after muS110 treatment.  
The mAb KoKt3yl (Ala-Ala) induced in vivo a mild cytokine release syndrome with stronger 
IL-10 release in ratio to IFN-g levels, increased the CD4+CD25+FoxP3+ regulatory T cells 
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numbers and the CD8+/CD4+ ratio (115). Therefore, animals adapted for one week with 10 
µg/kg/day muS110 were monitored for the presence of CD4+CD25+FoxP3+ regulatory T cells 
and the ratio of CD8+ to CD4+ T cells. Significantly elevated levels of CD4+CD25+FoxP3+ 
regulatory T cells (10% compared to normally 6% of CD4+ cells) were found in the spleen but 
not in the blood. Additionally a significantly higher CD8+/CD4+ ratio was found in the blood 
of adapted mice in comparison to vehicle treated control mice (Figure 26). 
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Figure 26: Induction of CD4+CD25+FoxP3+ regulatory T cells and changes in the 
CD8+/CD4+ ratio upon low dose muS110 adaptation 
Female BALB/c mice (n= 6) received daily i.v. injections of vehicle (control) or 10 µg/kg/day 
muS110 for 7 days in a volume of 200 µl. (A) 24 hours after the last injection splenocytes and 
PBMCs were stained with antibodies against CD4 and CD8 and analyzed for the CD8+/CD4+ T 
cell ratio by flow cytometry. (B) Additionally cells were stained intracellularly with antibodies 
against CD25 and FoxP3 for the presence of CD4+CD25+FoxP3+ T cells. Error bars indicate the 
SEM. Asterisk indicate P values < 0.02 obtained with student´s T test. The experiment is repre-
sentative for two individual experiments 
5.2.5.2 Ex vivo T cell activation after repeated administration of muS110  
Stimulation of T cells via the TCR in the absence of co-stimulatory signals can lead to T cell 
anergy, which is characterized by down regulation of effector functions in re-stimulated T 
cells (116). Redirected lysis by muS110 in vivo involved repeated TCR signaling in the ab-
sence of co-stimuli. Almost complete elimination of EpCAM+ lymphocytes abrogated the 
second binding partner in healthy mice and T cell activation took place in the presence of high 
IL-10 concentrations. Hence, reduction of systemic cytokine levels after repeated administra-
tion of muS110 could have also been a consequence of T cells anergy, possibly imposed by 
regulatory T cells. Thus, T cells isolated from low dose muS110 adapted animals were tested 
for signs of anergy, e.g. impairment of the proliferative potential. Female BALB/c mice re-
ceived i.v. injections of 10 µg/kg/day muS110, or vehicle, for 7 consecutive days. One day 
A B 
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after the 7th administration, half of the animals were sacrificed (‘acute phase’). The remaining 
animals were killed after a ‘recovery phase’ of 7 days. Splenocytes were isolated from each 
animal and labeled with CFSE, a dye visualizing cell cycling by FACS analysis. The CFSE-
labeled splenocytes were restimulated in vitro in the presence of recombinant human IL-2 
using the Dynabeads CD3/CD28 T Cell Expander, or were left untreated to obtain back-
ground values. The capacity to enter the cell cycle and proliferate in response to an exogenous 
stimulus was monitored by the dilution of the CFSE signal in T cells.    
No significant difference in the proliferation between re-stimulated T cells from muS110 or 
vehicle treated animals could be observed after treatment or a 1-week recovery period (Figure 
27A). T cells had not lost their proliferative potential during repetitive treatment of mice with 
muS110. Analysis of the FACS histograms of CFSE-labeled cells revealed a difference with 
respect to the synchronicity of cell division (Figure 27B). T cells isolated from muS110 
treated animals divided synchronously by showing just one major species of labeled cells, 
while T cells isolated from vehicle control animals divided asynchronously, showing discrete 
cell populations of various cell generations. Upon in vitro re-stimulation the cytokine release 
of cells from muS110-treated animals was significantly lower than that from vehicle treated 
ones (p<0.02 using the student’s t test) (Figure 27C). Recovery for one week normalized the 
cytokine secretion levels upon re-stimulation (Figure 27D).  
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Figure 27: Repeated administration of muS110 does not impair restimulation of T cells. 
Female BALB/c mice (n= 12) received daily intravenous bolus injections of vehicle (control) or 
10 µg/kg/day muS110 for 7 days in a volume of 200 µl. Six animals were killed 24 hours after 
the 7th injection (Acute Phase) whereas 6 animals were allowed to recover for additional seven 
days (Recovery Phase). Splenocytes were isolated 24 hours after 7th injection, labeled with 
CFSE, and stimulated with Dynabeads CD3/CD28 T Cell expander in the presence of 10 U/ml 
rhIL-2. (A) After 72 hours, proliferation was monitored by FACS analysis of CFSE distribution. 
(B) Mean fluorescence intensity is shown. (C, D) Supernatant of samples with splenocytes ob-
tained after (C) acute phase or (D) recovery phase were analyzed for concentrations of TNF-a, 
IL-2, IL-10, IFN-g, IL-6, and IL-3. Error bar indicated the SEM. Experiment was performed 
twice.   
5.2.5.3 Cytotoxic and proliferative capacity of T cells after repeated administration 
of muS110 
To rule out a relieve of a potential muS110-induced T cell anergy by addition of IL-2, which 
could have explained the observed synchronous cell proliferation, T cells were tested for redi-
rected lysis after acute and recovery phase in the absence of recombinant human IL-2. As 
shown in Figure 28A, T cells from vehicle and muS110 treated animals showed a similar po-
tency to induce lysis of CHOmuEpCAM+ cells with almost identical EC50 values for half 
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Figure 28: Cytotoxic and proliferative capacity of T cells after repeated administration of 
muS110  
Female BALB/c mice (n= 12) received daily intravenous bolus injections of vehicle (control) or 
10 µg/kg/day muS110 for 7 days in a volume of 200 µl. Six animals were killed 24 hours after 
the 7th injection (Acute Phase) whereas 6 animals were allowed to recover for additional seven 
days (Recovery Phase).  (A) Splenocytes were isolated after acute or recovery period and were 
used as effector cells for redirected target cell lysis of CHO/muEpCAM+ target cells. Cell lysis 
was determined by FACS analysis of nuclear PI uptake. The assay was performed in triplicates. 
Data represents global fit for 6 animals. (B) Absolute cell number/ well of CD4+ and CD8+ T 
cells were analyzed pre and 72 hours after redirected lysis in samples containing 100 ng/ml 
muS110 (C, D) Supernatants of samples containing 100 ng/ml muS110 were analyzed for (C) 
TNF-a, IL-2, IL-10, IFN-g IL-6, IL-3 and (D) TGF-b content. Error bars indicate SEM. Ex-
periments were repeated twice.  
This suggests that muS110 treatment does not impair the cytotoxic capacity of T cells. The 
BiTE control antibody muMEC14 did not mediate lysis of CHOmuEpCAM+ cells (data not 
shown). To evaluate the ability of T cells to proliferate the absolute count of living CD4+ and 
CD8+ T cells was measured before and after redirected lysis using flow cytometry. Absolute 
cell counts after redirected lysis were amplified 3-4 fold for CD8+ T cells and 2-3 fold for 
CD4+ T cells independently of prior in vivo treatment with or without muS110 and of exoge-
nous addition of IL-2 (Figure 28B). In fact, IL-2 was not detectable in culture supernatants 
after in vitro re-stimulation of muS110-pretreated T cells with muS110 (Figure 28C).  
D C 
B A 
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As observed in the proliferation experiment, cytokine release upon in vitro re-stimulation with 
muS110 was much reduced in muS110-treated animals compared to vehicle controls (Figure 
28C). As in vivo no latent or active TGF-b was found in the cell culture supernatant (Figure 
28D). The ratio of CD8+ to CD4+ cells slightly shifted toward CD8+ T cells after muS110 in 
vivo stimulation, which became even more prominent 72 hours after in vitro re-stimulation of 
T cells with muS110 (data not shown). As in the control group a dose dependent up-
regulation of CD69 and CD25 on CD4+ and CD8+ T cells was observed after the acute as well 
as after the recovery phase (Figure 29). Of note, again CD8+ cells seem to be more activated 
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Figure 29: MuS110 induced ex vivo T cell activation after low dose adaptation  
T cells of low dose muS110 adapted animals activated upon ex vivo re-stimulation with muS110 
and did not show signs of anergy. Female BALB/c mice (n= 10) received daily intravenous bo-
lus injections of vehicle (control) or 10 µg/kg/day muS110 for 7 days in a volume of 200 µl. Six 
animals were sacrificed 24 hours after the 7th injection. Splenocytes were isolated after (A, B) 
acute period or (C, D) recovery period and were used as effector cells for redirected target cell 
lysis of CHO/muEpCAM+ target cells for 72 hours. Afterwards cells were stained with antibod-
ies against CD4, CD8, CD25 and CD69 and analyzed with flowcytometry. Up-regulation of 
CD69 (left side) and CD25 (right) side is shown as function of muS110 concentration. Error 
bars indicate the SEM for triplicates of six animals. Experiment was repeated twice. 
A B 
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Conclusively no signs of anergy were found for lymphocytes isolated from muS110 adapted 
animals. However, these T cells had impaired ability for cytokine secretion after in vitro re-
stimulation via an anti-CD3 stimulus, which was normalized after one week free of muS110 
injections. Even in the face of a full T cell activating stimulus T cells from adapted animals 
did hardly produce cytokines in comparison to those of untreated animals, although they were 
not hampered in their ability to proliferate, up-regulate activation markers and lyse target 
cells. This indicated again that mere loss of EpCAM+ target cells upon repeated treatment 
with muS110 was not the only cause of adaptation to muS110. 
 
5.2.6 Impact of glucocorticoids on muS110 tolerability in vivo 
Glucocorticoids, like methylprednisolone (mPDS) and dexamethasone, repress the expression 
of a wide variety of cytokines including IL-2, IL-3, IL-4, IL-6, IL-8, and IFN-γ (117). They 
are used for treatment of a variety of allergic, inflammatory, and autoimmune disorders (118). 
Cytokine-related side effects of anti-CD3 antibodies have been shown to be significantly re-
duced by glucocorticoid pre-treatment (99, 119). Hence, the impact of dexamethasone and 
mPDS on the tolerability of single dose and repeated administrations of muS110 was tested.  
The safety profile of muS110 was analyzed in 20 female BALB/c mice following i.v. injec-
tion of 50 µg/kg mus110 with or without pre-treatment with 10 mg/kg dexamethasone one 
hour before muS110 administration. At the indicated time points serum concentrations of 
muS110 were determined in order to evaluate muS110 exposure. Overall, dose-dependent 
muS110 exposure was similar for both treatment groups (Figure 30A).  
In both groups a time- and dose-dependent onset of side effects was observed for up to 24 
hours after administration of muS110 ( Figure 30B). Most prominent side effects were hypo-
motility, piloerection, hypothermia and diarrhea (Table 7). Hypomotility and piloerection 
were significantly reduced in animals treated with dexamethasone. The onset of diarrhea was 
completely prevented in dexamethasone treated animals and the observed hypothermia was 
less pronounced (2°C versus 5.7°C) and reversible already after 4 hours.  
In general, tolerability of 50 µg/kg muS110 with dexamethasone pre-treatment was compara-
ble to that of single muS110 doses between 5 and 15 µg/kg. Dexamethasone slightly de-
creased the overall systemic T cell activation as indicated in Figure 30C, where CD25+ and 
CD69+ expression of T cells isolated from mesenterial lymph nodes is shown. Dexamethasone 
was also able to significantly reduce the following cytokine release (Figure 30D). With excep-
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tion of IL-10, the peak levels of all cytokines analyzed were reduced by 50 to 90% after dex-
amethasone pre-treatment and were comparable to serum concentrations obtained after ad-
ministration of 5 – 15 µg/kg muS110.  
 
Table 7 : The effect of glucocorticoid pre-treatment on the tolerability of muS110 
MuS110 Pretreatment
[µg/kg] Dexamethasone 0-4 hrs 4-10 hrs 10-24 hrs 0-4 hrs 4-10 hrs 10-24 hrs 0-4 hrs 4-10 hrs 10-24 hrs
50 -  +  +/-  -  +  +   +/-  +  +/-  -
50 10 mg/kg  +/-  +/-  -  +/-  +/-  +/ -  -  -  -
- No effects
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Figure 30: Effects of glucocorticoid pre-treatment on the tolerability of muS110 
Female BALB/c mice (n= 20) received i.v. injection of 50 µg/kg muS110 with or without pre-
treatment with 10 mg/kg dexamethasone one hour before muS110 administration. (A) Serum 
concentrations of muS110 (n=4) were determined 5 min, 1, 2, 4, 6, 8, 10, and 24 hours after 
muS110 injection. (B) Body temperature was determined at the indicated time points after 
muS110 administration. (C) Mesenteric lymph nodes (n=2) were isolated before and 1, 2, 4, 10, 
and 24 hours after muS110 administration. CD25 and CD69 surface expression were deter-
mined for CD4+ T cells by flow cytometry. Error bars indicate SEM. (D) Animals (n=4) were 
bled 2 hours after muS110 injection and pooled serum samples were analyzed for IL-2, IFN-g, 
TNF-a, IL-6, IL-4 and IL-10 concentrations. The experiment was performed twice.  
C D 
B A 
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Glucocorticoid treatment was clearly able to increase tolerability to single dose muS110 injec-
tion; therefore, it was analyzed whether this could also be observed for repetitive muS110 
administration. 30 mg/kg mPDS was administered one hour before and after the first injection 
of muS110. Thus, the capability of mPDS to prevent or decrease the first dose effect and the 
impact of mPDS on muS110 dose adaptation was analyzed.    
BALB/c mice received i.v. bolus injections of 10 µg/kg/day muS110 for 7 days with or with-
out intra-peritoneal injection of 30 mg/kg mPDS one hour before and after the first injection 
of muS110.  Administration of muS110 resulted in an average loss of body weight by 4% and 
a mild but reversible reduction of motility for up to 4 hours after the first and second injec-
tion. Both adverse effects were completely prevented by pre-administration of mPDS. Serum 
cytokine levels of IL-2, TNF-a, IL-6, and IL-10 were found to be increased 2 hours after in-
jection of muS110 with a significant adaptation after the third injection. Co-administration of 
mPDS efficiently inhibited cytokine release after the first injection of muS110 but, with the 
exception of IL-10, was no longer effective after the second injection of muS110. As ob-
served before, IL-10 concentration was stronger elevated upon the second administration of 
muS110, but decreased in total by pre-treatment with mPDS (Figure 31A and B). Although 
mPDS treatment effectively curbed the release of IL-10 in response to muS110, this did not 
prevent the adaptation effect on cytokine release later on. 
Splenocytes isolated 24 hours after the 7th muS110 injection were stained with antibodies 
against CD127 and CD62L to determine distribution of naive, intermediate, effector, central 
and effector memory T cells. Additionally intracellular staining with antibodies against gran-
zyme B, IFN-g and CD152 was performed. The shift from TNaive/CM and TEM towards TEff and 
TInt compartment was smaller after repeated treatment with 10 µg/kg/day than after 25 
µg/kg/day muS110 (compare Figure 31 and Figure 23). Treatment with mPDS did not prevent 
induction of TEff cells (Figure 31C). CD8+ T cells were to a similar extent positive for gran-
zyme B, IFN-g and CD152 whereas these effects were even more pronounced for CD4+ T 
cells after combined glucocorticoid/ muS110 treatment than after muS110 treatment alone 
(Figure 31D). 
It has been shown that treatment with anti-CD3 antibodies induced CD8+ regulatory T cells, 
which down-regulate activation of CD4+ T cells (120). Figure 23 shows that muS110 induced 
slightly more CD8+ than CD4+ cytotoxic effector cells and that CD8+ T cell numbers in-
creased stronger than that of CD4+ T cells (Figure 26). Therefore, regulation of CD4+ T cells 
 - RESULTS - 90 
 
might play a role in BiTE induced adaptation as well, however, no regulatory CD8+ T cells 
were found so far. It was speculated that glucocorticoids might hamper this adaptation process 
(121). This could be an explanation for the slightly more activated appearance of CD4+ T 
cells after glucocorticoid co-treatment.     
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Figure 31: Impact of mPDS on muS110 induced T cell activation and systemic cytokine 
levels 
Female BALB/c mice (n= 12) received intravenous bolus injections of 10 µg/kg/day muS110 
for 7 days with or w/o intraperitoneal injection of 30 mg/kg mPDS one hour prior and one hour 
after the first muS110 injection. (A, B) Animals (n= 6) were bled 2 hours after first muS110 
administration and serum samples were analyzed for IL-10, TNF-a, IL-4, IL-6 IL-2, and IFN-g 
of animals treated (B) with mPDS or (A) w/o mPDS. (C, D) Splenocytes were isolated 24 hours 
after 7th muS110 injection. A part of the cells were stained with antibodies against the surface 
marker CD127, CD62L. (C) Percentage of naive/ central memory T cells (TNaive/ CM, CD62L+ 
CD127+), intermediate T cells (TInt, CD62L+ CD127-), effector T cells (TEff, CD62L- CD127-) 
and effector memory T cells (TEM, CD62L- CD127) are shown. (D) Intracellular staining with 
antibodies against CD44, granzyme B, IFN-g, and CD152 was performed after PMA/ Ionomy-
cin/ Brefeldin A stimulation. Error bars indicate SEM. Cytokine determination was performed 
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The glucocorticoid mPDS did not impair cytotoxic T cell effector functions. Splenocytes from 
animals receiving muS110 or a combination of muS110 and mPDS were isolated after the 7th 
muS110 injection.  The cytotoxic capacity of these cells was evaluated by muS110 induced 
redirected lysis of CHOmuEpCAM+ target cells (Figure 32A). Similar EC50 values for redi-
rected lysis were obtained with T cells from animals treated with or without mPDS. Cells 
from animals treated with muS110 revealed EC50 values of 0.28 +/- 0.06 ng/ml, those from 
muS110 plus mPDS-treated animals EC50 values of 0.35 +/- 0.04 ng/ml. Likewise, their po-
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Figure 32: Impact of mPDS co-administration during muS110 low dose adaptation on T 
cell effector functions  
Female BALB/c mice (n= 12) received i.v. injections of 10 µg/kg/day muS110 for 7 days with 
or without i.p administration of 30 mg/kg mPDS one hour prior and one hour after the first 
muS110 treatment. Six animals were sacrificed 24 hours after 7th injection (acute) whereas 6 
animals were allowed to recover for additional seven days (recovery). (A) Splenocytes were iso-
lated and used as effector cells for redirected target cell lysis of CHOmuEpCAM+ cells. Cell ly-
sis was determined by FACS analysis of PI incorporation. Data represents global fit of 6 ani-
mals. (B, D) Splenocytes were labeled with CFSE and stimulated with Dynabeads CD3/CD28 T 
cell expander in the presence of 10 U/ml rhIL-2. After 72 hours, (B) proliferation was moni-
tored by FACS analysis of CFSE distribution. (C, D) Supernatants of tests using splenocytes ob-
tained after (C) acute phase or (D) recovery phase were analyzed for concentrations of TNF-a, 
IL-2, IL-10, IFN-g , IL-6, and IL-3. Error bar indicated the SEM of six animals.  
A B 
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After the acute phase, the cytokine release by cells from muS110/ mPDS-treated animals was 
significantly lower upon in vitro re-stimulation for most cytokines compared to cells from 
only mPDS treated animals (p<0.05) (Figure 32C). After recovery for one week, comparable 
cytokine levels were induced upon re-stimulation in cells from both groups (Figure 32D).  
Hence, mPDS was able to increase the tolerability of muS110 by improving the first dose 
response and simultaneously allowing muS110 induced self-adaptation. This suggests that 
glucocorticoid hormones are suited to further improve the tolerability of muS110 in combina-
tion with a muS110 low-dose adaptation regimen. 
5.3 In vivo efficacy 
5.3.1 MuS110 efficacy and toxicity in mouse pulmonary metastasis models 
The in vivo anti-tumor efficacy of muS110 was tested in syngenic B16F10muEpCAM+ and 
CT-26muEpCAM+ mouse pulmonary metastasis models. Therefore, either 1 x 105 CT-
26muEpCAM+ or 1x105 B16F10muEpCAM+ tumor cells were i.v. injected into the lateral tail 
vein of BALB/c (8-12 per group) and C57BL/6 mice (6 mice per group), respectively. The 
tumor cells were trapped in the small pulmonary venules around the alveoles of the lung 
where they formed small tumor colonies on the lung surface. In the B16F10muEpCAM+ tu-
mor model treatment started one hour after tumor cell inoculation. Until day 17 after tumor 
cell inoculation animals were i.v. injected five times a week with PBS control buffer or dif-
ferent doses of muS110 (0.5, 2, 5 and 12.5 µg/kg/day or increasing doses from 12.5-200 
µg/kg/day, in which the starting dose was doubled every second injection after the fourth 
treatment day). In the CT-26muEpCAM+ tumor model muS110 administration was initiated 
three days after tumor inoculation to allow formation of lung colonies. Until day 17 after tu-
mor cell inoculation animals were treated daily i.v. with PBS control buffer or different doses 
of muS110 (0.5, 2, 5 and 12.5 µg/kg/day or increasing doses from 12.5-400 µg/kg/day, in 
which the starting dose of 12.5 µg/kg was doubled every second day after the fourth injec-
tion). The growth kinetic of lung colony formation was monitored with PBS treated sentinel 
animals. All animals were killed on day 17 of the study due to a strong lung tumor burden and 
number of tumor cell colonies on the lung surface was determined macroscopically. 
In both cases daily i.v. treatment with muS110 led to a significant and dose dependent inhibi-
tion of lung tumor colony formation (Figure 33). 
In the B16F10muEpCAM+ tumor model treatment with 0.5 μg/kg did only show a reduction 
of lung tumor colonies by 24%, which was not significant. Treatment with 2 or 5 μg/kg re-
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sulted in a significant reduction by 40% and 60%, respectively. Treatment with 12.5 μg/kg 
muS110 reduced the number of lung tumor colonies by 75%. The strongest effect was seen in 
the intra-animal dose escalation group (12.5-200 µg/kg muS110) in which tumor growth was 
prevented in 1/6 animal totally and the number of tumor colonies was reduced in the remain-
ing animals by 87% (Figure 33B and D).   
The in vivo efficacy of muS110 was less pronounced in the delayed treatment of 
CT26muEpCAM+ lunge metastases. Treatment with 0.5 μg/kg had a non-significant effect on 
the number of lung tumor colonies (reduction by 6.7%), whereas treatment with 2 µg/kg, 5 
µg/kg and 12.5 µg/kg resulted in a significant reduction by 38.9%, 50.6% and 56% of tumor 
burden, respectively. With a reduction by 63% the strongest effect was seen again in the intra-
animal dose escalation group (12.5-400 µg/kg muS110). All animals developed lung metasta-
ses (Figure 33A and C). 
Side effects in the highest dose groups such as loss of body weight, diarrhea, and mild seda-
tion/excitation were only transient. The loss of body weight was approximately 5-7.5% with a 
rapid recovery thereafter. However, total recovery of the body weight to pre-experimental 
values was delayed in the intra-animal dose escalation group. In the lower dose groups, no 
such treatment related side effects were observed (Figure 33).  
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Figure 33: MuS110 efficacy and toxicity in mouse pulmonary metastasis models 
(A, C) Eight to twelve mice per group i.v inoculated with 1x105 CT26muEpCAM+ tumor cells 
on day 0. Mice were treated from day 3 after tumor cell inoculation with the indicated dose of 
muS110 by daily i.v. injections (200 µl). (B) Six mice per group were i.v. inoculated with 1x105 
B16F10muEpCAM+ tumor cells on day 0. Mice were treated i.v. daily starting 1 hour after tu-
mor cell inoculation with the indicated doses of muS110 (B) Mice were killed on day 17 of ex-
periment and lungs examined macroscopically for the presence of tumor nodules. (C) Body 
weight was determined 3 times a week. SEM is shown. Asterisks indicate significant differences 
between the treatment and the control group as calculated with the Student’s T Test (*P<0.05; 
** P< 0.01).  Experiments with B16F10muEpCAM+ tumor cells were repeated twice, that with 
CT26muEpCAM+ tumor cells three times.  
Serum cytokine level of IL-2, IL-12p70, IFN-g, TNF-a, IL-6, IL-4, IL-5 and IL-10 were de-
termined two hours after each muS110 administration for 2 animals of the intra-animal dose 
escalation group (12.5-400 µg/kg muS110) using the mouse TH1/TH2 CBA Kit and the mouse 
inflammation CBA kit (both BD Bioscience). Coincident with the induction of clinical signs, 
daily dosing of 12.5 µg/kg muS110 induced a systemic and transient release of inflammatory 
cytokines, including IL-2, IL-12p70, IFN-g, TNF-a, IL-6, IL-4, IL-5 and IL-10 (Figure 34).  
The cytokine release was self-limiting and, with the exception of IL-10, much reduced after 
the fourth injection of muS110. Although the dose of muS110 was doubled every second day 
A B 
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after the fourth injection only small amounts of cytokines were detectable in the serum after 
each following injection.  This is most probably due to muS110 induced suppression of cyto-
kine release by activated T cells, which was already shown in section 5.2.5. An exception was 
IL-10, which showed only a slight increase after the first muS110 injection but a strong eleva-
tion after each following muS110 administration. This is in accordance with the strong IL-10 
release upon high dose muS110 challenges after low dose adaptation (Figure 25) and might be 
another proof for the immune-suppressive effects of this cytokine. The superiority of the dose 
escalation schedule over administration of a constant muS110 shows that muS110 induced 
immune modulation suppresses the systemic release of cytokines and limits related adverse 
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Figure 34: Serum cytokine level during dose escalation of muS110 in a CT26muEpCAM+ pul-
monary metastasis model   
Eight to twelve mice per 
group were intrave-
nously inoculated with 
1x105 CT26muEpCAM+ 
tumor cells on day 0. 
Mice were treated from 
day 3 after tumor cell 
inoculation with the 
indicated doses of 
muS110 (12.5-400 
µg/kg muS110) by daily 
intravenous injections 
(200 µl). Serum cyto-
kine level of IL-2, IL-
12p70, IFN-g, TNF-a, 
IL-6, IL-4, IL-5 and IL-
10 were determined 2 
hrs after each daily 
muS110 administration 
for 2 animals using the 
Mouse TH1/TH2 CBA 
Kit and the mouse in-
flammation CBA kit 
(both BD Bioscience). 
Serum of 2 animals was 
prior to measurement. 
Error bars show SEM 
and are representative 
for deviations of results 
between the two differ-
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5.3.2 MuS110 efficacy and toxicity in an orthotopic 4T1 breast cancer model 
The in vivo anti-tumor efficacy of muS110 against solid tumors was tested in a syngenic, or-
thotopic 4T1 mouse breast carcinoma model. A mixture of 5 x 103 mouse T cells and 2 x 104 
4T1 tumor cells was inoculated into the mammary fat pad of 6 BALB/c mice per group and 
animals were s.c. treated daily with either PBS or muS110 (0.5, 1, 5, or 15 µg/kg/day). The 
tumor volumes were measured on the indicated days with a caliper, and the tumor weight of 
dissected tumor at the end of the experiment (Figure 35A and E).  
Daily s.c. treatment with 5 or 15 µg/kg/day muS110 starting at day 0 induced a significant 
reduction of tumor growth while 0.5 and 1.5 µg/kg/day muS110 were not effective, but all 
animals developed a tumor until the end of the study. However, treatment with 5 µg/kg/day 
muS110 was with 82% reduction of tumor volume at day 30 after tumor inoculation slightly 
more effective than the 15 µg/kg/day dose resulting only in 68% reduction.  
S.c. treatment with muS110 induced mild dose dependent side effects. Only the highest dose 
group (15 µg/kg/day) showed a transient loss of body weight after the first two injections, 
which normalized on the third day (Figure 35B). Repeated s.c. administration seemed to be 
better tolerated than similar i.v. doses of muS110 (compare Figure 33E and Figure 35 B).  
Skin irritations occurred at the area of injection at all dose levels and scar tissue developed at 
about 7 days after start of treatment. After the third week of treatment all side effects had van-
ished. The escalating dose schedule was also tested in the solid 4T1 breast carcinoma model. 
A mixture of 2 x 104 4T1 tumor cells and 5 x 103 (E:T = 1:5), 1 x 104 (E:T = 1:1) and 5 x 104 
(E:T = 5:1) mouse T cells, respectively, was inoculated into the mammary fat pad of 6 
BALB/c mice per group. Until day 18 after tumor cell inoculation animals were s.c. injected 
five times a week with PBS control buffer or escalating doses of muS110 (12.5-200 
µg/kg/day, in which the starting dose was doubled every second injection after the fourth 
treatment day). The tumor volumes were determined on the indicated days with a caliper. Af-
ter the end of treatment the tumor growth was monitored for additional 17 days without fur-
ther treatment. Thereafter animals were killed and dissected tumors were weight (Figure 35C 
and F).   
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Figure 35: MuS110 efficacy and toxicity in an orthotopic, syngenic 4T1 breast cancer 
model 
(A, B and E) Mixtures of 5x103 mouse T cells and 2x104 4T1 tumor cells were orthotopically 
injected into the mammary fat pad of six BALB/c mice per group and tumor size measured 
daily. Mice were treated daily by s.c. injection (50 µl) with 0.5, 1, 5, or 15 µg/kg/day muS110 
or PBS control vehicle starting one hour after tumor inoculation. (C, D and E) Mixtures of 2 x 
104 4T1 tumor cells and 5 x 103 (E:T = 1:5), 1 x 104 (E:T = 1:1) and 5 x 104 (E:T = 5:1) mouse 
T cells, respectively, were inoculated into the mammary fat pad of 6 BALB/c mice per group. 
Until day 18 after tumor cell inoculation animals were s.c. injected (50 µl) five times a week 
with PBS or escalating doses of muS110 (12.5-200 µg/kg/day). After the end of treatment the 
tumor growth was monitored for additional 17 days. (A and C) Tumor volume and (B and D) 
body weight of muS110-treated BALB/c mice was determined during treatment. (E and F) 
Weight of dissected tumors was determined at the end of the study.  Error bars show SEM. Ex-







 - RESULTS - 99 
 
The escalating dose regimen had clearly enhanced anti-tumor efficacy in comparison to 
treatment with constant muS110 doses. The overall tumor reduction was higher than 76% at 
day 35 after tumor inoculation for all muS110 treated animals in comparison to the control 
group and correlated with the E:T ratio at the day of tumor inoculation. The smallest effect of 
76% reduction was observed at an E:T ratio of 1:5. Equal amount of T cells and tumor cells 
(E:T=1:1) resulted in a reduction of 90% tumor volume. The best result with a reduction by 
99% of tumor volume was obtained at an E:T ratio of 5:1. Of note, 17 days after treatment 
stop, 2 out of 6 animals with an E : T ratio of 1:5 and 5 out of 6 animals with an higher E:T 
ratio were still tumor free.  
Only mild muS110 induced dose dependent side effects occurred and were similar to those 
observed after constant muS110 dosage in the highest dose group (15 µg/kg/day). All animals 
showed initially a transient loss of body weight by ~2.5% after the first two injections, which 
normalized on the third day (Figure 35D). However, as already observed in the 
CT26muEpCAM+ tumor model (Figure 33) the increase of body weight was slower after re-
peated escalated than after constant muS110 doses. Again skin irritations occurred at the site 
of injection in all muS110 treated animals independently from the E:T ratio and scar tissue 
developed at about 7 days after start of treatment. After the third week of treatment all side 
effects had vanished.  
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6 DISCUSSION 
6.1 The bioactivity of muS110 
MuS110 is a BiTE designed to lyse mouse EpCAM positive tumor cells utilizing mouse T 
cells. In the presence of EpCAM+ target cells muS110 induced dose-dependent proliferation 
of T cells, cytokine secretion and up-regulation of activation marker CD69 and CD25. A 
transformation of resting to cytotoxic effector T cells correlated with lysis of all analyzed Ep-
CAM+ target cell lines. The effects of muS110 in vitro were almost completely saturated at 
concentrations from 10 - 100 ng/ml and the EC50 values of its bioactivity ranged between 0.3 
and 5 ng/ml.  
MuS110 mediated T cell activation was similar to that obtained by CD3/CD28 stimulation in 
the presence of IL-2 and independent from any physiological co-stimulation. Although the 
expression of CD134 (Ox40) is normally delayed and of fourfold lower level upon stimula-
tion solemnly via the CD3 antigen, even this marker showed a comparable up-regulation after 
muS110 and after CD3/CD28/IL-2 stimulation (95). MuS110 might fully activate all T cells, 
and not only a small fraction of CD28 independent memory T cells. This is indicated by a 
high percentage of activated T cells (>80 % CD25+ and CD69+ cells) already after 24 hours of 
stimulation, the generation of over 80% granzyme B positive CD8+ CTLs and the almost 
complete absence of TNaive/CM cells after 48 hours. This rapid and sound answer of almost all T 
cells argues against a mere expansion of only a small pool of co-stimulation independent 
cells. However, it cannot be ruled out that CD28 independent memory T cells might be acti-
vated first and facilitate thereafter muS110 induced activation of naive T cells, for example by 
providing co-stimuli like IL-2. It was published for MT103, a human CD19 specific BiTE, 
that CD8+ memory CTLs were most potent with MT103, whereas sorted naive T cells, posi-
tive for CD45RA, were not able to mediate redirected lysis (64). Carefully performed analysis 
of activation kinetics can finally address this question for muS110. 
For concentrations below 1 µg/ml muS110-induced T cell activation was strictly dependent 
on the presence of EpCAM+ target cells. Additionally, no up-regulation of the most sensitive 
marker CD69 was observed in the absence of appropriate target cells for the control BiTE 
muMEC14. However, in contrast to the human system, higher doses of muS110 or muMEC14 
were able to induce a slight T cell activation independent of a second binding partner (79). 
This loss of strict target cell dependency might be a direct consequence of higher afinity of 
mouse BiTEs to CD3e, resulting in a higher receptor occupancy at used concentrations. The 
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potency of CD3-mediated activation is defined by receptor cross-linking, assembly of an im-
munological synapse and frequency of receptor occupation over time (122). At the highest 
BiTE concentration used in cytotoxicity assays roughly 90% of mouse CD3 receptors but 
only 15% of human CD3 receptors were occupied by the respective BiTEs (Figure 36) 


























Figure 36: Comparison of CD3 occupation for muS110 and MT110. 
At the highest concentration used in cytotoxicity assays roughly 90% of mouse CD3 receptors 
but only 15% of human CD3 receptors were occupied. Based on the equation [F=[mAb] / 
([mAb] + KD], the fraction (F) of all receptor molecules that are bound to the respective ligand 
was calculated for both, MT110 and the human CD3e target  and muS110 and the mouse CD3e 
target. The T cell receptor occupancy was plotted against the various BiTE concentrations. The 
dashed line indicates the highest concentration used in cytotoxic assays.  
Triggering of almost all CD3 receptors of a T cell at once might induce a signal sufficient to 
overcome the need for a second binding partner, which is observed analogous with high doses 
of anti-CD3 antibodies in the absence of co-stimulatory signals (123, 124). In vivo, target cell 
independent activation might be of minor importance. T cell activation induced by the control 
BiTE was of minor strength and only a small fraction of T cells was affected. Additionally, 
the cmax of the highest applied single dose, ~ 200 ng/ml, was not enough to saturate the CD3 
antigen.   
6.2 MuS110 as murine surrogate of MT110 
MT110 uses a systemic immunotherapeutic approach against EpCAM+ tumor cells. Acute 
pancreas toxicity was induced by two other EpCAM-specific, monoclonal antibodies tested in 
clinical phase I studies, suggesting accessibility of EpCAM on normal pancreas tissue to these 
antibodies (50, 125). Two other anti-EpCAM antibodies showed good tolerability in man, 
suggesting differences in EpCAM antigen recognition by the various antibodies (126, 127). 
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Thus, it was mandatory to evaluate potential damage to EpCAM positive tissue by MT110. 
However, cross-reactivity was only found with chimpanzee. Consequently, the mouse specific 
surrogate muS110 was developed, to establish a pre-clinical model in an immune-competent 
host with a similar EpCAM distribution as in human.  
Two premises were analyzed to validate the surrogate approach. First, similar EpCAM ex-
pression in mouse and man, as significant differences in target expression would have limited 
the use of mice as a toxicological test species; second, comparability of in vitro properties of 
MT110 and muS110.  
Prior to this work the tissue distribution of EpCAM in mouse and human was analyzed in a 
histo-pathological study. In both species, EpCAM staining patterns were largely confined to 
the cell surface, showed no difference with respect to polarized expression on epithelial cells, 
and stained a similar proportion of cells in tissues. In particular pancreas, a critical organ for 
toxicity of anti-EpCAM antibodies, showed comparable EpCAM expression in man and 
mouse. Differences in EpCAM expression between man and mouse were noted for adrenal 
gland and testis tissues, which were positive in human but not in mouse tissue samples. How-
ever, a key difference was EpCAM expression on 2-4% of mouse lymphocytes, which was 
not seen on human lymphocytes. As reported for the B cell-specific BiTE antibody MT103 in 
chimpanzee, the immediate encounter of T cells and B target cells in blood can cause transient 
cytokine release by MT103 (128). The toxicity of a BiTE targeting only localized EpCAM 
antigen in tumor tissue might be less pronounced. Thus, the presence of easily accessible Ep-
CAM+ lymphocytes in mice may rather enhance the toxicity profile of muS110 in relation to 
MT110. However, only a careful dose escalation clinical phase I study will ultimately deter-
mine the tolerability of MT110 in humans.  
MuS110 was constructed to yield structural, biochemical and biological characteristics similar 
to those of MT110. But after all, distinct antibodies had to be used for generation of muS110 
and MT110, and the comparison of the two BiTE antibodies was hampered by the use of dif-
ferent effector and target cells, and species differences.  
The binding affinity to EpCAM was comparable for muS110 and MT110 (21 +/- 2.6 nM to 
13 +/- 0.25 nM). Epitope mapping showed that MT110 bound to the same sub-domain of hu-
man EpCAM as muS110 in mouse EpCAM. Most probably only a glycine residue in position 
44 and a leucine residue in position 40 of mouse EpCAM, which are absent in the human pro-
tein, prevent cross-reactivity of MT110 to the mouse protein (Amann et al., in press). How-
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ever, the binding affinity to the CD3 antigen was about 35 times stronger for muS110 than for 
MT110 (2.9 +/- 0.4 nM to 100 +/-15 nM; (85)). Thus, MT110 binds preferably to the tumor 
antigen, turning the cell surface into a T cell activating matrix before it recruits T cells.  
MuS110 binds more likely first to T cells and enables these cells to specifically bind to anti-
gen positive tumor cells. 
Activation of their respective effector cells was highly comparable for both BiTEs. MT110 
and muS110 induced  proliferation of T cells, up-regulation of activation markers like CD69 
and CD25, induction of granzyme B positive cytotoxic T cells, release of the same cytokines, 
and finally elimination of antigen positive target cells in vitro (79). For both BiTEs the half 
maximal kill of CHO cells transfected with the respective target antigen was comparable, 
namely for MT110 in the human system 0.65 +/- 0.5 ng/ml (n=5) and for muS110 in the 
mouse system 2.51 +/- 1.2 ng/ml (n=10) (85). The amplitude of specific lysis was less pro-
nounced in the mouse than in the human setting. Both BiTEs were restricted to the presence 
of target cells expressing the respective EpCAM, to elicit full T cell activation, although high 
doses of mouse control BiTEs mediated weak activation of T cells in the absence of appropri-
ate target cells as well. Human specific BiTEs never showed unspecific T cell activation (79).  
While higher CD3 affinity may have increased the risk of non-conditional T cell activation by 
muS110, it apparently did not positively affect the potency of redirected lysis by muS110. If 
anything, MT110 was more potent with human T cells than muS110 with mouse splenocytes 
in redirected lysis of human or mouse EpCAM-expressing CHO target cells, respectively (79, 
85). 
Taken together, the surrogate approach might lead to an overestimation of MT110 toxicity 
and an underestimation of its potency. Therefore, it was considered to be safely applicable 
despite differences between host species and drug candidates.    
6.3 The therapeutic window of muS110 
6.3.1 First dose response to muS110 
MuS110 induced a dose dependent onset of side effects including hemoconcentration, hypo-
motility, piloerection, body weight reduction, hypothermia, gastrointestinal symptoms and 
diarrhea up to 24 hours after injection. Most probably these adverse side effects of muS110 
were caused by a transient release of inflammatory cytokines through systemically activated T 
cells.  
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T cells in blood, spleen and various lymph nodes were found to newly express activation 
markers CD69 and CD25 in response to muS110 injections. Simultaneously, the serum levels 
of several inflammatory cytokines, e.g. IL-2, IFN-g, TNF-a, IL-4, IL-6 and IL-10, increased 
shortly after injection of muS110. Most cytokine concentrations peaked after 2 hours and 
were back to baseline level after 24 hours. Serum cytokine peak levels as well as kinetics 
seemed to coincide with the intensity and the course of clinical symptoms observed at differ-
ent dose levels. Glucocorticoids reduced T cell activation and cytokine release, which in turn 
considerably increased the tolerability of muS110 for mice. 
The systemic T cell activation was accompanied by a fast and profound peripheral lymphocy-
topenia for up to 48 hours. This might have been due to activation induced upregulation of 
adhesion molecules like CD44. Anti-CD3 mAbs are known to induce peripheral lymphocyto-
penia in mice as well (102). The release of  certain cytokines, like IL-2 and TNF-a, may fos-
ter lymphocyte adhesion and migration further (129, 130). 
 All observed clinical signs were described previously in mice in response to agonistic anti-
CD3 monoclonal antibodies or direct administration of inflammatory cytokines (97, 98, 101, 
131-135). The anti-CD3-induced acute syndrome is likewise caused by polyclonal activated T 
cells, releasing cytokines in the circulation. Activation of the complement system and Fc re-
ceptor-bearing accessory cells plays here an additional role. The increasing systemic levels of 
pro-inflammatory cytokines like TNF-a, IFN-g, IL-2, IL-6 and IL-3 resulted in similar acute 
but transient systemic symptoms like hypothermia, hypoglycemia, hypomotility, piloerection, 
diarrhea and hypotension, neutrophil activation, activation of coagulation and fibrinolysis, 
which resembles altogether a septic shock (136-138). A pneumonia-like picture, including 
inflammatory cell infiltration, diffuse vascular congestion and even thrombosis was observed 
in the lung. Cell vacuolization, cell necrosis and vascular congestion were the rule in the liver. 
Doses exceeding 2.5 mg/kg were associated with high mortality (101).  
The effects induced by 50 µg/kg muS110 and 5 mg/kg of the anti-CD3 antibodies clone 145-
2C11 or KT3 were comparable. The onset of side effects, T cell activation and cytokine re-
lease was delayed for two hours using conventional antibodies but all symptoms were other-
wise of similar quality. The delay might reflect the dependence of anti-CD3 mAbs on the in-
teraction of Fc-part with Fc-receptors on accessory cells to fully evolve their activating 
potential (104-108). The expression of these receptors is up-regulated by T cell-released cyto-
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kines, is therefore self energizing but needs time to evolve. MuS110 in contrast needs only the 
presence of EpCAM positive target cells to develop its full activating potential. 
These evidences suggest that the high T cell activating potential of muS110 might also be the 
reason for its dose limiting toxicity in mice. Doses higher than 100 µg/kg muS110 were lethal 
within 24 hours. The maximum tolerated dose (MTD) of muS110 in mice was 50 µg/kg 
muS110. Doses of 10 µg/kg muS110 were determined as no observed adverse effect level 
(NOAEL).  
Clinically, glucocorticoids are used to reduce the adverse effects of the anti-CD3-induced 
acute syndrome (99). Glucocorticoids hamper cell-mediated immunity by reduction of T cell 
proliferation and activation, down-regulation of adhesion molecules and induction of gluco-
corticoid induced apoptosis (139). This class of anti-inflammatory and immune-suppressive 
steroid hormones is characterized by the ability to bind to the cytosolic glucocorticoid recep-
tor and is used to suppress various allergic, inflammatory and autoimmune disorders. The 
formed receptor-ligand complex translocates in the cell nucleus. There it can either trigger 
transactivation of target genes containing glucocorticoid response elements, or interact with 
specific transcription factors like AP-1, NF-AT or NF-kB resulting in transrepression of their 
targeted genes. Additionally corticosteroids act at a posttranscriptional level by suppressing 
the cytokine protein synthesis (140). Suppressed genes are that coding for various cytokines 
like IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-12, TNF-a, GM-CSF and IFN-g (141).  
High doses mPDS (50 mg/kg) given 1-3 hours before injection of the anti-mouse CD3 mAb 
145-2C11 decreased the systemic release of IFN-g, TNF-a, IL-2 and IL-6 and significantly 
reduced mortality, hypothermia, diarrhea, nephrotoxicity and other lesions induced to lymph 
nodes and kidneys (99). Likewise, co-administration of dexamethasone and mPDS, respec-
tively, enhanced tolerability of muS110 by a similar mechanism. However, BiTE mediated 
target cell lysis was not decreased. Therefore glucocorticoids can be used in clinical settings 
to prevent putative BiTE induced adverse effects. 
Mouse EpCAM positive target cells as second binding partner were mandatory to elicit a pro-
found T cell activation with muS110 in vitro. Administration of the control BiTEs hyS110 or 
muMEC14, which share the anti-CD3 binding moiety of muS110 but lack specificity for a 
second mouse specific protein, were well tolerated. Thus, side effects of muS110 related to 
systemic T cell activation had to rely on a bispecific binding of the BiTE antibody to both, 
CD3 on T cells and to EpCAM on an easy accessible binding partner. Appearance of CD8+ 
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CTLs after muS110 treatment in vivo indicated that target cells most probably would be 
eliminated over time by redirected lysis. One possible target could have been epithelial cells, 
which frequently and highly express EpCAM in mice. However, histo-pathological analysis 
of mice daily dosed with muS110 doses up to 100 µg/kg/day for 35 days revealed no evidence 
for lesions in normal tissues expressing the EpCAM target antigen. Essentially, all histo-
pathological findings noted with EpCAM+ tissues in 30 muS110-treated animals were ob-
served at a similar frequency in the 32 vehicle control animals. Absence of any significant 
damage of normal EpCAM-expressing epithelia suggests that EpCAM on normal epithelial 
tissues was not accessible to muS110-redirected T cells.  
A number of recent studies have shown that EpCAM on normal epithelial cells is in complex 
with other proteins in the plasma membrane within so-called tetraspanin webs. Protein part-
ners of EpCAM include tetraspanins CD9 and 14.1, claudin 7 and CD44 (12, 44, 142). These 
protein-protein interactions may reduce the accessibility of EpCAM on the surface of normal 
tissue and leave only a few epitopes for recognition by antibodies. Upon neoplastic transfor-
mation, EpCAM can be over-expressed on certain tumor cells, which may overcome seques-
tration by certain protein partners. Likewise, free EpCAM may arise from loss of protein 
partners or de novo expression during transformation, as has been reported for CD9 (143). 
Accessibility of EpCAM-expressing cells to both, antibodies and immune effector cells may 
further increase upon degradation of extracellular matrix by tumor cell-derived proteases, and 
by loss of tight junctions in tumor tissue. In support for a sequestration of EpCAM in normal 
epithelia, immunohistochemical studies showed that EpCAM is concentrated within intercel-
lular boundaries, while it is evenly distributed on the surface of tumor cells (144).  
There may in fact be three levels contributing to a differential recognition of EpCAM. First, a 
molecular level, where accessibility of certain EpCAM epitopes is controlled by protein part-
ners, second, a cellular level, where EpCAM is sequestered at least in part by its sub-cellular 
distribution within highly structured normal epithelium, and third, a tissue level, where access 
of immune effector cells to epithelium is diminished by intact extracellular matrix. Future 
research is required to investigate these various possibilities and determine their contribution 
to a therapeutic window as seen with some, but not all EpCAM-directed therapeutic ap-
proaches.  
It is thus conceivable that EpCAM on cells of structurally sound epithelia was either not 
bound by BiTE antibody, or that cell-bound BiTE antibody had no reach to local T cells be-
cause a close contact to them was hampered by extracellular matrix, basal membranes, tight 
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junctions, and other mechanical barriers. On the other hand, the proteolytic environment and 
disorder of cancer cells in tumor tissue may give both, BiTE antibodies and T cells, much 
improved access to EpCAM+ target cells. The observation that even high doses of muS110 
apparently did not elicit detectable damage to normal epithelia in a mouse model, may indi-
cate that certain EpCAM-specific BiTE antibodies can have a robust therapeutic window for 
treatment of cancer (112). The finding that muS110 and MT110 bound their respective Ep-
CAM proteins with the same affinity and in the same sub-domain suggests that the safety data 
obtained with muS110 in mice regarding the EpCAM target toxicity may have predictive 
value for MT110 in humans (Amann et al. in press). 
However, a low percentage of mouse lymphocytes were found that express EpCAM. These 
were mostly peripheral B cells and to a lesser extent T cells. EpCAM expression on mouse 
lymphoid cells has been noted earlier but thus far only dendritic cells, plasma cells, thymo-
cytes and thymic epithelial cells were reported to express EpCAM (46, 145, 146). Unlike in 
healthy EpCAM+ tissue repeated muS110 treatment resulted in a reduction of EpCAM+ lym-
phocytes. Moreover, reduction of EpCAM+ B and T cells in peripheral blood samples via re-
directed lysis in vivo or by column/ FACS removal ex vivo significantly reduced T cell activa-
tion by muS110. A human cell culture system allowed demonstration that addition of only 2% 
EpCAM+ cells triggered T cell activation and cytokine release by MT110, which was compa-
rable in intensity to what has been observed with muS110 in the mouse cell culture system. 
Of note, MT110 did not induce any T cell activation in human blood samples, unless Ep-
CAM+ cells were added. Together, these findings support the notion that muS110-mediated 
activation of T cells was triggered by EpCAM+ lymphocytes in blood and lymphoid organs of 
mice, and may have been responsible for the acute side effects seen after injection of muS110.  
MuS110 could well discriminate between EpCAM found exposed on circulating lymphocytes 
and the EpCAM embedded in normal epithelial tissues. The absence of any significant dam-
age to normal EpCAM-expressing epithelia by muS110-redirected T cells in mice treated with 
very high doses of muS110 suggests that EpCAM+ solid epithelial tissues in mice could not 
substitute for EpCAM+ lymphocytes for activation of T cells in the presence of BiTE antibody 
muS110. This is in contrast to EpCAM on tumor cells where anti-tumor activity was already 
evident in mice at doses as low as 2 µg/kg muS110 (85). Should the human EpCAM-specific 
BiTE antibody MT110 likewise make this distinction, it may have a larger therapeutic win-
dow than muS110 in mice. In humans EpCAM+ lymphocytes are largely absent. T cells may 
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only be locally activated if they encounter MT110 that is bound to accessible EpCAM antigen 
on tumor cells. 
6.3.2 Adaptation to repeated injections of muS110 
At the beginning, consecutive muS110 administrations slightly intensified the first dose 
symptoms, as the onset was faster and the duration was longer. However, animals after the 
forth muS110 injection tolerated subsequent ones well, even at doses normally lethal when 
given only once. Thus, dose-dependent side effects were self-limiting and animals adapted to 
repetitive treatment with muS110.  
The cytokine release was also self-limiting and, with the exception of IL-10, much reduced 
after the second and third injection of muS110. No further cytokine release was detectable 
after the forth to seventh injection. Especially the disappearance of IFN-g, TNF-a and IL-6, 
known to be the central figures of the cytokine release syndrome, could explain the observed 
decline of symptoms despite ongoing medication.  
One explanation for the transient nature of muS110 induced side effects might be their de-
pendency on EpCAM+ lymphocytes. The activating stimulus would decrease gradually by 
progressive elimination of EpCAM+ lymphocytes. As the magnitude of cytokine release cor-
related with the amount of target cells present, the systemic cytokine secretion would decrease 
as well. This would in turn result in a reduction of adverse symptoms and recovery from the 
systemic T cell response. Persistent side effects could be due to a limited T cell activation 
triggered by the remaining 0.5% EpCAM+ lymphocytes, consistent with the in vitro data 
obtained with EpCAM depleted T cells.  
However, the immune-suppressive cytokine IL-10 behaved different from all other cytokines 
in response to a first and second high-dose challenge with muS110 after muS110 mediated 
eradication of EpCAM+ lymphocytes. IL-10 serum concentrations were not decreased but 
strongly elevated 2 hours after the first high-dose challenge of animals pre-treated with 10 
µg/kg/day muS110. Induction of IL-10 was not as pronounced in animals pretreated with 2 
and 0.4 µg/kg/day muS110, respectively. Thus, IL-10 serum levels correlated with the protec-
tion from side effects elicited by muS110 challenge. This counter wise behavior of IL-10 was 
also observed throughout muS110 dose escalation in an efficacy model. The persistent eleva-
tion of serum IL-10 concentrations ruled against a mere depletion of EpCAM+ target cells as 
solemn cause for increased tolerability, which should have affected all cytokines in a similar 
way. 
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Adaptation to repeated anti-CD3 stimulation was also described after the use of anti-CD3 an-
tibodies 145-2C11 and KT3. The cytokine induced syndrome was only observed after the first 
injections and spontaneously reversible after 2-3 days (101). The initial systemic hyper-
activation of the immune system was followed by an immunosuppression. The immunosup-
pressive abilities of anti-CD3 antibodies are in fact used to prevent and treat allograft rejec-
tion or type I diabetes (114).  
Our immune system evolved excessive control loops to limit self-damage by its necessarily 
harsh effector functions and to prevent hyper-activation of the immune system. Some of these 
mechanisms mediate immunosuppression after administration of anti-CD3 antibodies as well. 
First, a general short term immunosuppression after anti-CD3 stimulation is partly a result of 
activation induced down-modulation of the CD3 – TCR surface complex impairing alloanti-
gen induced T cell activation by APCs (109). This down-regulation is completely reversed 
nine days after a single administration of 145-2C11 (100). Second, a transient depletion of T 
cells from the peripheral lymphoid organs and the blood can persist for several weeks after a 
single administration of 145-2C11 and decreases immune functions furthermore (147-150). 
This lymphocytopenia is resultant from increased adhesiveness of T cells to the vascular epi-
thelium and lysis of antibody-opsonized T cells. A third mechanisms adding to the immuno-
suppressed state is anergy of the remaining T cells, characterized by diminished capacity to 
produce IL-2 and proliferate upon re-stimulation ex vivo (147-150). Treatment with the anti-
mouse CD3 mAb 145-2C11 additionally results in selective inhibition of TH1- type cytokine 
secretion upon in vivo and in vitro re-stimulation, whereas the production of TH2-type cyto-
kines, e.g. IL-4 is not altered and that of anti-inflammatory cytokines like IL-10 and TGF-b is 
even boosted (100).  
However, short term treatment with anti-CD3 specific antibodies also elicits long term opera-
tional tolerance in transplantation and autoimmunity (114). This permanent and active antigen 
specific unresponsiveness is most probably due to selective expansion and activation of TGF-
b dependent regulatory T cells that control pathogenic T cells (151). A consecutive five day 
treatment with anti-CD3 mAb induced a complete remission of overt diabetes. Belghith et al. 
showed that TGF-b played a central role in this restoration of peripheral T cell tolerance to 
pancreatic islet cells. First, the anti-CD3 mAb induced remission was suppressed by admini-
stration of a neutralizing anti-TGF-b antibody. Second, isolated CD4+ T cells of actively tol-
erized mice produced TGF-b but hardly other cytokines after in vitro re-challenge. The pe-
ripheral tolerance was mediated by CD4+CD25++ regulatory T cells, which were particularly 
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enriched in the draining pancreatic lymph nodes of tolerized mice (151). Interestingly, no rise 
in systemic TGF-b levels were found, which stresses the compartmentalization of the toler-
ance phenomenon (114). However, it was also shown that depletion of Treg and usage of anti-
TGF-b antibodies could not totally abrogate immune tolerance suggesting a further, maybe T 
cell intrinsic level of activation regulation (152).  
Chautenaud L. hypothesized that the tolerogenic capacity of anti-CD3 mAbs may develop in 
two consecutive phases: First, systemic, complete blockade of the pathogenic immune re-
sponse by T cell depletion, down-modulation of the TCR/ CD3 complex and immune devia-
tion to TH2 immune response; second, expansion and activation of TGF-b and IL-10 depend-
ent regulatory cells, acting in a more spatially ruled way. Thereby the TH1 subset is more 
rendered to anergy whereas the TH2 cells show proliferation and IL-4 production (153).   
Unlike bivalent anti-CD3 mAbs, muS110 treatment did not significantly down-regulate the 
CD3 antigen on T cells (111). However, it resulted in a transient, peripheral T cell lymphocy-
topenia. T cell depletion by anti-CD3 antibodies relies on the presence of the Fc part induced 
complement depending cytotoxicity (CDC) or antibody dependent cell-mediated cytotoxicity 
(ADCC), which are not mediated by BiTEs. In some cases redirected T cells obtained the 
BiTE specific antigen from the surface of target cell due to the close cell contact (data not 
shown) and thus become a target to redirected lysis by themselves. But this concerned only 
for a very small fraction of T cells. Upregulation of adhesion markers like CD44 on the other 
hand, was found on more than 80% of all CD8+ T cells after a 7 day treatment with muS110. 
The onset of the observed lymphocytopenia was very fast, so almost all T cells vanished 
within 2 hours after injection. But unlike after a single dose of 145-2C11, where lymphocyto-
penia lasted for several weeks, blood T cell numbers were back to baseline level within 48 
hours after a single dose of muS110 (100). Total number of CD8+ splenocytes was not de-
creased and the size of all dissected lymph nodes after muS110 treatment even increased (data 
not shown). Thus, the observed lymphocytopenia was most probably not a result of T cell 
depletion but redistribution of these cells.  
No deviation towards a TH2 cytokine pattern but a complete suppression of all analyzed cyto-
kines was observed after repeated muS110 treatment. This was partly caused by elimination 
of EpCAM+ target cells and the induced lymphocytopenia. However, the coincidental occur-
rence of high levels of immunosuppressive IL-10 evidenced another immune regulatory proc-
ess.  
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IL-10, also described as a “cytokine synthesis inhibitory factor”, is an anti-inflammatory cy-
tokine and has pleiotropic effects in immune regulation and inflammation (113). It down-
regulates the expression of TH1 cytokines IL-2 and IFN-g, that of IL-3, TNF-a and GM-CSF. 
Treatment with the humanized, FcR non-binding anti-CD3 antibody kOKt3yl (Ala-Ala) in-
duced a mild cytokine release syndrome with stronger IL-10 release in ratio to IFN-g -levels. 
It increased CD4+CD25+FoxP3+ regulatory T cells numbers, the CD8+/CD4+ ratio and in-
duced a sub-population of IL-10 secreting CD4+ T cells, expressing high levels of surface 
TGF-b and IL-10, which resembled Tr1 regulatory T cells (115).  
Significantly elevated levels of CD4+CD25+FoxP3+ regulatory T cells in splenocytes (10% to 
6% of CD4+ cells) and a significantly higher CD8+/CD4+ ratio in blood were also found after 
muS110 treatment. Together with the prominent appearance of IL-10, this might indicate a 
similar immune regulatory mechanism for adaptation to repeated muS110 than to kOKt3yl 
(Ala-Ala) administration. On the other side, no evidence for involvement of TGF-b, which is 
an important mediator of T cell suppression, was found after muS110 treatment in vivo or 
upon ex vivo re-challenges.  
T cell activation in the presence of IL-10 can render T cells hypo-responsive, which is ob-
served after administration of 145-2C11. T cell anergy describes a state in which lymphocytes 
are intrinsically functionally inactivated following an antigen encounter, but remain alive for 
an extended time in a hypo-responsive state. Functional limitations might occur in cell prolif-
eration, cell differentiation, effector functions and cytokine production (116). There are two 
main categories of anergy. First, clonal anergy, which develops after incomplete T cell activa-
tion mainly in already previously activated T cells. This is an IL-2 reversible growth arrest 
state and needs no antigen persistence. Second, adaptive tolerance, which arises mostly after 
stimulation of naive T cells in an environment with high co-inhibition or no co-stimulation, 
and is not IL-2 reversible. During antigen encounter proliferation and differentiation happens 
to varying degrees, which is followed by down-regulation of activities (e.g. proliferation, se-
cretion of IL-2, IFN-g, IL-4) to varying degrees in the face of persistent antigen (116).  
Redirected lysis by muS110 in vivo involved repeated TCR signaling in the absence of co-
stimuli. Almost complete elimination of EpCAM+ lymphocytes abrogated the second binding 
partner in healthy mice over time and T cell activation took place in the presence of high IL-
10 concentrations. Hence, reduction of systemic cytokine levels after repeated administration 
of muS110 could have been a consequence of T cells anergy, possibly imposed by regulatory 
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T cells. However, under all conditions tested, T cells from low-dose adapted mice were as 
competent as T cells from untreated mice with respect to proliferation, redirected lysis, and 
responsiveness to either muS110 (re)stimulation or classical T cell stimuli. Presence or ab-
sence of IL-2 did not seem to affect T cell activity. Additionally, potentially induced regula-
tory T cells were present in all assays used to characterize T cells from adapted mice and 
hence, should have been able to exert their negative regulatory effects. Therefore, low-dose 
adaptation to muS110 was not the result of compromised effector functions of cytotoxic T 
cells.  
However, all T cells from adapted mice showed an impaired ability for cytokine secretion 
upon in vitro re-stimulation, which was normalized one week after end of muS110 dosing. 
Even in the face of a full T cell activating stimulus, T cells from adapted animals did hardly 
produce cytokines in comparison to those of untreated animals. Additionally, they showed a 
synchronized, profound proliferation in absence of IL-2. This is in contrast to in vitro re-
stimulation upon a challenge with anti-CD3 mAbs, where secretion of some cytokines, e.g. 
IL-4, can be even enhanced (154). Interestingly, T cells from low-dose adapted mice did not 
require production of inflammatory cytokines, to achieve the same potency of redirected lysis 
as T cells from vehicle treated mice. This supports the finding that lysis by BiTE-activated T 
cells depends on cytolytic synapse formation, but not on collateral effects of secreted cyto-
toxic cytokines or other death receptor ligands (82),(66, 155). Both CD4+ and CD8+ T cells 
could well proliferate during redirected lysis but at some point in time, again the ratio ap-
peared to change in favor of CD8+ cells.  
Taken together, muS110 induced  a transient lymphocytopenia but most probably no T cell 
depletion, no down-regulation of the TCR/ CD3 complex, no immune deviation to TH2 im-
mune response and no anergy of T cells. However, it resulted in a transient, not IL-2 reversi-
ble block of cytokine secretion upon re-stimulation. In vivo, administration of muS110 in-
duced a persistent release of IL-10, an expansion of CD4+CD25+FoxP3+ regulatory T cells in 
the spleen and an increase of the CD8+/CD4+ T cell ratio in the blood. This might be indica-
tive for the involvement of regulatory cells, which, however, seemed to have no impact on 
muS110 mediated lysis of EpCAM+ target cell. These immune-modulating effects together 
with the elimination of EpCAM+ lymphocytes might be the reason of adaptation to repeated 
treatment with muS110. 
How can such a difference of immunosuppression arise after anti-CD3 stimulation with anti-
CD3 antibodies and the BiTE antibody, although their first dose response seemed to be so 
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similar? No satisfying answer to this question can be given at this point. The concrete differ-
ences in T cell activation have to be considered. The BiTE system solemnly relies on the 
presence of a second binding partner to elicit full T cell activation. The concrete physical 
properties of target or BiTE necessary to fully activate redirected T cells are not yet known. 
There seem to be a relation to clustering ability and distance to the cell surface. However, the 
pre-requisite to full T cell activation are well established for anti-CD3 antibodies. 
 In vitro, mitogenic activation of T cells by anti-CD3 mAbs is dependent on the interaction of 
the Fc- part with Fc-receptors (FcR) on accessory cells (152, 153, 156). The lower the affinity 
of the respective anti-CD3 antibody for FcR, the lower is the induced mitogenic activation 
and the better is the drug tolerated in vivo (IgG2a > IgG1 > IgG2b > IgG3 > IgA > F´(ab)2) 
(101, 104-108, 157). Full T cell activation could be restored for all formats by the supply of 
co-stimulatory signal, e.g. CD28 or IL-2 (101, 157). Enhanced in vivo T cell activation is 
caused either indirectly by the inclusion of further cytokine sources, like activated monocytes, 
and an enlargement of the addressed immune network, or directly by a different quality of the 
TCR transmitted signal in terms of co-stimuli and receptor clustering. Signals transmitted by 
the various anti-CD3 antibodies vary in terms of presented co-stimuli (e.g. CD28 on FcR-
expressing cells), duration (e.g. terminated by CD3 down-regulation and antibody serum half 
life) and surface density (e.g. antibody cross-linking). The different quality of the activation 
signal is translated first, in varying strength of cellular Ca2+ influx and second, in varying 
quantity and quality of phosphorylation of adaptor proteins and receptor tyrosine kinases. All 
this different events work together to induce a special setting of T cell response in terms of 
proliferation, TCR down-regulation, activation marker up-regulation and cytokine release, 
which is in general similar for all anti-CD3 antibodies but subtly differs between the respec-
tive isotypes.  
Administration of only the F(ab´)2  part of the 145-2C11 mAb for example resulted in down-
modulation of the TCR complex but did not induce CD25 up-regulation, lymphokine secre-
tion, T cell proliferation or hypothermia (98). This is thought to be due to the lack of multiva-
lent cross-linking of the CD3 antigen, which impedes development of a functional immune 
synapse (111). The ability to systemically clear LCMV infection was not reduced after F(ab´)2 
fragment administration, although this was observed after administration of intact 145-2C11, 
whereas protection from diabetes was mediated by both drugs (158). IL-2 secretion upon in 
vitro re-stimulation of T cells as well as in vitro CTL function was impaired after administra-
tion of both formats for several months. However, exogenous supplied IL-2 could rescue in 
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vitro CTL function after application of the F(ab´)2 fragment, but not after that of intact mAb 
(156, 159). Negative effects upon T cell effector function were more prominent in CD4+ than 
in CD8+ T cells after application of the F(ab´)2 fragment, but, vice verse after administration 
of the intact anti-CD3 mAb. Therefore, the imposed immune suppression varied directly with 
the TCR activating signal (156).   
Administration of a mAb against CD3, in which the high affinity IgG1 part was replaced by 
an IgG3 domain with reduced affinity to Fcg receptors, showed similar results (152). Naive 
mouse T cells did not proliferate, produce IFN-g or up-regulate surface activation marker in 
response to the IgG3 isotype. Administration resulted in immune tolerance and a reduction of 
TH1 mediated immunity. No immune deviation from a TH1 to a TH2 dominated immune re-
sponse took place as after injection of 145-2C11. All cytokine level where reduced in a simi-
lar way upon in vitro re-stimulation. Interestingly, lower binding affinity of the IgG3 isotype 
to monocytes translated in a less sound T cell anergy. T cells after in vivo anti-CD3 stimula-
tion with IgG3 isotype were capable to proliferate and to secrete IL-2 upon in vitro re-
stimulation. Such T cells in vivo stimulated with IgG1 or IgG2a isotypes were not (152). 
Interesting results were obtained with CLBT3/4, a non FcR-binding CD3 mAb of the mouse 
IgA isotype. It induced a rise in intracellular Ca2+ levels in T cells comparable to that after 
anti-human OKT3 (IgG2a) stimulation, however, phosphorylation of LAT was only partly 
achieved. In vitro, it was not mitogenic, did not induce cytokine secretion but caused up-
regulation of CD25 and CD69 and down-regulation of the CD3-TCR complex. After in vivo 
administration lymphocytopenia and cytokine release was observed, but T cells were not 
hypo-responsive after an ex vivo re-challenge (104, 157).   
Taken together, the nature of secondary binding of anti-CD3 antibodies defines the balance 
between T cell activation versus suppression and controls thus the induced immune response. 
There seemed to be a correlation between high affinity of anti-CD3 antibodies to Fc-receptor-
expressing cells, strong activation in vivo and following profound hyporesponsiveness of T 
cells to an ex vivo re-challenge. The lower the binding to Fc-receptor-expressing cells was 
during in vivo challenge, the lower was the anergic impact on TH1 cells and CTL after a re-
challenge (104, 157). This was not true for antigen specific operational tolerance, which was 
always imposed independently of the used anti-CD3 antibody format (114). MuS110 induced 
a new combination of T cell response to CD3 stimulation, as it fully activated T cells but im-
posed no T cell anergy, which ensures the best anticipated anti-tumor efficacy (Table 8).  
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Table 8: Effects of different anti-CD3 antibody formats (98), (101, 104-108, 157) (111, 114, 152, 
153, 156, 159) 
 
6.3.3 Efficacy 
This unique ability of muS110 was implemented in a special escalating dose-schedule to im-
prove its efficacy. Anti-tumor activity of muS110 was observed at constant doses as low as 2 
µg/kg/day. However, the strongest effect was seen in intra-animal dose escalation experi-
ments with a 99% reduction of tumor burden in comparison to untreated control animals, 
whereby tumor growth was still completely prevented in 5 out of 6 animals 17 days after 
treatment stop. Only minor side effects, like a small reduction of body weight, were observed 
despite this high anti-tumor activity.   
Co-treatment with a glucocorticoid might be a possibility to even enhance this dose schedule. 
Glucocorticoids were shown to reduce muS110-induced adverse effects but not BiTE medi-
ated tumor cell lysis (160). Thus, the dose escalation could already start with higher doses of 
muS110, controlling its adverse effects with mPDS co-treatment at the initial days. As it was 
shown that mPDS does not hinder adaptation to muS110, BiTE doses can be escalated there-
 Format IgG2a IgG1 IgG3 F´(ab)2 IgA muS110 





Cytokine secretion + +    + 
Down-regulation of CD3-TCR  + + + + +  
Up-regulation of CD69/ CD25 + +   + + 
Cytokine secretion + +   + + 
Deviation to Th2 cytokine profile + +     


















- Operational tolerance + + + + + ? 
T cell hypo-responsiveness + + (+) +   









Impaired secretion of all cytokines    + + ? + 
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after. Increased starting dose of this putative model could result in improved anti-tumor effi-
cacy.  
The surrogate approach suffered from the presence of EpCAM+ lymphocytes in the mouse 
system, which are absent in the human system. These cells are most probably responsible for 
the cytokine induced syndrome minimizing the therapeutic window of muS110. On the other 
hand, their elimination demonstrated discrimination of muS110 between EpCAM found ex-
posed on circulating lymphocytes (or in tumors) and EpCAM embedded in normal epithelial 
tissues. Should the human EpCAM-specific BiTE antibody MT110 likewise make this dis-
tinction, it may have a larger therapeutic window than muS110 in mice. T cells may only be 
locally activated if they encounter MT110 that is bound to accessible EpCAM antigen on tu-
mor cells. MT110 and muS110 binding to orthologous epitopes might facilitate this possibil-
ity (Amann et al., in press).  
Glucocorticoid treatment and low dose muS110 adaptation allows the administration of 
higher BiTE doses without reducing its potency and enlarge therefore the therapeutic window 
of muS110. Higher doses of muS110 show an exceptionally good efficacy against solid 4T1 
tumor, being almost completely able to prevent the outgrowth of these rapid and aggressive 
tumors. This might more closely resemble the therapeutic window to be expected of MT110 
in humans and would promise high clinical potential. Nevertheless, BiTEs address with CD3e 
a central protein in the immune response, might induce various cytokines and represent a new 
technology based on genetic engineering. Thus, MT110 has to be classified as high risk anti-
body and starting doses for clinical trials will therefore rely not on the NOAEL level, ob-
served in pre-clinical animal models, but on the minimum anticipated biological effect level 
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7 ABBREVATIONS 
Term or Abbreviation Description 
aa  Amino acid 
ADCC Antibody Dependent Cell-mediated Cytotoxicity 
ADP Adenosindiphosphate 
AK Adenylate Kinase  
ATP Adenosintriphosphate 
BiTE Bispecific T Cell Engager 
BSA Bovine Serum Albumine  
CAM Cell Adhesion Molecule 
CBA Cytometric Bead Array 
CD Cluster of Differentiation 
CD3 Part of the T cell receptor, required for signal transduction by the 
TCR 
CD4 Co-receptor for MHC class II, marker for helper T cells  
CD8a Co-receptor for MHC class I, marker for cytotoxic T cells 
CD11b Marker for myeloid and NK cells, subunit of the integrin CR3 
CD11c Marker for myeloid cells, subunit of the integrin CR4 
CD16 Fcg receptor III on neutrophils, NK cells and myeloid cells 
CD19 Pan B cells marker 
CD25 IL-2 receptor a chain, up-regulated during T cell activation 
CD28 Receptor for co-stimulatory signals on T cells, binds to CD80/ 86 
CD44 Binds hyaluronic acid and mediates adhesion of leukocytes, 
upregulated upon T cell activation 
CD45 Leukocyte marker 
CD45R/B220 Isoform of CD45 on B cells 
CD49b Marker of mouse NK cells, a2 integrin 
CD56 Isoform of neural cell adhesion molecule on NK cells 
CD62L Leukocyte adhesion molecule, mediates roling interaction with en-
dothelium  
CD69 Early activation antigen on macrophages, T, B and NK cells 
CD80 Co-stimulator, ligand for CD152 and CD28 on B cells 
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Term or Abbreviation Description 
CD86 Co-stimulator, ligand for CD152 and CD28 on monocytes, acti-
vated B cells and dendritic cells 
CD134 Marker of T cell activation, may act as adhesion molecule costimu-
lator, also known as Ox40 
CD152 Marker of T cell activation, negative regulator, receptor of CD80 
and CD86, also known as CTLA-4 
CDC  Complement Dependent Cytotoxicity 
CFSE Carboxy-Fluorescein diacetate, Succinimidyl Ester 
CHO Chinese Hamster Ovary 
CT Cytotox 
CTL Cytotoxic T Lymphocytes  
dHFR diHydro Folate Reductase  
DNA Desoxyribo Nucleic Acid 
EC50 Drug concentration where the half maximal effect is observed   
EDTA Etylenedinitrotetraaceticacid  
E -FABP Epidermal Fatty Acid Binding Protein 
EGF Epidermal Growth Factor  
EM Extracellular Matrix 
EpCAM Epithelial Cell Adhesion Molecule or Epithelial Cell Activating 
Molecule 
E:T Effector to Target 
ELISA Enzyme Linked Immuno Sorbent Assay 
FACS Fluorescence Activated Cell Sorting 
Fc Constant Fragment of an Antibody 
FcR Fc Receptor 
FCS Fetal Calf Serum 
F Fraction 
GMCSF Granulocyte Macrophage Colony Stimulating Factor 
hu Human 
Ig Immunoglobulin  
ICAM-1 IntraCellular Adhesion Molecule -1 
IFN Interferon 
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mAb Monoclonal Antibody 
Lck Leukocyte specific protein tyrosine kinase 
LFA Leukocyte Functional Antigen 
LNmes Lymph Node mesenteriales,  
LNing Lymph Node inguinalis superficialis 
LNcer Lymph Node cervicales  
MDC Myeloid Derived Cells (summarizes all bone marrow derived cells 
that are not lymphocytes) 
MABEL Minimal Anticipated Biological Effect Level  
MHC Major Histocompatibility Complex 
mPDS Methyl-Prednisolone 
mu Murine 
MSD Meso Scale Discovery 
MTD Maximal Tolerated Dose 
MTX Methotrexate 
NEA Non Essential Amino Acids  
NFkB Nuclear Factor kappa B 
NK Natural Killer 
NOAEL No Observed Adverse Effect Level  
PBMC Peripheral Blood Mononuclear Cells 
PBS Phosphate buffered Saline  
PE Phycoerythrin 
PI Propidium Iodide 
Pi3K Phosphatidylinositol 3 Kinase 
PKC Phosphokinase C 
PM Plasmamembrane 
PMA Phorbol Myristate Acetate 
KD Dissociation Constant 
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Term or Abbreviation Description 
rhuIL-2 Recombinant human IL-2  
RT Room Temperature 
s.c. Subcutaneous 
scFv Single-chain antibody Fragments variable 
SEM Standard Error of the Mean 
siRNA Small interfering RiboNucleid Acid 
SP Signal Peptide 
TNaive/ CM Naïve or Central Memory T cell (CD62L+CD127+) 
TInt Intermediate T cell (CD62L+CD127-) 
TEff Effector T cell (CD62L-CD127-) 
TEM Effector Memory T cell (CD62L+CD127+) 
TCR T Cell Receptor 
TGF-β Tumor Growth Factor β  
TH1 or TH2 Helper Cell Type 1 or Helper Cell Type 2 
TM Transmembrane 
TNF Tumor Necrosis Factor 
TY Thyroglobulin  
VH or VL Variable domains of the Heavy or Light chain  
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